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Abstract 
Oxidative stress (OS) plays a critical role in the pathogenesis of 
atherosclerosis potentially through interaction with nitric oxide (NO) generated by the 
inducible nitric oxide synthase (iNOS) pathway. Although considerable literature 
supports a pro-atherogenic role for iNOS-induced NO, recent evidence suggest an 
anti-atherogenic property for this enzyme where iNOS-induced NO attenuates 
atherosclerotic lesions after immune injury, enhancing endothelial integrity, survival, 
protecting against OS-induced apoptosis and necrosis. We therefore hypothesize 
that iNOS may have a cardio-protective role in the atherosclerotic vessel and that 
under conditions of OS, expression and function of this enzyme may be impaired, 
thus contributing to the deleterious consequences of OS. Experiments have therefore 
been conducted to establish whether pro-oxidants regulate iNOS expression/function 
in rat cultured aortic smooth muscle cells (RASMCs). These cells were induced for 
24 hours with LPS and IFN-γ to mimic inflammatory conditions. Oxidative stress 
inducers may modulate iNOS-induced NO production through alteration of the 
expression and/or function of the inducible L-arginine-NO pathway. We examined the 
effects of hydrogen peroxide (H2O2), antimycin A and diethyl maleate (DEM) on this 
pathway in vascular smooth muscle cells. H2O2 had little effect on NO production or 
L-arginine transport while antimycin A and DEM independently caused a 
concentration dependent inhibition of both processes. Only DEM induced heme-
oxygenase-1 (HO-1) expression, monitored by western blotting as a marker of OS. 
The effects of statins on NO synthesis and L-arginine transport in the presence and 
absence of OS were also investigated. The benefits of statins therapy in 
cardiovascular medicine are ascribed in part to their lipid-lowering effect by inhibiting 
3-hydroxy-3-methoxyglutaryl coenzyme A (HMG-CoA) reductase, the rate limiting 
enzyme for cholesterol synthesis. However, statins may possess anti-inflammatory 
properties and are able to improve endothelial function, stabilize atherosclerotic 
plaque, and inhibit platelet aggregation, vascular smooth muscle cells proliferation 
and vessel wall inflammation. These effects may be exerted through novel actions of 
statins that include interaction with specific signalling pathways in cells which may be 
associated with the induction of iNOS and/or cationic amino acid transporters 
(CATs). Thus, we have extended our investigations to include an examination of the 
effects of statins on both iNOS and CAT function and expression under control 
conditions and following exposure of cells to OS. Atorvastatin caused a bell shaped 
response on NO production and iNOS expression and also enhanced L-arginine 
transport but in a non-concentration dependent manner. Simvastatin only affected 
NO synthesis without altering transporter activity. Pravastatin was without effect on 
either system. Further studies demonstrated that that atorvastatin was able to 
reverse the effects of antimycin A and DEM but only on NO production.  
These findings confirm that the inducible L-arginine-NO pathway can be down-
regulated by pro-oxidants. This mechanism may therefore contribute to the 
deleterious effects observed in disease states associated with OS. Moreover, statins 
(in particular atorvastatin) appear to be effective in reversing the inhibition of NO 
production caused by inducers of OS. This, together with the fact that atorvastatin 
and simvastatin can potentiate iNOS-induced NO production and indeed L-arginine 
transport (with atorvastatin), highlights a potential novel mechanism through which 
the cardio-protective actions of these compounds could be mediated. 
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1.1 . Oxidative stress 
 
Oxidative stress (OS) occurs when the generation of reactive oxygen species 
(ROS) in a biological system exceeds the ability of the system to neutralize and 
eliminate these pro-oxidants. The imbalance can result from overabundance of ROS 
due to an environmental or behavioural stressor, or a lack of antioxidant capacity 
caused by disturbance in production and/or distribution of the antioxidant agents in 
the system (Sies 1991). 
 Reactive oxygen species may be generated in biological systems through 
various sources including certain drugs and various environmental stressors such as 
tobacco smoke (Noakes et al. 2007; Yeh et al. 2007), pollution (Diouf et al. 2006; 
Peretz et al. 2007), radiation and ultra violet (U.V.) light (Voss et al. 2007), pesticides 
(Lopez et al. 2007) and ozone (Calderon Guzman et al. 2006; Morrison et al. 2006; 
Chuang et al. 2007). Within cells, free radicals may be produced by different 
processes that may include mitochondria (Risom et al. 2005; Ago and Sadoshima 
2006; Coughlan et al. 2007; Seddon et al. 2007; Zhang and Shah 2007), phagocytes 
(Sheeran and Pepe 2006), peroxisomes, xanthine oxidase (Ago and Sadoshima 
2006; Seddon et al. 2007; Zhang and Shah 2007), myeloperoxidase, nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, uncoupled nitric oxide synthase 
(NOS) (Madamanchi et al. 2006; Sheeran and Pepe 2006; Seddon et al. 2007; 
Zhang and Shah 2007), auto-oxidation of glucose (Tan et al. 2007) or reactions 
involving iron and other transition metals (Risom et al. 2005). 
 Free radicals have a highly reactive molecular structure due to the presence 
of unpaired electrons in one or more of the atomic or molecular orbitals (Valko et al. 
2007). This makes these oxygen species highly reactive in biological systems and 
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often cytotoxic. Some of these cytotoxic actions may however be physiologically 
relevant in terms of host defence mechanisms (Valko et al. 2007). During the 
inflammatory response, ROS and reactive nitrogen species (RNS) modulate 
phagocytosis, secretion, gene expression and apoptosis (Fialkow et al. 2007). 
Besides their potential toxic effects, ROS also play an important role as signalling 
molecules (Voeikov 2006; D'Autreaux and Toledano 2007; Sugino 2007). This is 
perhaps aided by the fact that ROS molecules are small, diffusible and ubiquitous in 
the body  (Fialkow et al. 2007). As signalling molecules, ROS modulate contractile 
activity in skeletal muscle (Ji 2007; Niess and Simon 2007), regulate the redox 
sensitive transcription pathway of gene expression (Fialkow et al. 2007; Niess and 
Simon 2007), play a role in mitosis by redox sensitive processes (Chiarugi and 
Fiaschi 2007), are necessary for memory formation and synaptic plasticity (Kishida 
and Klann 2007), regulate cardiomyogenesis and vasculogenesis (Sauer and 
Wartenberg 2005), regulate apoptosis (Bickers and Athar 2006; Shen and Liu 2006), 
mediate signalling involved in vascular endothelial growth factor-2 (VEGFR-2) linked 
to endothelial cells migration and proliferation (Ushio-Fukai 2007), oxidise protein 
kinase C (PKC) and protein tyrosine phosphates (PTPs) and regulate mitogen 
activated protein kinase (MAPK) and P21-activated kinase (PAK) (Wu 2006; Fialkow 
et al. 2007; Zhang and Gutterman 2007). 
 
 
1.2 . Oxidative stress and endogenous antioxidant systems 
 
To control the redox state, cells possess systems that comprise of intracellular 
antioxidants such as ascorbic acid, glutathione (GSH), α-tocopherol, and several 
 17
ROS scavenging enzymes including superoxide dismutase (SOD), catalase, 
glutathione peroxidase and heme-oxygenase.  
Mammals possess three types of SODs: Cu,Zn-SOD, Mn-SOD and an 
extracellular, (EC)-SOD. Their action is to convert superoxide (O2.-) into hydrogen 
peroxide (H2O2) (Leopold and Loscalzo 2005; Sugino 2007). Cu,Zn-SOD is present 
in cytosol, lysosomes, peroxisomes, nucleus and mitochondrion while Mn-SOD is 
also present in mitochondria (Sugino 2007). Vascular smooth muscle cells (VSMCs) 
synthesise EC-SOD that binds extracellular matrix, and minimizes superoxide-
dependent inactivation of endothelial derived nitric oxide (NO) (Leopold and 
Loscalzo 2005). 
Catalase is composed of four monomers, each with one heme-active group. 
This enzyme acts by reducing H2O2 to water. Glutathione peroxidases on the other 
hand reduce hydrogen and lipid peroxides to water and alcohols, respectively. The 
glutathione enzymes have diverse functions: glutathione reductase reduces 
glutathione disulfide to reduced glutathione. In parallel, glutathione-S-transferase 
detoxifies oxidants by glutathiolation while the thiol-disulfide oxireductases and 
peroxiredoxins maintain redox state of protein thiol (Leopold and Loscalzo 2005). 
Catalases and glutathione peroxidases are part of the GPx family characterised by 
the unique amino acid selenocysteine within the active sites that use low molecular 
weight thiols such as glutathione (GSH) to reduce hydrogen and lipid peroxides to 
the correspondent alcohols. In the endothelium, the major superoxide metabolizing 
enzymes are Cu,Zn-SOD and Mn-SOD (Harrison 1997). 
Heme-oxygenase is responsible for heme catabolism that is cytoprotective 
against oxidative injury and maintains tissue homeostasis (Maines 1988; Maines 
1997; Dennery 2004; Maines and Gibbs 2005; Calabrese et al. 2006). There are 
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currently three isoforms referred to as: heme-oxygenase-1 (HO-1); heme-
oxygenase-2 (HO-2) and heme-oxygenase-3 (HO-3). Heme-oxygenase-1 is a 32 
kilodaltons (kDa) heat shock protein that is encoded by the Hmox1 gene and is 
inducible but has low levels of expression under normal physiological conditions. In 
contrast, HO-2 and HO-3 are constitutive proteins with HO-2, a 36 kDa protein, being 
highly expressed in the brain (Motterlini et al. 2002; Dennery 2004). Expressed in the 
spleen, liver, thymus, prostate, heart, kidney, brain and testis, HO-3 is a 33 kDa 
protein lacking in catalytic activity and exhibits a 90 % homology with HO-2 
(McCoubrey et al. 1997; Farombi and Surh 2006). 
 Induction of HO-1 can be initiated by several stress conditions including 
exposure to hyperthermia, U.V. irradiation, H2O2 and heavy metals. Moreover, HO-1 
is also induced under inflammatory conditions and diseases such atherosclerosis. In 
the latter, expression of HO-1 may be coupled to iNOS-induced NO production 
(Kitamura et al. 1998) indicating that NO (i.e. iNOS-induced NO), acting through 
induction of HO-1, may protect against OS, thus preserving cellular homeostasis 
(Dennery 2004). Expression of HO-1 has been associated with an anti-inflammatory 
role and this is supported by the fact that mice lacking HO-1 develop a progressive 
inflammatory state while humans lacking the ability to express HO-1 may potentially 
die from a condition referred to as inflammatory syndrome (Otterbein et al. 2003). 
The anti-inflammatory and cytoprotective actions of HO-1 may be mediated through 
catabolism of heme, as shown in Figure 1.1, to carbon monoxide (CO), biliverdin 
(rapidly converted to bilirubin) and free iron (which leads to the induction of ferritin, 
an iron-binding protein). These metabolites can act as anti-inflammatory, anti-
atherogenic and cytoprotective molecules. For instance, bilirubin has direct 
antioxidant effects while CO may exert tissue protective actions primarily through its 
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vasodilator and anti-platelet effects (Motterlini et al. 2002; Otterbein et al. 2003). 
Moreover, in rodent models of ischemia-reperfusion, allograft and xenograft survival, 
intimal hyperplasia following balloon injury or in chronic graft, the administration of 
CO, biliverdin, bilirubin or iron-binding compounds is reported to exert protective 
actions (Kitamura et al. 1998). 
 20
 
 
 
 
 
Figure 1.1. Catabolism of heme by heme-oxygenase-1 to carbon monoxide 
(CO), biliverdin and free iron. 
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Recent reports have suggested that there may be cross-talk between the NO 
synthase and CO systems (Kitamura et al. 1998; Otterbein et al. 2003). Both 
molecules have similar properties and cause smooth muscle cell relaxation (Dennery 
2004). Like NO, HO-derived CO activates soluble guanylate cyclase (sGC) and 
elevates cyclic guanosine monophosphate (cGMP) production which serve to 
regulate both blood pressure and vascular contractility (Motterlini et al. 2002; 
Dennery 2004). It is worth noting however that CO has a much lower affinity for sGC 
than NO (Siow et al. 1999). 
 
In addition to the above systems, several genes are also induced and 
regulated in the presence of oxidants which may activate factors such as metal 
response element-binding transcription factor 1 (MTF-1); the antioxidant response 
element (ARE); the MAF and the cap-n-collar (CNC-bZIP) transcription factors 
(Dalton et al. 1999). The activation of these elements contributes to the enhanced 
anti-oxidant response that may occur as a consequence of the oxidative stress. 
Moreover, the genes encoding for HO-1; γ-glutamylcysteine synthethase; thioredoxin 
reductase; glutathione-S-transferase and NADPH:quinone oxidoreductase may also 
be  induced through the cis-acting transcriptional regulatory element ARE (Mann et 
al. 2007) resulting in the expression of their respective anti-oxidant proteins and 
these genes could potentially be targets for therapeutic interventions in the 
prevention of cardiovascular disease (Dalton et al. 1999; Mann et al. 2007; Siow et 
al. 2007).  
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1.3 . Oxidative stress and disease 
 
Oxidative stress, linked to ROS and RNS, has been widely reported in several 
disease states including cancer (Valko et al. 2006), atherosclerosis (Lee and Hirani 
2006), heart failure (Valko et al. 2006), hypertension, ischemia/reperfusion injury, 
diabetes mellitus, rheumatoid arthritis (Griffiths 2005), neurodegenerative diseases 
such as Alzheimer's (Adam-Vizi 2005; Moreira et al. 2007) and Parkinson's diseases 
(Adam-Vizi 2005), or even ageing (Davies 1995; Yu and Chung 2001). These 
disorders can be exacerbated, perhaps even initiated, by numerous environmental 
pro-oxidants and/or pro-oxidant drugs and foods (Davies 1995), including those 
highlighted above. In view of the focus of this thesis, the discussion will now 
concentrate on the role of OS in atherosclerosis. 
 
 
1.3.1 . Atherosclerotic disease 
 
Atherosclerosis is one of the most prevalent and major cardiovascular 
diseases, accounting for a high percentage of mortality rates in industrialised 
countries (Hansson and Libby 2006). Associated with blood vessels, atherosclerosis 
is characterized by the formation of atherosclerotic plaques in the vessel wall in 
response to chronic multifactorial injury. The development of this disease is however 
complex and may start as early as childhood and progress during adolescence and 
young adulthood (McMahan et al. 2006). Although asymptomatic, atherosclerosis 
was unveiled in a post mortem study by Tuzco in 17 % of children aged 13 to 19 
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years old. Moreover, in people aged over 50 the prevalence of coronary artery 
disease is about 85 % (Tuzcu et al. 2001). 
Various stages of atherosclerosis show evidence of endothelial and smooth 
muscle dysfunction and metabolic abnormalities of the vessel wall which include: 
inflammation, OS and alterations of hormonal balance. Low-density lipoprotein (LDL) 
also accumulates in the vessel wall in the disease state and is modified through 
oxidation. Oxidised LDL (oxLDL) is subsequently accumulated in macrophages 
through scavenger receptors, resulting in the formation of foam cells (Linares et al. 
2006). Macrophages, together with agents such as interferon-γ (IFN-γ) contribute to 
ROS formation (Schroecksnadel et al. 2006) which may then induce lipid 
peroxidation and oxidation of several substrates leading to vascular damage, 
signalling alterations and impairment of vascular tone (Chen et al. 2006). The 
precise mechanisms associated with the latter have been extensively studied but 
without clear consensus on the actual cellular events that lead to the observed 
changes in vascular tone. Part of the reason for this is that there may be multiple 
events which all culminate in the impairment of the vascular tone. One potential 
target is the disruption of NO synthesis and/or actions by ROS and/or other 
atherogenic agents. A multifactorial disease like atherosclerosis, may also be 
attributed to an increased anthropological pressure on the human genome by 
environmental stimuli (Lamon and Hajjar 2008). 
 
 
 24
1.3.2 . Formation of the atherosclerotic plaque 
 
The advanced disease state is associated with the formation of a plaque 
which is composed of a cholesterol-rich lipid core, CD4+T cells, macrophages and 
foam cells, covered by the injured endothelial cell layer (Ross 1993; Ross 1995; 
Pulido et al. 2004; Antohe 2006; Crouse 2006; Saam et al. 2007). Smooth muscle 
cells (SMCs) migrate to the intima, proliferate and produce abundant extracellular 
matrix during the early stages of the disease. 
The progress of the atherosclerotic plaque starts with a combination of factors 
that induce endothelium imbalance, secretion of adhesion molecules, adhesion and 
infiltration of monocytes, release of more pro-inflammatory and adhesion molecules, 
SMCs proliferation, migration and finally the formation of an unstable plaque with a 
necrotic lipid core. Activated cells within the lesion, namely macrophages, release 
growth factors such as platelet-derived growth factor (PDGF); epidermal growth 
factor (EGF); fibroblast growth factor (FGF); transforming growth factor (TGF) which 
boost inflammation and SMCs proliferation (Lamon and Hajjar 2008). In addition, the 
proliferation of macrophages and their subsequent morphological alteration through 
accumulation of oxLDL generates foam cells (Schleicher and Friess 2007) which 
exist as fatty streaks and also release inflammatory cytokines such as TNF-α and 
interleukin-1β (IL-1β). The latter contribute to the subsequent inflammatory response 
(discussed below, Section 1.3.3), and are linked to proliferation of SMCs as well as 
their differentiation and subsequent apoptosis (Popa et al. 2007; Lamon and Hajjar 
2008). 
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Smooth muscle cells recruited into the intima proliferate and dedifferentiate 
from the adult to the foetal phenotype becoming secretory cells, releasing growth 
factors and pro-inflammatory molecules (Bentzon et al. 2006; Doran et al. 2008). 
Smooth muscle cells also produce large amounts of collagen and extracellular matrix 
proteins (Doran et al. 2008), thereby facilitating the accumulation of sub-endothelial 
LDL to the negatively charged proteoglycans in the extracellular matrix (Schleicher 
and Friess 2007). Thus, the changes that SMCs undergo are not simply a 
consequence of the disease but in fact contribute to the pathogenesis of 
atherosclerosis. Moreover, the proliferation of SMCs together with fibres associated 
with the cells, cover the lipid necrotic core and contribute to plaque stability (Lamon 
and Hajjar 2008). Paradoxically, the lack of SMCs augments risk of thrombosis in 
patients with advanced plaque and there is a close relation between plaque 
instability caused by platelets and thrombus formation. 
 
 
1.3.3 . Atherosclerosis as an inflammatory disease 
 
The inflammatory aspects of atherosclerosis are associated with the release 
of PDGF, transforming growth factor β (TGF-β), macrophage inhibitory factor (MIF), 
cytokines and monocyte chemotactic protein-1 (MCP-1) (Doran et al. 2008). In the 
progression stages of the plaque, platelets become major players in releasing pro-
inflammatory mediators and stimulating adhesion molecule expression in other cells 
(e.g. endothelium), modulating vascular inflammation, which may lead to vascular 
wall homeostatic imbalance (Langer and Gawaz 2008).  
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It is possible that inflammation together with hyperlipidemia act concomitantly 
in progressing atherosclerosis; and hyperlipidemia alone may not be as critical as 
initially thought. This suggestion is based on the fact that cardiovascular events 
associated with atherosclerosis may also occur in patients in whom plasma lipids 
concentrations are considered normal (Ross 1993; Lamon and Hajjar 2008). In the 
context of inflammation, the release of inflammatory cytokines such as TNF-α and 
IL-1β may, as already stated above, contribute in the subsequent inflammatory 
response that may cause further endothelial impairment. 
A breach in endothelium homeostasis has been established as being the 
trigger for atherosclerosis. The homeostatic properties of the endothelium in healthy 
blood vessels provide a physical barrier to circulating blood constituents and also 
maintains the patency of the vessels (Lamon and Hajjar 2008). In response to 
endothelial damage, there seems to be an innate immune response (Lamon and 
Hajjar 2008) which is sustained by oxLDL, and this is believed to strongly amplify the 
release of cytokines causing the adherence and infiltration of leukocytes into the 
intima (Granger et al. 2004; Cook-Mills 2006). 
In the inflammatory response, the endothelium is primarily defended by 
macrophages, which begin to digest oxLDL stimulating other cells of the immune 
system into action. In response, phagocytes migrate to the affected site and are 
activated to take up and destroy the modified LDL. Once activated, they also 
produce other cytokines that further activate other cells of the immune system. In a 
sense, the initial immune reaction leads to a cascade of other immune events. The 
inflammatory response is programmed to end with the phagocytic cells eliminating 
the foreign elements and this may subsequently result in apoptosis of these cells. 
Should the process fail, phagocytic cells which are unable to digest and thus 
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eliminate cholesterol may become irreparably damaged and thus undergo necrotic 
death. If the inflammatory stimulus is continuous, the helper T cells and the immune 
cells receive the “stay-alive” signal developing chronic inflammation within the lesion. 
As a response to an inflammatory injury, the plasma levels of C-reactive 
protein (CRP) increase by up to a 1000 fold (Westhuyzen and Healy 2000). This 
protein is usually synthesised in hepatocytes at low rates and retained by the 
endoplasmic reticulum, but released into the blood stream following an inflammatory 
stimulus (Westhuyzen and Healy 2000). The build up of CRP in circulation is 
associated with, and used as a marker of, an increased risk of cardiovascular 
disease  even though its mechanism of action is still not fully understood (Amezcua-
Guerra et al. 2007; Pereira and Borba 2008). This protein exists in atherosclerotic 
plaque within foam cells (Vigushin et al. 1993; Westhuyzen and Healy 2000) and is 
believed to bind to damaged lipoproteins, microbial polysaccharides, 
phosphatidylcholine and also activates phagocytes and the complement cascade. 
These actions result in direct effects on vascular cells, including the induction of 
cytokines and pro-thrombotic factors (Westhuyzen and Healy 2000; Amezcua-
Guerra et al. 2007).  
One other consequence of the inflammatory process is the generation of ROS 
which may be produced from several sources including NADPH oxidase (Yokoyama 
et al. 2000; Sorescu et al. 2001; Cave et al. 2006; Lambeth 2007; Brandes and 
Schroder 2008; San Jose et al. 2008). The NADPH oxidase enzyme is composed of 
six subunits (see Table 1.1) including the GTPase Rho guanosine triphosphatase 
(usually Rac1 or Rac2) and five phagocytic oxidases (phox): p22phox, p40phox; 
p47phox; p67phoxand gp91 (Cross and Segal 2004; Quinn and Gauss 2004). In 
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VSMCs, gp91 is believed to be replaced by its homologous proteins nox1 and nox4 
together with nox2 (Wassmann et al. 2002; Higashi et al. 2003; Ushio-Fukai 2006).  
The NADPH oxidase enzyme is primarily described in phagocytises and 
fundamental in host defence generation of ROS to eliminate invading 
microorganisms. However, when deregulated, NADPH oxidase may contribute to the 
pathogenesis of diseases like atherosclerosis, hypertension and ischemia/ 
reperfusion injury (Aldieri et al. 2008). Its expression in vascular smooth muscle 
cells, adventitia  or endothelium acts as a prominent source of ROS in the vascular 
wall even in the absence of inflammatory cells (Lambeth 2007; Brandes and 
Schroder 2008). Moreover, the generation of superoxide anions, by univalent 
reduction of oxygen, provides an environment of OS with the superoxide radicals 
readily reacting with NO forming the highly reactive peroxynitrite species with 
detrimental consequences (Forstermann 2006; Aldieri et al. 2008). Furthermore, the 
overproduction of NADPH, a co-factor for NADPH oxidase (and indeed NOS), by 
glucose-6-phosphate dehydrogenase activity induces OS by increasing the 
production of O2.- enhancing endothelial and vascular dysfunction (Gupte 2008). 
The implication of the NADPH oxidase in atherosclerosis is supported by the 
fact that its expression is specially activated in endothelial cells at arterial 
bifurcations or branching points within the vascular bed where atherosclerotic lesions 
are most likely to occur (Wyatt et al. 2004; Rouhanizadeh et al. 2008). The increase 
in ROS generation could contribute toward endothelial dysfunction, a key 
precipitating factor in the development of atherosclerosis (Ross 1995). In addition 
ROS generation could lead to oxidation of LDL generating oxLDL which can play a 
crucial role in the onset and progression of atherosclerosis, mediating its effects in a 
two phase process. In the early phase the monocytes recruited into the vessel wall 
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will differentiate into macrophages and accumulate oxLDL through scavenger 
receptors such as SR-A, CD36 and lectin-like receptor-1 (LOX-1) becoming foam 
cells (Hofnagel et al. 2006; Lee et al. 2008).  
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Table 1.1. NADPH oxidase homologues.  
Adapted from (Gao and Mann 2009). 
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 In a second phase, oxLDL together with other unknown local factors may 
negatively regulate anti-inflammatory and antioxidant response (Maziere and 
Maziere 2008; Watanabe 2008). These effects, together, could enhance pro-
inflammatory events leading to further damage to the endothelium and hence help 
progress the disease. Inhibition of ROS generation in the disease state may 
therefore help protect against some of the deleterious effects of the disease. In this 
context, studies using antioxidants have claimed to significantly inhibit cardiovascular 
events associated with ROS generation. However, the majority of other reports have 
failed to show any beneficial effects or any significant alteration of the atherosclerotic 
process following treatment with antioxidants (Jialal and Devaraj 2003). As examples 
of these contradictory findings, studies in patients on hemodialysis or  suffering from 
diabetes with increased levels of ROS appear to have reduced incidences of 
myocardial infarction when administered with vitamin E (Boaz et al. 2000). In 
contrast, vitamin E was ineffective in reducing cardiovascular events in animal and 
human models of atherosclerosis. Interestingly, two other antioxidants, probucol and 
succinobucol, significantly reduced macrophage accumulation, VSMCs proliferation 
and stimulated endothelial repair (Wu et al. 2006; Tardif et al. 2008). Such 
discrepancies question the role of OS and ROS in the pathogenesis of diseases 
such as atherosclerosis and it has been suggested that OS may in fact not be a 
cause but rather aggravates the disease (Stocker and Keaney 2005; Forstermann 
2008). It is also possible that these variations may reflect differences in the actions of 
antioxidants or even the complexity of in vivo redox reactions (Schleicher and Friess 
2007). 
An additional component to the inflammatory process may involve the 
induction of the enzyme NOS which generates nitric oxide. This molecule (discussed 
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below, Section 1.4.1), although physiologically relevant in regulating vascular tone 
and homeostasis, could contribute to the inflammatory process in atherosclerosis 
through its interaction with ROS to generate peroxynitrite (ONOO-) (Pacher et al. 
2007). The latter, in turn, can cause major alterations in cells that impair normal 
cellular function, thus consequences of OS (Upmacis et al. 2007). 
 
 
1.4 . Nitric oxide pathways in the vessel wall  
1.4.1 . Nitric oxide molecule 
 
Nitrogen monoxide or NO is a natural gaseous signalling molecule that 
crosses biological membranes with ease. It has an unpaired electron, making NO an 
extremely reactive molecule which does not need a receptor to cross membranes 
(Stamler et al. 1992). Initially described as endothelium-derived relaxation factor 
(EDRF) in the eighties by Furchgott (Furchgott and Zawadzki 1980), NO has been 
extensively studied since its discovery and some excellent reviews summarising its 
biological properties and actions have been published (Moncada et al. 1988; 
Furchgott and Vanhoutte 1989; Moncada et al. 1991; Furchgott 1993; Kelly and 
Smith 1996; Fleming and Busse 1999; Ignarro 2002). The NO molecule has a short 
half life of between 4 and 50 seconds and due to its high reactivity forms 
intermediate molecules such as nitrogen dioxide (NO2); nitrite (NO2-) and nitrate 
(NO3-) (Beckman et al. 1990). 
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1.4.2 . Nitric oxide synthases 
 
The NOS family of enzymes is composed of three isozymes which are the 
constitutive endothelial NOS (eNOS; Type III, NOS-III and NOS-3), and neuronal 
NOS (nNOS; Type I, NOS-I and NOS-1) and the inducible NOS (iNOS; Type II, 
NOS-II and NOS-2). Both iNOS and nNOS are cytosolic but eNOS is specifically 
localized in the plasmalemmal membrane caveolae (Alderton et al. 2001; Wyatt et al. 
2004). The human isoforms of these enzymes show 51 to 57 % homology and are 
products of three different genes (Alderton et al. 2001). Constitutive nNOS in the 
human genome is located on chromosome 12 and the protein is composed of 1434 
amino acids with a 161 kDa weight. eNOS, a 131 kDa protein, is on chromosome 17 
and composed of 1153 amino acids, while the 133 kDa inducible enzyme is 
composed of 1203 amino acids and located on chromosome 7 (Alderton et al. 2001). 
All the NOS enzymes share a common bi-domain structure where the N-terminal 
oxygenase domain binds haem and tetrahydrobiopterin (BH4). The C-terminal 
reductase domain contains flavin adenine dinucleotide (FAD), flavin mononucleotide 
(FMN) and NADPH binding sites with that for L-arginine linked by a calmodulin 
recognition site by this C-terminal (Richards and Marletta 1994; Ghosh and Stuehr 
1995; McMillan and Masters 1995; Alderton et al. 2001). The constitutive isoforms 
require Ca2+/calmodulin for activation while iNOS appears to be Ca2+ insensitive as it 
already has calmodulin tightly bound to its structure (Alderton et al. 2001). The 
primary structure of iNOS and the constitutive nNOS and eNOS differ in 40 to 50 
amino acids in the FMN sub domain that is referred to as the auto-inhibitory loop of 
iNOS (Salerno et al. 1997; Alderton et al. 2001). Endothelial NOS can be activated 
by various agents including acetylcholine which binds to G protein-coupled 
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muscarinic receptors, activating phospholipase C, leading to a Ca2+ cytosolic 
increase. The increase in cytosolic Ca2+ in turn, results in activation of calmodulin 
and subsequently eNOS (Fleming and Busse 1999). Once activated, eNOS 
catalyses the formation of NO from oxygen and arginine, utilising various co-factors 
including NADPH, FMN, FAD and BH4 (Figure 1.2.) (Ignarro 1990). Synthesis of NO 
via this enzymatic pathway is now widely accepted to perform as a physiological 
regulator of vascular tone, acting through the activation of sGC and generation of 
cGMP to induce smooth muscle relaxation (Silver 1985; Nakatsu and Diamond 1989; 
Luscher 1991). Guanylate cyclase is a heme-protein with a high affinity for NO 
(Stone and Marletta 1994; Koesling et al. 2004). Any changes within the vessel wall 
that impair eNOS activity would result not only in reduced NO synthesis but also in 
impaired vascular relaxation. 
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Figure 1.2. Synthesis of NO from L-arginine and Oxygen. 
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 In contrast to eNOS, nNOS is expressed mostly in neuronal tissue and thus 
plays a less significant role in regulating vascular tone directly. By comparison, iNOS 
is often induced in the vessel wall following exposure to pro-inflammatory mediators 
such as bacterial lipopolysaccharide (LPS) and cytokines (Ravalli et al. 1998). This 
induction peaks after 18 hours of induction and generates nanomolar amounts of NO 
which are significantly higher than the low picomolar amounts produced by the 
constitutive isoforms (Ignarro 1999). The large amounts of NO produced by iNOS 
could have detrimental consequences, contributing to the pathophysiology of 
diseases such as atherosclerosis, where expression of iNOS may contribute to 
vascular damage through generation of ONOO-. The latter is formed by the reaction 
between NO and O2.- thereby reducing NO bioavailability (Buttery et al. 1996; Cooke 
and Davidge 2002). More importantly, ONOO- can induce oxidation of BH4 and 
nitration of proteins resulting in OS and impaired cellular function (Vasquez-Vivar et 
al. 1998; Kohnen et al. 2001; Kuzkaya et al. 2003; Alp and Channon 2004; 
Forstermann 2006; Forstermann and Munzel 2006; Upmacis et al. 2007). 
Peroxynitrite may also induce iNOS through nuclear factor kappa B (NF-κB) 
activation in endothelial cells resulting in sustained overproduction of NO and thus 
further vascular damage (Cooke and Davidge 2002). 
 
 
1.4.3 . Nitric oxide, oxidative stress and atherosclerosis 
 
 As already indicated, atherosclerosis is considered to be a chronic 
inflammatory disease characterized by enhanced expression of pro-inflammatory 
cytokines, chemokines, and adhesion molecules. The cross-talk between cytokines, 
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chemokines and infiltrating immune cells amplifies the inflammatory cascade in the 
vessel wall, resulting in atherogenesis (Chandrasekar et al. 2006) and potentially the 
induction of iNOS. Immunostaining and in situ hybridization have indeed confirmed 
the presence of iNOS in atherosclerotic vessels, specifically localized to CD68-
positive macrophages, foam cells and VSMCs (Buttery et al. 1996; Hemmrich et al. 
2003). More importantly, the overexpression of iNOS may potentially contribute to 
the inflammatory response and further influence the pathologic features associated 
with the disease through, for instance, induction of nitrosative stress (Upmacis et al. 
2007). A pathological role for iNOS-induced NO in atherosclerosis is supported by 
reports that iNOS knockout mice show lower plasma levels of lipoperoxides, often 
used as an index for OS (Chen et al. 2003). 
Peroxynitrite and other RNS are responsible for the in vivo toxic damage 
resulting from ROS reaction with NO (Cooke and Davidge 2002; Nanetti et al. 2007; 
Cooper and Magwere 2008). Oxidative stress also uncouples the NOS enzymes by 
oxidising BH4 to BH3 (Landmesser et al. 2003; Alp and Channon 2004) and 
administration of BH4 or its precursor to animal models could restore NO bioactivity 
(Vasquez-Vivar et al. 1998; Laursen et al. 2001). The ROS generated by NADPH 
oxidase may directly cause vascular injury by oxidizing cellular constituents such as 
contraction proteins and depletion of NO either by formation of peroxynitrite or 
modification of NO binding sites (Abu-Soud et al. 1996; Elahi et al. 2007). 
Although an increase of NO in cardiovascular disease has been argued to be 
detrimental, not only because of the actions described above but also because of 
NO-mediated depression of inotropy, mitochondrial respiration and β–adrenergic 
responsiveness, new lines of evidence have indicated that reduced NO 
bioavailability may impair vasodilation contributing to vascular dysfunction (Elahi et 
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al. 2007). Additionally, iNOS-induced NO production has been shown to have a 
protective role in the cell-mediated oxidative modification of LDL (Buttery et al. 1996; 
Suschek et al. 2003) and in an in vivo model, iNOS attenuated atherosclerotic 
lesions after immune injury and increased endothelial integrity and survival, 
protecting against OS-induced apoptotic or necrotic cell death (Rikitake et al. 1998; 
Hemmrich et al. 2003). These beneficial properties of iNOS may be associated with 
the NO generated by this enzyme. Furthermore, under inflammatory conditions, 
hepatocytes have been reported to increase NO generation through iNOS as a 
protection mechanism (Kuo et al. 1997). Moreover, macrophages challenged with 
pro-inflammatory mediators generate NO that appears to inhibit oxLDL formation 
(Yates et al. 1992). The beneficial effects of antioxidants have also been shown to 
be related to an increase in iNOS activity and decreasing ROS (Bernatova et al. 
2002). These findings indicate a beneficial rather than a deleterious role of iNOS-
induced NO. Such a notion, although gaining some credence, is however still 
controversial in light of the plethora of information saying otherwise. Detailed studies 
investigating the beneficial anti-atherosclerotic properties of iNOS are therefore 
essential. Moreover, a better understanding of the mechanisms that regulate iNOS 
expression in atherosclerosis may prove beneficial in developing novel strategies in 
controlling the disease state. This may be particularly relevant with regards to 
understanding how certain drugs used by atherosclerotic patients regulate iNOS 
expression and/or function. This also applies to the parallel regulation of the L-
arginine cationic amino acid transporters (CATs) which, as discussed below (Section 
1.4.4), clearly influence the activity of iNOS and could potentially be involved in the 
pathogenesis of atherosclerosis and/or OS. 
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1.4.4 . L-arginine transport in vascular cells  
 
In inflammatory diseases, substrate supply to iNOS as well as expression and 
activity of the transporter(s) responsible for L-arginine influx into the cell (Durante et 
al. 1995; Simmons et al. 1996; Durante 2001; Kagemann et al. 2007) may be critical 
for sustained NO synthesis and thus the pathogenesis of the disease. Once induced, 
the ability of iNOS to generate NO may be critically regulated by L-arginine transport 
into cells (Baydoun et al. 1990; Bogle et al. 1992; Wileman et al. 1995). 
The availability and transport of L-arginine may be critical for NO synthesis 
within the vasculature and could have a significant impact in atherosclerosis. To 
date, at least four systems (y+, y+L, bo,+ and Bo,+) that mediate the uptake of cationic 
amino acids have been described. These are characterised according to their affinity 
for cationic amino acids and by their dependence on sodium (Deves and Boyd 1998; 
Palacin et al. 1998). The y+L system has at least two distinct transporters that have 
in common the heavy chain 4F2hc glycoprotein and the light chains y+LAT-1 or 
y+LAT-2 (Torrents et al. 1998; Pfeiffer et al. 1999; Broer et al. 2000). This 
heterodimeric protein family characteristically transport neutral and basic amino 
acids via Na+-dependent and independent mechanisms respectively. While y+LAT-1 
has a higher affinity for neutral amino acids (Km≈20-30 mM vs Km≈340 mM for L-
arginine (Pfeiffer et al. 1999), y+LAT-2 seems more specific for cationic amino acids 
(L-arginine Km≈120 mM vs leucine Km≈236 or glutamine ≈295) (Broer et al. 2000). 
The expression of these two proteins vary in different tissues with y+LAT-1 being 
expressed preferentially in intestine, kidney, lung and leukocytes (Torrents et al. 
1998; Pfeiffer et al. 1999) while y+LAT-2 appears predominant in the brain, heart, 
testis, small intestine and parotids (Broer et al. 2000). 
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 Systems bo,+ and Bo,+ are broad-scope carriers, able to accept both neutral 
and cationic amino acids (Van Winkle et al. 1985; Bauch et al. 2003). The 
heteromeric amino acid transporter bo,+ is Na+ independent unlike Bo,+ which is Na+ 
dependent (Bauch et al. 2003). bo,+ however seems to be crucial as an exchanger at 
normal membrane potential in epithelial cells, showing higher affinity for L-cysteine 
than for cationic or large neutral amino acids (Bauch et al. 2003). This transporter is 
a transmembranar protein with a light chain catalytic subunit b0,+ (glycoprotein 
associated) and the covalently associated heavy chain, type II glycoprotein r-broad 
scope amino acid transporter (rBAT) (Bauch et al. 2003). Although accepting a broad 
range of amino acids, Bo,+ shows selectivity for branched chained or benzonoid 
amino acids like leucine, isoleucine, tryptophan and phenylalanine (Van Winkle et al. 
2006). First described in mouse blastocysts, Bo,+ is suggested to be functionally 
important in blastocyst implantation and adulthood complications such as obesity in 
humans (Van Winkle et al. 2006). 
Of the transporters listed above, systems y+ is perhaps the most diverse and 
widely studied. It is described as a widespread classical system, with high affinity (Km 
in the micro-molar range) for cationic amino acids and is sodium independent (White 
et al. 1982; Closs and Mann 1999). In addition, this carrier is modulated by changes 
in membrane potential, with depolarization distinctly reducing L-arginine influx after 
stimulation with agonists such as bradykinin (Sobrevia et al. 1995; Bogle et al. 1996).  
System y+ is now known to comprise of a family of different cationic amino acid 
transport (CAT) proteins referred to as CAT-1 (Closs et al. 1993; Closs et al. 1993), 
CAT-2A (Closs et al. 1993), CAT-2B (Closs et al. 1993) and CAT-3 (Hosokawa et al. 
1997; Ito and Groudine 1997). A more recent member of this family, hCAT-4, has 
been described and is expressed predominantly in brain, testis and placenta. This 
 41
carrier is encoded by the SLC7A4 human gene which has a high homology with the 
SLC7A1 and SLC7A2 CAT genes that encode for CAT-1 and CAT-2 (Sperandeo et 
al. 1998; Dall'Asta et al. 2000). There is however some controversy as to whether 
the CAT-4 protein is in fact an actual transporter since it does not seem to exhibit the 
classical function of CATs (Sperandeo et al. 1998; Wolf et al. 2002; Closs et al. 
2006). Expression of hCAT-4 complementary deoxyribonucleic acid (cDNA) in 
Xenopus laevis oocytes or human testis teratocarcinoma cell line NT2 did not result 
in the expression of a functional CAT protein that could transport neutral, anionic or 
cationic amino acids (Wolf et al. 2002). This therefore questions whether hCAT-4 is 
indeed a CAT. It is possible however that the protein may need additional factors to 
be functional (Wolf et al. 2002). 
 Of the CATs, CAT-1, a high-affinity carrier, was the first to be characterised at 
a molecular level with the deduced amino acid sequence of the cloned cDNA 
revealing a 622 amino acid glycoprotein of about 67 kDa with 12 to 14 
transmembrane spanning domains (Closs et al. 1993; Closs et al. 1993). A truncated 
Cat-2 gene was cloned shortly after Cat-1 and initially named Tea (T-cell early 
activation receptor) because of its induction early in the response of normal T cells to 
mitogens. The full length cDNA which encodes a 658 amino acid protein (CAT-2B) 
was subsequently isolated and shown to have a 61 % homology with CAT-1 and 98 
% homology with CAT-2A (Closs et al. 1993). Like CAT-1, CAT-2B has a high affinity 
for L-arginine (Km: 0.04-0.3 mM) despite its high sequence identity with CAT-2A. 
However, unlike CAT-1 and CAT-2A, CAT-2B is believed to be an inducible protein 
and the product of a differentially spliced CAT-2 gene that also encodes for CAT-2A 
(Closs et al. 1993; Kakuda et al. 1999). These two products (CAT-2A and CAT-2B) 
differ by only 20 amino acids within a stretch of 41 amino acids in an alternatively 
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spliced region in the predicted fourth extracellular loop (Closs et al. 1993). This is 
however sufficient to render CAT-2B a high affinity carrier with CAT-2A now 
described as a high capacity but low affinity transporter of L-arginine. Moreover, this 
protein, unlike CAT-1 and CAT-2B is expressed more abundantly in the liver where it 
serves to remove surplus cationic amino acids from the portal circulation (Closs et al. 
2006). 
 
 
1.4.5 . L-arginine transport and NO synthesis  
 
Concentrations of L-arginine in human plasma are reported to be between 80 
to 120 µM (Mendes Ribeiro et al. 2001) or up to a normal maximum of 210 µM (Chin-
Dusting et al. 2007). By comparison, concentrations in cells range between 0.1 to 0.8 
mM (Baydoun et al. 1990; Mitchell et al. 1990). Despite the high intracellular 
concentrations, NO production by iNOS in cultured cell systems appears to be 
dependent not only on the presence of extracellular arginine (Granger et al. 1990; 
Mitchell et al. 1990; Assreuy and Moncada 1992; Bogle et al. 1992), but also directly 
related to the rate of transport of exogenous arginine (Assreuy and Moncada 1992; 
Bogle et al. 1992), and is inhibited following blockade of L-arginine entry into cells 
(Bogle et al. 1992). Removal of exogenous L-arginine or direct inhibition of L-
arginine transport through these carriers also attenuates NO synthesis in blood 
vessels obtained from endotoxemic rats (Schott et al. 1993) and in SMCs exposed to 
endotoxin and inflammatory cytokines (Hattori et al. 1999; Wileman et al. 2003). 
Moreover, in knockout studies, suppression of L-arginine transport through abolition 
of CAT-2B expression results in a marked attenuation in NO production (Nicholson 
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et al. 2001). These findings demonstrate the important functional link between L-
arginine transport and iNOS mediated NO synthesis. The close coupling between 
the two processes may be of particular clinical relevance as induction of iNOS 
generally coincides with the induction of transporter activity. This phenomenon, 
demonstrated in vitro in cultured cell systems, including SMCs (Durante et al. 1995; 
Wileman et al. 1995; Gill et al. 1996; Hattori et al. 1999), in experimental models of 
endotoxin-induced shock in vivo (Hattori et al. 1999; Schwartz et al. 2003; Huang et 
al. 2004; Chu et al. 2005; Yang et al. 2005) and, more importantly, in patients with 
septic shock (Reade et al. 2002) provides a mechanism for sustained substrate 
supply during enhanced NO synthesis. 
Of the three CATs, there are strong indications that expression of the high 
affinity CAT-1 and/or CAT-2B may play an important regulatory role in determining 
the rate of NO synthesis within the vasculature. These carriers may be the critical 
targets for the regulation of NO synthesis and crucial because of their induction by 
inflammatory mediators which could provide a mechanism for substrate delivery 
critical for sustained NO production (Baydoun and Mann 1994; Rotoli et al. 2005; 
Baydoun et al. 2006). 
In atherosclerosis, it is still not clear whether alterations in CATs activity 
contribute to the impaired vascular responses seen in the disease state. Moreover, 
there are conflicting reports on the effects of OS on L-arginine transport, some 
studies indicate that OS inhibits transport by system y+, reducing L-arginine 
availability in endothelial cells, leading to eNOS uncoupling and OS (Zhang et al. 
2006; Jin et al. 2007). Other report suggests that despite decrease of L-arginine 
availability, the transporters were not affected, instead, this has been linked to over 
expression of arginase-II which may deplete intracellular L-arginine pools by 
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breaking it in ornithine and urea thus increasing ONOO- concentration (Noris et al. 
2004). In human aortic endothelial cells oxLDL induced an increase of arginase 
activity in a time and concentration dependent manner, contributing to the 
uncoupling of NOS and an increase of RNS. Arginase may therefore play a central 
role, contributing to the pathophysiology of lipid mediated endothelial damage (Ryoo 
et al. 2006; Ryoo et al. 2008). Furthermore, since arginase regulates cell 
proliferation, its inhibition may halt the progression of atherosclerosis (Hayashi et al. 
2006). 
The reasons for the discrepancies above are unclear and need careful 
investigation, paying particular attention to the systems used in the studies and to 
the conditions under which OS is being induced. It is not unreasonable to speculate 
however that part of the consequences of OS in atherosclerosis involves altered 
CATs expression and/or function. Such events would limit substrate supply to the 
NOS enzymes which in endothelium would attenuate eNOS-mediated NO and thus 
relaxation of vascular tone. By comparison, suppression of L-arginine supply to iNOS 
would attenuate iNOS-mediated NO production which should prove beneficial in the 
disease state because of the proposed potential pathological role of iNOS in 
atherosclerosis. More recent findings would however refute this notion and argue 
that the deleterious effects of OS may, in part, be associated with the suppression of 
iNOS-induced NO production through as yet undefined mechanisms that could 
potentially involve an action on the enzyme itself or on the CATs. 
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1.5 . Drug therapy for atherosclerosis 
 
In view of the role of OS in the pathophysiology of atherosclerosis, one 
approach in treating the disease may be to diminish the status of OS within the 
vasculature. This could be achieved directly using pharmacological tools such as 
ascorbic acid, α-tocopherol, β-carotene or indirectly through enhancing the body’s 
natural antioxidant defence mechanisms including up-regulating intracellular 
antioxidant defence mechanisms such as SOD, catalase and/or GPx (Inagi 2006). 
However, large trials of treatment with antioxidants in humans have failed when 
comparing with the successes in in vitro or animal studies. These differences may be 
due to the fact that gene regulation through long term and adequate dose of 
antioxidants may be more important than reducing ROS directly (Mann et al. 2007). 
In addition to antioxidants, the fact that high levels of LDL directly correlate 
with cardiovascular complications, make targeting the lowering of plasma cholesterol 
levels critical for therapy. This could be achieved using well established lipid lowering 
drugs including anion-exchange resins, fibrates, nicotinic acid, and statins (Knopp et 
al. 2008). Of these, the statins have become the most effective and widely used 
drugs which act by reversibly and competitively inhibiting 3-hydroxy-3-
methoxyglutaryl coenzyme A (HMG-CoA) reductase, the rate limiting enzyme for 
cholesterol synthesis (Goldstein and Brown 1990; Chong et al. 2001). These drugs 
are discussed in further detail below (Section 1.5.1). 
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1.5.1 . Statins: 3-hydroxy-3-methoxyglutaryl coenzyme A (HMG-
CoA) reductase inhibitors 
 
Statins were discovered over 30 years ago and demonstrated to have a high 
capacity for reducing cholesterol levels (Endo et al. 1976; Endo et al. 1977). As 
mentioned above, these drugs are now increasingly prescribed for patients with 
coronary heart disease due to their efficiency in lowering cholesterol and protecting 
patients from cardiovascular events (Kronmann et al. 2007; Bartholomeeusen et al. 
2008). In addition to lowering cholesterol, statins such as atorvastatin may reduce 
TNF-α-induced hypoxia-inducible factor-1α activation, indicating that these 
compounds may exert anti-inflammatory properties (Chandrasekar et al. 2006). 
Moreover, statins may also exert antioxidant effects which may be associated with 
their ability to inhibit O2.- production by NADPH oxidase, as demonstrated in a 
monocytes cell line (Delbosc et al. 2002a) and prevented angiotensin-II (Ang-II)-
NADPH stimulation (Delbosc et al. 2002b). These actions may improve endothelial 
function, stabilize atherosclerotic plaque, and inhibit platelet aggregation, vascular 
SMC proliferation and vessel wall inflammation (Chandrasekar et al. 2006). 
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Figure 1.3. The mammalian mevalonate pathway.  
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It is worth noting that although all statins inhibit HMG-CoA reductase, this 
characteristic does not reflect a homology of structure and origin. Statins can be 
natural, synthetic or semi-synthetic and their molecular structure may vary (Manzoni 
and Rollini 2002) (Figure 1.4.). The derivate pravastatin can be obtained by the 
biotransformation of mevastatin obtained from Penicillium citrinum. Lovastatin on the 
other hand is obtained from the Aspergillus terreus strain whereas the semi-synthetic 
simvastatin is synthesised from lovastatin (Manzoni and Rollini 2002). The statins of 
natural origin share a characteristic hydroxy-hexahydro naphthalene ring system 
within the polyketide portion and differ on the linked varied side groups (Manzoni and 
Rollini 2002).  
The molecular structure of statins is formed by three main groups: the HMG-
CoA analogue; an hydrophobic ring that links the HMG-CoA analogue and a 
complex hydrophobic ring structure and finally the side groups linked to the rings 
(Schachter 2005). These structures confer the specific molecular properties of each 
statin. Synthetic atorvastatin and fluvastatin are derived from mevalonate and 
pyridine, respectively. Another insight is that statins can be lipophilic and hydrophilic, 
leading to different actions. Rosuvastatin although synthetic and hydrophilic is 
retained in circulation for 19 hours (Schachter 2005). Pravastatin is the most 
hydrophilic and simvastatin the most lipophilic, but the clinical relevance of the 
differences in solubility among the statins is not completely clear. Lipophilic statins 
may penetrate cells by passive diffusion, differing from pravastatin and rosuvastatin, 
both hydrophilic molecules that require a transporter system for entry into cells 
(Turner et al. 2007). 
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Figure 1.4. Chemical structure of HMG-CoA reductases.  
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1.5.2 . Statins pharmacology 
 
In general, the pleiotropic effects of statins have been described in 
endothelial, other vascular cells and in platelets. Some of these effects include anti-
inflammatory actions, vascular tone relaxation, plaque stabilization and anti-
thrombotic effects (Boyle 2005; Mangat et al. 2007). Other actions include decrease 
of oxLDL (Hogue et al. 2008), ROS and NADPH oxidase activity (Rueckschloss et al. 
2001; Wassmann et al. 2002; Yu et al. 2005; Forstermann 2008); the promotion of 
eNOS expression (Laufs et al. 1998) and activity by protein kinase B (Akt) 
phosphorylation (Nakata et al. 2007); down-regulation of caveolin expression that in 
excess binds eNOS reducing NO bioavailability (Feron et al. 2001); the inhibition of 
the farnesylation and geranylgeranylation of protein Ras homolog gene family, 
member A (RhoA) as well as RacC and cell division cycle 42 (Cdc42) in the 
mevalonate pathway resulting in the suppression of expression of eNOS (Ruperez et 
al. 2007). Vascular relaxation may also be improved by the diminished expression of 
endothelin-I, Ang-II receptor as well as the improvement in eNOS expression and 
hyperpolarization of calcium activated potassium channels (Hernandez-Perera et al. 
1998; Mangat et al. 2007). In addition, vascular inflammation may be ameliorated 
through the inhibition of (i) LDL oxidation, (ii) leukocyte-endothelial cell adhesion, (iii) 
NF-кB activation, (iv) CRP and (v) homocysteine levels (Mangat et al. 2007) and (vi) 
release of pro-inflammatory cytokines. In human umbilical vein endothelial cells 
(HUVECs) simvastatin can induce neovascularization suggesting a mechanism of 
salvaging tissue from critical ischemia (Kureishi et al. 2000). In plaque stabilization 
statins may inhibit accumulation of cholesterol in macrophages, matrix 
metalloproteinases (MMPs) production and infiltration of inflammatory cells, which 
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together with the inhibition of platelets and tissue factor (TF) expression would have 
anti-thrombotic effects and could prove beneficial in atherosclerosis in preventing 
plaque rupture (Saini et al. 2005; Rubba 2007; Nakamura et al. 2008). 
Treatment with statins reduces LDL levels which significantly correlates with 
plaque volume reduction, regression and a decline in arterial remodelling (Paciaroni 
et al. 2007). Interestingly, lipophilic but not hydrophilic statins apparently reduce 
neointimal formation and SMCs proliferation (Arnaboldi et al. 2007; Turner et al. 
2007). The lipophilicity of statins may indeed reflect the more powerful pleiotropic 
effects of atorvastatin, simvastatin, fluvastatin and lovastatin. 
Clinically, the dosage of statins given to patients appears to depend on the 
statin being used and varies between 20 and 80 mg/day. Their plasma half-life is 
normally between 2 to 4 hours, with the exception of atorvastatin which has a longer 
half-life of 14 to 20 hours (Chong et al. 2001; Manzoni and Rollini 2002). The plasma 
level of the drugs also depends on the statin used, with simvastatin for instance, 
reaching concentrations of 0.1 µM to 10 µM (Lin et al. 2005). After a 40 mg single 
therapeutic administration of lovastatin, peak serum concentrations vary between 
0.1–0.3 µM (Pentikainen et al. 1992). In rats, plasma levels of atorvastatin reached 1 
µM just after administration of 2 mg/ml, decreasing to a minimum of 0.1 µM, 2 to 4 
hours after administration of this drug (Lau et al. 2006). Whereas simvastatin and 
lovastatin are available for patient use as lipophilic lactone pro-drugs, the other 
statins are given in the acidic form (Neuvonen et al. 2008). The pharmacokinetic 
differences between the statins may be crucial in clinical situations. The 
bioavailability of statins taken orally may vary accordingly with the activity of 
cytochrome P450 3A4 (CYP3A4) transporter proteins, the contents and pH of the 
gastrointestinal tract and is greater for fluvastatin (24 %), pravastatin (17 %) and 
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atorvastatin (12 %) but low for lovastatin and simvastatin (5 %) (Chong et al. 2001; 
Neuvonen et al. 2008). Different satins at varied concentrations show higher or lower 
potency in blocking LDL synthesis (see Error! Reference source not found.). 
Atorvastatin 80 mg has the most efficient lowering rate, decreasing cholesterol by 54 
%, and the minimum dose (10 mg) reduces cholesterol by 38 %. Lovastatin at 80 mg 
reduces cholesterol levels by up to 48 %; while simvastatin at the same 
concentration reduces by up to 46 %. Similarly, at 40 mg, pravastatin reduced 
cholesterol by 34 %, and this was more efficient than fluvastatin which at the same 
concentration only inhibited by 23 % (Jones et al. 1998). 
A vast majority of studies distinguish statins according to their lipophilicity 
which correlates with their pleiotropic effects. Lipophilic statins can enter cells by 
passive diffusion in contrast to hydrophilic molecules which are unable to penetrate 
the plasma membrane and therefore require a transport mechanism for entry into the 
cells. This involves the Na+-independent organic anion transporting polypeptide 
(OATP) family (Hsiang et al. 1999; Ohtawa et al. 1999) expressed in several tissues: 
intestine, heart, liver, brain, kidney or testis (Hagenbuch and Meier 2003; Konig et al. 
2006). Where these transporters are not expressed, it is possible that statins 
dependent on transport for entry into cells may not be effective. One such statin is 
pravastatin which comprises of a polar hydroxyl group and rosuvastatin, a methane 
sulphonamide group, conferring this molecule its hydrophilicity (McTavish and Sorkin 
1991; McTaggart et al. 2001). These hydrophilic statins target, specially, hepatic 
cells and their lack of effect in other cell types, including smooth muscle cells, have 
been associated with their incapacity to cross cellular membranes (Rosenson and 
Tangney 1998; Schachter 2005). The lipophilic statins such as atorvastatin, 
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simvastatin or fluvastatin are less selective to hepatocytes as they are able to 
transpose membranes of peripheral cells (Schachter 2005). 
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Table 1.2. Percentage of reduction of LDL levels by statins. 
Adapted from (Jones et al. 1998). 
 
Statins/LDL reduction (%) 
Dose (mg) Atorvastatin Pravastatin Simvastatin Fluvastatin Lovastatin 
10 38 19 28 No data No data 
20 46 24 35 17 29 
40 51 34 41 23 32 
80 54 No data 46 36 48 
Solubility Lipophilic Hydrophilic Lipophilic Lipophilic Lipophilic 
 
 55
From the OATP family: OATP1B1, OATP2B1, OATP1A2 and sodium 
dependent taurocholate co-transporting polypeptide (NTCP) are responsible for the 
uptake of statins into hepatocytes (Kivisto and Niemi 2007; Neuvonen et al. 2008). 
Once in the cells, statins are oxidatively modified (hydroxylation) by the cytochrome 
P450 enzymes to a more water-soluble form for renal excretion (Aviram et al. 1998; 
Davidson 2000). Of the 50 CYP450 enzymes, CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, CYP3A4 and CYP3A5 metabolise 90 % of the drugs in humans (Lynch 
and Price 2007). Lovastatin, simvastatin and atorvastatin, like steroid drugs, are 
processed by CYP 3A4 (Davidson 2000).  
Simvastatin and lovastatin lactones are oxidized by CYP3A4 (and CYP3A5) 
into their acidic forms in the intestinal wall and liver (Neuvonen et al. 2008). 
Pravastatin, unlike the other statins, is partially degraded in the stomach (Neuvonen 
et al. 2008). Finally statins are eliminated by their transport from the portal circulation 
to bile through multi-drug resistance associated protein-2 (MRP2), breast cancer 
resistance protein (BCRP) and bile salt export pump (Neuvonen et al. 2008). 
Although the common belief is that statins are well tolerated and don’t have 
dramatic side effects, these drugs may have hepatic and skeletal muscle toxicity with 
increased transaminase levels and may also cause myopathy (weakness and 
muscle pain), that could lead to rhabdomyolysis and renal failure (Chong et al. 
2001). These effects may become more prevalent in the presence of CYP3A4 
inhibitors (Davidson 2000) such as cyclosporin (immunosuppressant), erythromycin 
(arrhythmias medicine), ketoconazole and itraconazole (antifungals), nefazodone 
(antidepressant), mibefradil (calcium channel blocker) and grapefruit juice (Davidson 
2000; Chong et al. 2001). Fluvastatin and pravastatin are less likely to exhibit drug-
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drug interaction, thus making them the safest over the counter statins but they are 
definitely not the most effective at lowering cholesterol (Neuvonen et al. 2008). 
 
 
1.5.3 . Statins and oxidative stress 
 
The antioxidant properties of statins are not fully understood. However in 
macrophages and endothelial cells, involved in the onset and progression of 
atherosclerosis, simvastatin and cerivastatin (withdrawn from the market in 2001) 
blocked the production of free radicals (Terblanche et al. 2007). Statins also induce 
the stress protein HO-1 in rat and human aortic smooth muscle cells (HASMCs) and 
this could contribute in regulating antioxidant and anti-inflammatory events in 
atherosclerosis (Lee et al. 2004). These beneficial effects would have direct 
implications in clinical coronary interventions in patients with high levels of CRP, 
potentially being capable of reducing mortality. 
The induction of HO-1 and subsequent production of CO by HO-1 provides 
protection against oxidative injury, cell death and inhibits cell proliferation 
(Terblanche et al. 2007) and could do this through bilirubin, a potent scavenger of 
free radicals. Moreover, atorvastatin metabolites inhibit lipoprotein oxidation (Aviram 
et al. 1998) and in human mesanglial cells, pitavastatin attenuates high glucose 
induced and Ang-II-induced activation of p42/44 MAP kinase and NADPH oxidase 
activity (Yu et al. 2005). Similarly, statin inhibition of Ang-II-induced stimulation of 
NADPH oxidase derived O2.- production was demonstrated in a monocytes cell line 
(Delbosc et al. 2002; Delbosc et al. 2002). Atorvastatin and pravastatin may also 
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reduce ras-related C3 botulinum toxin substrate 1 (rac1)-GTPase activity and thus 
NADPH oxidase induced ROS production which is dependent on rac1 
(Korantzopoulos et al. 2006). In animal and in vitro experiments, inhibition of rac1 by 
statins inhibits NADPH oxidase related ROS production in VSMCs and cardiac 
myocytes leading to a reduction of cardiac hypertrophy (Maack et al. 2003). 
Furthermore, simvastatin blocked the translocation of p21 rac2 and p67phox, and 
subsequently NADPH oxidase activation, suggesting that this enzyme depends on 
geranylgeranylation for activation (Delbosc et al. 2002). All these effects would again 
be cardio-protective, providing additional beneficial effects beyond simply lowering 
blood cholesterol. 
In endothelial cells, lovastatin and simvastatin induced NO production by 
increasing messenger ribonucleic acid (mRNA) stability (Laufs and Liao 1998). 
Atorvastatin seems to improve the endothelium homeostasis by blunting the p21-Rac 
mediated NADPH oxidase assembly, reducing therefore the production of 
superoxide and increasing NO bioavailability (Wagner et al. 2000). Additionally, this 
statin depresses the expression of NADPH oxidase 1 (Nox1) and p22phox in SMCs 
and endothelial cells respectively, thus highlighting another beneficial action as Nox1 
and p22phox are NADPH subunits that contribute to the production of superoxide in 
the vessel wall (Wassmann et al. 2002). In the same study by Wassmann et al. an 
increase of catalase was detected, further contributing to the antioxidant effects of 
statins (Wassmann et al. 2002). In the same way, simvastatin lessen the oxidation of 
LDL and high density lipoprotein (HDL), the production of pro-inflammatory and 
cytotoxic aldehydes analysed from patients plasma as well as the oxidation of LDL in 
macrophages (Girona et al. 1999). Fluvastatin acts directly as a scavenger of O2.- 
and .OH when tested in rat liver microsomes, inhibiting lipid peroxidation (Yamamoto 
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et al. 1998). A controversial study from Parker at al. suggested that lipophilic statins 
could in some conditions actually impair NO production through eNOS localization 
and promote OS (Parker et al. 2003), where other studies have shown the opposite 
(Ortego et al. 2005; Hofnagel et al. 2007; Adam and Laufs 2008; Singh et al. 2008). 
Whether any of these mechanisms contribute to the regulation of NO production 
and/or CATs is an interesting notion that is to be investigated. 
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1.6 . Aims and objectives  
 
The iNOS-induced NO production may play a complex role in the 
pathogenesis of atherosclerosis. However, the putative role of iNOS, and indeed 
CATs, in the development and clinical expression of atherosclerosis is not yet clear. 
To further intricate the issue, it is even more confusing as to whether iNOS activity 
does in fact cause the observed oxidative damage seen in the disease state and 
whether iNOS and/or CATs expression and/or function may be regulated under OS. 
This thesis was therefore aimed at unravelling how iNOS and CATs 
expression and function may be modified under conditions of OS by examining the 
effects of OS inducers on these proteins in rat cultured aortic smooth muscle cells. 
Smooth muscle cells were chosen for the studies due to their critical physiological 
role in regulating vascular tone, and the fact that some of the deleterious effects of 
OS are targeted at these cells.  
Because of the central role of the endothelium in atherosclerosis it was 
intended that parallel studies would be carried out using endothelial cells isolated 
form porcine aorta. However, because of the restriction in tissue supply it was 
impossible to continue studies with this cell type. The limited data generated with the 
small samples of aortae obtained is presented but unfortunately has not been 
extended.  
Cultured rat aortic smooth muscle cells were used to study the effects of 
oxidative stress inducers: H2O2 (from 0.01 to 1000 mM), antimycin A (25 to 150 µM) 
and DEM (1 to 150 µM). These cells were induced with LPS (100 µg/ml) and (IFN-γ 
100 U/ml) for 24 hours to mimic inflammatory conditions. The induction and 
subsequent production of NO was measured using the Griess assay and the iNOS 
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protein expression detected by western blotting. The levels of L-arginine transport 
into RASMCs were detected using [3H]L-arginine.  
Additionally, studies examining the effects of atorvastatin, simvastatin and 
pravastatin (1 to 100 µM) on both iNOS and CATs function and on iNOS expression 
were also carried out to determine whether the cardio-protective effects of these 
compounds extend to regulating these proteins. Studies were performed over short 
incubation periods, (5 minutes to 3 hours) or over long incubation periods (24 hours 
incubation) when there is full induction of iNOS and the CAT transporters. 
Considering the anti-inflammatory and antioxidant properties of statins, the following 
stage was to co-incubate statins and oxidative stress inducers in our system to 
observe if there was any reversible effect. 
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2 . Methods 
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2.1.1 . Isolation and culture of rat aortic smooth muscle cells 
 
Rat aortic smooth muscle cells (RASMC) were freshly isolated from the aortae 
of male Wistar rats (approximately 250 g) and collected in complete culture medium 
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10 % 
foetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin, as 
initially described by Campbell and Campbell (1993). Each aorta was transferred into 
a Class II tissue culture hood, cleaned of connective and other tissue and cut open 
to expose the lumen which was gently scraped with a scalpel blade to remove the 
layer of endothelial cells. The aorta was then cut into approximately 2 mm sections 
and placed in a T25 flask containing 5 ml of complete culture medium. The flasks 
were initially incubated vertically in a tissue culture incubator (37ºC and 5 % CO2) to 
allow aortic explants to attach following an overnight incubation. Flasks were then 
placed horizontally, ensuring that explants were covered in medium. An extra 5 ml of 
media was added to the explants and incubated for a period of approximately 5 
days. During this period, cells migrated from the explants and proliferated in the 
flask. These cells were subsequently trypsinized (see Section 2.1.4), transferred to a 
T75 flask and allowed to grow to confluency. 
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2.1.2 . Maintenance of cells in culture 
 
Cell cultures were maintained in complete culture medium throughout with the 
medium replenished on alternate days. When required, cells were used for 
experimentation from passage 2 to 6. 
 
 
2.1.3 . Isolation and culture of porcine aortic endothelial cells 
 
 Porcine aortae were collected and maintained in ice-cold DMEM 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 2.5 mg/ml 
gentamycin and 200 µg/ml fungizone. Each aorta was flushed with 1x phosphorous 
buffered saline (PBS) to remove blood and other residues in the lumen before filling 
with 0.5 mg/ml collagenase made up in PBS (1x). Each vessel was incubated for 10 
minutes at 37ºC in a tissue culture incubator. Cell suspension in collagenase was 
collected and centrifuged at 4ºC for 5 minutes at 2000 rpm. The supernatant was 
discarded and the cell pellet resuspended in complete culture medium supplemented 
with gentamycin (0.25 mg/ml) and fungizone (0.02 µg/ml). Cultures were incubated 
over night at 37ºC (5 % CO2) before replacing the medium with the standard 
complete culture medium. This procedure was based on protocols described 
previously by Bogle at al. (1991; 1996). 
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2.1.4 . Trypsinization of cells 
 
Prior to each study, confluent monolayers of cells were trypsinized by 
standard procedure. The spent culture medium was removed and the cell 
monolayers washed twice with PBS (1x) before incubating with 3 ml of 1 % trypsin-
EDTA for 5 minutes, at 37ºC. Each flask was observed at regular intervals over this 
period. Detached cells were resuspended in 5 ml of complete media, further diluted 
as required and then subdivided in cell culture flasks or plated for experimentation. 
Plated monolayers were allowed to grow to confluency before being used in various 
studies. 
 
 
2.2 . Biochemical characterisation of rat aortic smooth muscle 
cells for α-actin 
 
The RASMCs isolated were identified using monoclonal anti-α smooth muscle 
actin antibody and anti-mouse IgG FITC conjugated secondary antibody as 
described by (Skalli et al. 1986). Cells were plated in Lab-Tek® wells at sub-
confluent density and allowed to grow to 80 – 100 % confluency. The cells were then 
washed twice with PBS (1x) to remove media and serum before being fixed with ice-
cold methanol (99.8 %) for 45 seconds and rinsed once with ice-cold PBS (1x). Fixed 
cells were blocked for 20 minutes with a solution containing 5 % bovine serum 
albumin (BSA). A 1:50 dilution of the anti-α actin antibody was made up in blocking 
buffer (10 mM TRIS, 100 mM NaCl, 0.1 % Tween 20 and 5 % fat free milk) and 
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incubated with cells for 1 hour. Following the primary antibody incubation, cells were 
washed four times with PBS (1x), changing every 5 minutes and incubated for one 
hour with an anti-mouse IgG-FITC conjugated secondary antibody diluted 1:50 in 
blocking buffer. Cells were subsequently treated for 15 seconds with 30 % glycerol. 
This procedure was repeated using 50 % and 80 % glycerol solution respectively. 
Finally the cells were mounted in 2 to 3 drops of glycerol (100 %) and a cover slip 
was placed over the cells. A seal was made using nail varnish and visualised under 
the U.V. microscope. 
 
 
2.3 . Experimental procedures 
 
2.3.1 . Induction of nitric oxide synthesis in rat aortic smooth 
muscle cells 
 
 Cells were routinely activated with LPS 100 µg/ml and IFN−γ 100 U/ml by 
replacing spent media with fresh complete media containing LPS and IFN−γ. 
Induction of NO synthesis was determined 24 hours after induction by the Griess 
assay (Section 2.4). 
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2.3.2 . Treatment of cells with oxidative stress inducers 
 
2.3.2.1 . Short-term incubations  
 
Confluent monolayers of cells in 96 well plates were either incubated in 
culture medium alone or in medium containing LPS (100 µg/ml) and IFN-γ (100 U/ml) 
for 21 to 23.5 hours prior to exposure to H2O2 (1 to 1000 µM), diethyl maleate (DEM) 
(5 µM) or antimycin A (100 µM) for periods of 5 to 180 minutes. Activation of cells 
prior to treatment with OS inducers was confirmed by the detection of nitrite 
production using the Griess assay.  
 
For studies involving H2O2, a 20 mM stock solution was initially prepared in 
autoclaved double distilled water (DDW) and then diluted serially in complete or in 
serum-free culture media. In order to determine whether phenol red present in 
DMEM would mask any pro-oxidant action of H2O2 additional dilutions were prepared 
in media lacking phenol red but supplemented with 10 % FBS and 100 U/ml 
penicillin, 100 µg/ml streptomycin. 
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2.3.2.2 . Long-term incubation  
 
Confluent monolayers of cells in 6 or 96 well plates were washed twice with 
PBS (1x) at 37ºC and pre-incubated with either H2O2 (1 to 1000 µM), DEM (1 to 150 
µM) or antimycin A (25 to 150 µM) for 30 minutes before incubating in complete 
culture medium alone or in medium containing LPS (100 µg/ml) and IFN−γ (100 
U/ml) for a further 24 hours. Nitrite production was determined by the Griess assay. 
 
 
2.3.3 . Treatment of cells with statins 
 
Confluent monolayers of cells in 6 or 96 well plates were washed twice with 
PBS (1x) at 37ºC and then incubated with complete media containing atorvastatin, 
pravastatin or simvastatin over the concentration range of 1 - 100 µM for 30 minutes. 
After this incubation period, the cells were activated with LPS (100 µg/ml) and IFN−γ 
(100 U/ml) co-incubated with a select statin for 24 hours. 
Atorvastatin was prepared directly in DMEM at the concentration of 0.4 mM, 
and then serially diluted down to the concentration range of 1 µM to 100 µM. 
Simvastatin was prepared in 75 % ethanol and this solution used to prepare the final 
concentration solutions from 1 µM to 100 µM in complete medium. Pravastatin was 
diluted in sterile DDW at the concentration of 55 mM and in complete DMEM 
subsequently at the required concentrations.  
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2.3.4 . Treatment of cells with statins and oxidative stress 
inducers 
 
Confluent monolayers of cells in 96 well plates were washed twice with PBS 
(1x) at 37ºC and then pre-incubated for 30 minutes with complete media containing 
atorvastatin, pravastatin or simvastatin over the concentration range of 1 - 100 µM. 
Cells were subsequently exposed to DEM (5 and 100 µM) or antimycin A (100 µM) 
for a further 30 minutes prior to activating with LPS (100 µg/ml) and IFN−γ (100 U/ml) 
and co-incubated with the statins for 24 hours. 
When used, H2O2 was prepared initially in sterile MilliQ water at a 
concentration of 100 µM and dilution in DMEM supplemented with FBS at 
concentrations ranging from 0.01 µM to 1000 µM. DEM was prepared initially in 
ethanol 50 % at the concentration of 50 mM and then serially diluted in complete 
medium to obtain concentrations of 5 µM to 150 µM. Antimycin A was diluted in 
ethanol 75% and then in complete DMEM to obtain concentrations ranging from 25 
µM to 150 µM. 
 
 
2.3.5 . Treatment of cells with statins and mevalonate 
 
To determine whether the effects of statins could be reversed by mevalonate, 
confluent monolayers of cells in 96 well plates were washed twice with PBS (1x) at 
37ºC and then pre-incubated for 30 minutes with complete media containing 
mevalonate (10 – 100 µM). A stock concentration of 0.8 mM mevalonate was 
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prepared in 75 % ethanol and subsequently diluted in complete DMEM. The cells 
were then exposed to atorvastatin, pravastatin or simvastatin (each at 10 µM) for a 
further 30 minutes before subsequent activation with LPS (100 µg/ml) and IFN−γ 
(100 U/ml) for 24 hours. 
 
 
2.4 . Measurement of nitric oxide production 
 
Nitric oxide production was measured by the standard Griess assay (Green et 
al. 1982) as described by Wileman et al. (1995). This assay relies on a diazotization 
reaction that was originally described by Griess in 1879 and detects NO2– in solution 
as shown in Figure 2.1.. In our studies, a 100 µl of media was removed from each 
well and transferred to the inner wells of a new 96 well plate. For studies carried out 
in 6 well plates, 100 µl of media was removed from each well in triplicates and 
transferred to a new 96 well plate. Sodium nitrite standards (1 to 10 pmoles/well) 
made up in complete culture medium were transferred to the outer wells and all 
samples were incubated at room temperature for 15 minutes with 100 µl of Griess 
reagent (2 % sulfanilamideamine and 0.2 % napthylethylenediamine plus 10 % 
phosphoric acid). The absorbance of each well was read at 540 nm on a microplate 
Multiskan Ascent (Labsystems) reader and the levels of nitrite in the media from cells 
determined using the standard curve constructed. A representative sodium nitrite 
standard curve is shown in Figure 2.2. 
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Figure 2.1. Detection of NO2– in solution by the Griess assay.  
Nitrite is diazotized in sulfanilic acid and the product is then azo coupled with 1-
naphthylamine to produce a coloured chromophore. 
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Figure 2.2. A representative nitrite standard curve.  
Standards ranging from 1 to 10 pmoles per well were prepared in complete culture 
medium. A 100 µl aliquot from each standard was added in triplicate to the outer 
wells of a 96 well plate and incubated for 15 minutes with an equal volume of the 
Griess reagent. Absorbance values were taken at 540 nm on a Multiskan Ascent 
(Labsystems) plate reader. The data shown is the mean of three replicates for each 
concentration. 
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2.5 . Protein quantification using bicinchoninic acid 
 
The bicinchoninic acid assay (BCA) is based on the Biuret reaction and 
chelation of a cuprous cation as shown in Figure 2.3.. The method combines the 
reduction of Cu+2 to Cu+1 by protein in an alkaline medium with the highly sensitive 
and selective colorimetric detection of the chelation of Cu+1 by the BCA reagent to 
form a purple-coloured product. 
 
For the determination of total cell protein in our studies, 50 µl of DDW was 
added to each well containing cells. Protein standards (1 to 30 µg/ml) were made 
from a 1 mg/ml bovine serum albumin (BSA) stock solution in DDW and 50 µl of 
each standard was added in triplicates to the outer wells of the plate. The BCA 
reagent was prepared as instructed by the manufacturers by mixing BCA reagent B 
plus BCA reagent A at a ratio of 1/20 (v/v). A 100 µl aliquot of the reagent was added 
to each well and the plate incubated with mild shaking for 40 minutes and read at 
620 nm on a Multiskan Ascent (Labsystems) plate reader. The absorbance values of 
the samples were converted to protein using the BSA standard curve constructed 
(Figure 2.4.). For the western blot protein quantification, 5 µl aliquot of each sample 
was taken and added to 50 µl of double distilled water in the inner wells of a 96 well 
plate. A 5 µl aliquot of lysis buffer was also added to each protein standard in the 
outer wells prior to adding 100 µl of the BCA reagent. Absorbance readings were 
read on a plate reader after 40 minutes at 620 nm. 
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Figure 2.3. Protein detection method by the BCA method.  
The peptides bind and reduce Cu2+ ions from the cupric sulfate to Cu1+. The amount 
of Cu2+ reduced is proportional to the amount of protein present in the solution. Two 
molecules of bicinchoninic acid chelate with each Cu1+ ion, forming a purple-
coloured product that strongly absorbs light at a wavelength of 620 nm. 
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Figure 2.4. A representative protein standard curve. 
Standards of bovine serum albumin (BSA) ranging from 1 to 30 µg per well were 
prepared in DDW. A 50 µl aliquot from each standard was added in triplicate to the 
outer wells of a 96 well plate and incubated for 45 minutes with 100 µl of the BCA 
reagent. Absorbance values were taken at 620 nm on a Multiskan Ascent 
(Labsystems) micro plate reader. The data shown is the mean of three replicates for 
each concentration. 
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2.6 . Measurement of [3H]L-arginine transport into cells 
 
Transport of [3H]L-arginine was performed as described by Wileman et al. 
(1995). Briefly, plates were washed twice with 200 µl Krebs buffer (131 mM NaCl, 
5.6 mM KCl, 25 mM NaHCO3, 1 mM NaH2PO4, 5.5 mM D-glucose, 20 mM HEPES, 1 
mM MgCl2, 2.5 mM CaCl2) at 37ºC. Transport was initiated by the addition of 50 µl of 
transport buffer (Krebs buffer containing 1 µCi/ml [3H]L-arginine plus 100 µM 
unlabelled L-arginine) to the cells at 37oC. 
In time-course studies, cells were incubated with the transport buffer for 
varying periods ranging from 30 seconds to 60 minutes. All other experiments were 
carried out over 2 minutes. The uptake of L-arginine is linear at this time point, 
allowing for the analysis of transport rates under unidirectional flux. At the end of the 
incubation period, transport was terminated by placing the plates on ice and washing 
3x with ice-cold Krebs buffer containing 10 mM L-arginine. The plates were kept on 
ice until analysed for protein content. 
The protein quantification was performed as described above (section 2.5) 
and the content of each well was transferred into a scintillation vial. Scintillation liquid 
(4 ml) was added to each vial, mixed on a vortex and counted on a Beckman 
CoulterTM LS6500 β-scintillation counter. Blank disintegrations per minute (DPMs) 
were subtracted from each sample and the remaining DPMs converted to pmoles of 
L-arginine/µg protein/minute. The DPM value obtained from each sample was 
divided by the corresponding µg of protein (detected previously as described in 
section 2.5) and by the duration of incubation. 
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2.7 . Western blot analysis of inducible nitric oxide synthase and 
heme oxygenase-1 expression 
 
Rat cultured smooth muscle cells were plated in 6 well plates and allowed to 
grow to confluency prior to treatment with drugs. At the end of the treatment period, 
wells were washed with ice-cold PBS and the cells lysed with 200 µl of lysis buffer 
(10 mM TRIS, 10 % sodium dodecyl sulphate (SDS), pH 7.4) containing 200 µM 
sodium orthovanadate (Na3VO4), 200 µM phenyl methyl sulfonyl fluoride (PMSF) and 
1 mM sodium fluoride (NaF). The cells were scraped and transferred into an 
eppendorf tube. The samples were heated at 95ºC for 5 minutes and sonicated three 
times for 30 seconds. The protein quantification was performed as described above 
(Section 2.5). Samples were subsequently diluted with a 1:1 volume of loading buffer 
(250 µM TRIS, 4 % SDS, 10 % glycerol, 2 % β-mercaptoethanol, 0.006 % 
bromophenol blue, pH 6.8). 
Samples were loaded onto a mini gel (stacking gel: 0.5 M TRIS, 4 % 
acrylamide, 10 % SDS, 10 % APS, 6.6 mM TEMED, pH 6.8; resolving gel: 1.5 M 
TRIS, 12 or 8 % acrylamide, 10 % SDS, 10 % ammonium persulphate (APS), 4 mM 
TEMED, pH 8.8) and run at 100 V for approximately 60 minutes. The proteins in the 
gel were then transferred to a polyvinylidene difluoride (PVDF) membrane that was 
pre-soaked in methanol (99.8+%) for 15 seconds prior to blotting. The membrane 
was placed in the transfer cells on a blotting filter paper followed by the gel and a 
second filter paper (see Figure 2.5. ). The proteins were transferred for 90 to 150 
minutes at 140 mA per cm2 of membrane. The gel was stained in Coomassie brilliant 
blue reagent (0.1 % (w/v) Coomassie blue R350, 20 % (v/v) methanol, and 10 % 
(v/v) acetic acid) to check the efficiency of protein transferred to the membrane. The 
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gel was then incubated in destaining solution (50 % (v/v) methanol in water with 10 
% (v/v) acetic acid). The membrane itself was blocked in blocking buffer (10 mM 
TRIS, 100 mM NaCl, 0.1 % Tween 20 and 5 % fat free milk) for a minimum of 60 
minutes at room temperature with mild shaking, to prevent non-specific binding of 
antibodies to the membrane. An anti-iNOS monoclonal antibody was diluted in 
blocking buffer 1:2500 and incubated with the membrane over night. For detection of 
HO-1, a mouse monoclonal anti HO-1 antibody was diluted in blocking buffer 1:250 
and incubated with the membrane for 48 hours at 4 ºC. An anti-β actin monoclonal 
antibody diluted 1:5000 was also added to the membrane to detect β-actin, except 
for experiments detecting HO-1. The latter was used to determine the equal loading 
of samples into the wells. The membrane was washed for 30 minutes, changing 
washing buffer (10 mM TRIS, 100 mM NaCl, pH 7.5) every 5 minutes. This was 
followed by further incubation of the membrane with the secondary antibody (goat 
polyclonal to mouse IgG) diluted 1:5000 dilution in blocking buffer. A horse radish 
peroxidase (HRP)-conjugate secondary antibody to the molecular weight marker 
diluted 1:500 was also used. These antibodies were incubated with membranes for 
60 minutes. At the end of this incubation period, the membrane was again washed 
for 30 minutes changing washing buffer every 5 minutes. Protein bands were 
detected using the enhanced chemiluminescence (ECL) detection method. 
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Figure 2.5. Transfer to PVDF membrane. 
Scheme of protein transfer from the gel to the PVDF membrane in the semi-dry 
transfer cell. 
 
 
Blotting filter paper 
8% or 12% Gel  
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2.8 . Determination of cell viability by the MTT assay 
Cell viability was routinely determined by monitoring the metabolism of 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to purple formazan by 
viable cells (See Figure 2.6. ). This reduction takes place only when mitochondrial 
reductase enzymes are active, and thus conversion is directly related to the number 
of viable cells. The production of purple formazan in cells treated with an agent is 
measured relative to the production in control cells. 
 In our experiments, confluent monolayers of cells were treated according to 
the designated experimental protocol and then exposed to MTT. A 20 µl aliquot of 
0.5 mg/ml stock solution of MTT was added to cells and the plate incubated for 4 
hour at 37ºC in a tissue culture incubator. Isopropanol (100 µl) was subsequently 
added to each well and incubated for a further 10 minutes. The plate was read at 
540 nm, after mixing on the plate shaker. 
 
 
2.9 . Statistical analysis 
 The data is normally the mean+ standard error mean (S.E.M.) of at least three 
independent experiments with 3 or 6 replicates per experiments unless otherwise 
stated. Where indicated, statistical analysis was carried out using the Mann-Whitney 
test, a one way ANOVA and a two way ANOVA test. 
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Figure 2.6. Metabolism of MTT to formazan by cells in culture.  
Yellow MTT is reduced to purple formazan in living cells by common coenzymes 
NADH and NADPH that absorb U.V. light in their reduced forms, but do not in their 
oxidised forms. An ethanol solution, is added to dissolve the insoluble purple 
formazan product into a coloured solution. The absorbance of this coloured solution 
can be quantified by measuring at a certain wavelength (540 nm). The metabolism 
by mitochondrial reductase into purple formazan was described by (Mosmann 1983). 
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3 . Results 
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3.1 . Biochemical characterization of rat cultured aortic smooth 
muscle cells 
 
The characteristics of the cells isolated from rat or porcine aorta were 
determined morphologically. Rat aortic smooth muscle cells (RASMCs) were further 
biochemically characterized to ensure that studies were carried out on the required 
cell type. As described in the methods, SMCs were identified by staining for α-actin. 
As shown in Figure 3.1A, the confluent smooth muscle layer appear epithelioid in 
morphology consistent with a population of SMCs described in previous reports 
(Groves et al. 2005; Orlandi et al. 2005). The porcine aortic endothelial cells 
(PAECs) appeared cobbled-stoned but with the increase of passage number turned 
more elongated (Figure 3.1B). 
 Further biochemical characterisation revealed the positive α-actin staining of 
the SMCs (Figure 3.2). Moreover, cross staining of these cells with dil-labelled-
acetylated-low density lipoprotein (Dil-Ac-LDL) (Voyta et al. 1984) did not show any 
positive staining for endothelial cells suggesting pure populations of smooth muscle 
cultures with little or no cross contamination. 
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Figure 3.1. Morphology of rat cultured aortic smooth muscle cells (A), and 
porcine aortic endothelial cells (B). 
Freshly isolated cells were cultured to confluency in a T-75 tissue culture flask as 
described in methods and then viewed under an inverted light microscope at 100X 
magnification. 
A B
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Figure 3.2. α-actin staining of rat cultured aortic smooth muscle cells. 
Confluent cultures of rat aortic smooth muscle cells in Lab-Tek® wells were treated 
for α-actin staining as described in the Methods (Section 2.2) and viewed under U.V. 
microscope using a FITC filter at 400X magnification. The above picture is 
representative of at least three separate experiments carried out. 
 
A
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3.2 . Characterisation of L-arginine transport in porcine cultured 
aortic endothelial cells 
 
Studies were carried out to determine the characteristics of the transporter(s) 
responsible for L-arginine uptake in these cells. This information is currently not 
available in the literature and is required in order to have a better understanding of 
the precise transporter potentially regulated by OS in cardiovascular disease states. 
Thus, experiments were aimed at determining the time-course and kinetic of uptake. 
Although cross-inhibition studies were planned to identify the transporters associated 
with L-arginine uptake, these experiments were not carried out because of the lack 
of subsequent aortae supply. 
Represented in Figure 3.3 is the time-course of uptake of [3H]L-arginine into 
PAECs. As shown in the graph, L-arginine was transported in a time-dependent 
manner, saturating at 60 minutes. This is consistent with studies in other cell types 
including RASMCs (Wileman et al. 1995). Kinetic analysis revealed that L-arginine 
uptake is not saturable even when substrate concentrations of up to 5 mM were 
used (Figure 3.4). This would indicate the expression of a high capacity carrier but 
further studies are required to conclusively demonstrate it. 
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Figure 3.3. Time-course of L-arginine transport in PAECs. 
Confluent monolayers of PAECs in 96 well plates were incubated with 100 µM L-
arginine plus 1 µCi/ml [3H]L-arginine for the time periods shown on the graph. 
Incubations were terminated after each time point and the cells processed as 
described in the Methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. 
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Figure 3.4. Kinetics of L-arginine transport in PAECs. 
Confluent monolayers of PAECs in 96 well plates were incubated with transport 
buffer containing the concentrations of L-arginine indicated on the graph plus 1 
µCi/ml [3H]L-arginine. Incubations were terminated after 2 minutes and the cells 
processed as described in the Methods (Section 2.6). The data represents the mean 
± S.E.M. of at least 3 separate experiments with 3 replicates in each. 
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3.3 . Effect of H2O2 on L-arginine transport in porcine cultured 
aortic endothelial cells 
 
Cells were pre-exposed in an initial study to 0.01 – 100 µM of H2O2 but as 
these concentrations were found to have little or no effect (Figure 3.5), further 
experiments were carried out using H2O2 at 10 – 1000 µM and in the presence and 
absence of 10 % serum for periods ranging from 5 minutes to 180 minutes prior to 
initiating transport (Figure 3.6). The data represent single experiments and shows 
some degree of variability between conditions. Thus, it is difficult to draw any definite 
conclusions at this stage without increasing the n values. However, the indication 
from the preliminary data is that H2O2 may suppress L-arginine uptake when 
incubated with cells for 180 minutes at 1 mM. Preliminary cytotoxicity assays 
revealed that H2O2 may be cytotoxic at this concentration (Figure 3.7) and the effects 
observed may therefore be non-specific. 
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Figure 3.5. Time and concentration dependent effects of H2O2 on L-arginine 
transport in PAECs. 
Confluent monolayers of PAECs in 96 well plates were incubated in complete culture 
medium and exposed to increasing concentrations of H2O2 for periods of 5 (Panel A), 
15 (Panel B), 30 (Panel C), 60 (Panel D) and 180 (Panel E) minutes. L-arginine 
transport was carried out as described in the Methods (Section 2.6). The data 
represents the mean ± S.E.M. of at least 3 separate experiments with 3 replicates in 
each. 
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Figure 3.6. Time and concentration dependent effects of H2O2 on L-arginine 
transport in control and activated PAECs in complete media or without FBS. 
Confluent monolayers of PAECs in 96 well plates were either incubated in complete 
culture medium (Controls) or culture medium with 0 % FBS. Exposure to increasing 
concentrations of H2O2 was performed for periods of 5 (Panel A), 15 (Panel B), 30 
(Panel C), 60 (Panel D) and 180 (Panel E) minutes. Transport of [3H]L-arginine was 
initiated and monitored as described in the methods (Section 2.6). The data 
represents the mean ± S.D. of one single experiment with at least 3 replicates in 
each condition. 
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Figure 3.7. Effects of H2O2 on viability of PAECs. 
Confluent monolayers of PAECs in 96 well plates were either incubated in complete 
culture medium (Controls) or culture medium with 0 % FBS. Exposure to increasing 
concentrations of H2O2 was performed for periods of 5 (Panel A), 15 (Panel B), 30 
(Panel C), 60 (Panel D) and 180 (Panel E) minutes. Cell viability was monitored as 
described in the methods (Section 2.8). The data represents the mean ± S.D. of one 
single experiment with at least 3 replicates in each condition. 
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3.4 . Induction of nitric oxide synthesis and L-arginine transport in 
rat cultured aortic smooth muscle cells 
 
Confluent monolayers of RASMCs in 96 well plates were incubated with either 
complete culture medium alone or with medium containing LPS (100 µg/ml) and IFN-
γ (100 U/ml) for 24 hours. As expected, exposure of cells to LPS and IFN-γ resulted 
in the induction of NO synthesis. Consistent with many other studies, control 
RASMCs produced very little detectable nitrite (approximately 0.01 pmol/µg 
protein/24 hours) but the latter was significantly induced with average levels of 0.1 
pmol/µg protein/24 hours being detected following exposure to LPS and IFN-γ. 
In parallel with the induction of iNOS, L-arginine transport was also 
significantly increased in cells exposed to LPS and IFN-γ with rates increasing from 1 
pmoles/µg protein/minute in controls to 2 pmoles/µg protein/minute in activated cells. 
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Figure 3.8. Effects of LPS and IFN-γ on transport in RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were either incubated in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml) for at least 21 hours prior to transport studies. Transport of [3H]L-
arginine was initiated and monitored as described in the methods (Section 2.6). 
Values are expressed as the mean ± S.E.M. of 3 separate experiments with at least 
3 replicates in each. *denotes p<0.0001 when compared to the control. 
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3.5 . Effects of oxidative stress inducers on L-arginine transport 
and NO production in rat cultured aortic smooth muscle cells 
 
 
3.5.1 . Effects of acute exposure to oxidative stress inducers 
 
In order to determine the effects of H2O2 on both control and induced 
transporter activity, cells were exposed to LPS and IFN-γ for at least 21 hours before 
exposure to H2O2 at concentrations of 10 to 1000 µM for periods of 5, 15, 30, 60 and 
180 minutes prior to carrying out transport studies. Induction of cells was confirmed 
by determining nitrite levels in the culture medium 21 hours after activation. 
Activation of cells was successfully achieved in the experiments presented. 
H2O2 was able to inhibit L-arginine transport in both control and activated cells 
but only when applied at a concentration of 1 mM and for 180 minutes prior to 
initiating transport. Under these conditions transport rates were inhibited by 66+23 % 
in control and 54+5 % in activated cells respectively (Figure 3.9). H2O2 was however 
without effect at any of the other conditions or concentrations used (Figure 3.9 A-D). 
Moreover, the inhibitions caused by H2O2 (1 mM; 180 minutes pre-incubation) may 
reflect a non selective cytotoxic effect as this was associated with a marked 
decrease in viability in both control and activated cells (Figure 3.10 E). 
Phenol red is known to possess antioxidant properties (Grzelak et al. 2001; 
Briante et al. 2003; Lewinska et al. 2007), which may mask the effects of H2O2. 
Similarly, FBS may quench free radicals, thereby preventing any actions of oxidative 
stress inducers (Grzelak et al. 2001; Lewinska et al. 2007). Thus parallel 
 98
experiments were performed in media lacking FBS (Figure 3.11), phenol red (Figure 
3.13) or both (Figure 3.14). As shown in Figure 3.11 and 21, removal of either 
component from the culture medium did not significantly alter the effects of H2O2 on 
L-arginine transport. Elimination of both FBS and phenol red did not show inhibition 
of transport when either control or activated cells were subsequently exposed to 
H2O2 (Figure 3.14). Omitting FBS from the culture medium did not cause any 
significant cytotoxicity to the cells (Figure 3.12). 
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Figure 3.9. Time and concentration dependent effects of H2O2 on L-arginine 
transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were either incubated in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml) for at least 21 hours prior to exposure to increasing concentrations 
of H2O2 for periods of 5 (Panel A), 15 (Panel B), 30 (Panel C), 60 (Panel D) and 180 
(Panel E) minutes. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. 
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Figure 3.10. Time and concentration dependent effects of H2O2 on viability of 
RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were either incubated in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml) for at least 21 hours prior to exposure to increasing concentrations 
of H2O2 for periods of 5 (Panel a), 15 (Panel B), 30 (Panel C), 60 (Panel D) and 180 
(Panel E) minutes. Cell viability was monitored as described in the methods (Section 
2.8). The data represents the mean ± S.E.M. of at least 3 separate experiments with 
3 replicates in each. 
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Figure 3.11. Time and concentration dependent effects of H2O2 on L-arginine 
transport in control and activated RASMCs in media without FBS. 
Confluent monolayers of RASMCs in 96 well plates were incubated in culture 
medium in the absence (Controls) and presence of LPS (100 µg) and IFN-γ (100 
U/ml) for at least 21 hours prior to exposure to FBS-free culture medium containing 
increasing concentrations of H2O2 for periods of 5 (Panel A), 15 (Panel B), 30 (Panel 
C), 60 (Panel D) and 180 (Panel E) minutes. Transport of [3H]L-arginine was initiated 
and monitored as described in the methods (Section 2.6). The data represents the 
mean ± S.E.M. of at least 3 separate experiments with 3 replicates in each.  
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Figure 3.12. Time and concentration dependent effects of H2O2 on viability of 
RASMCs in media without FBS.  
Confluent monolayers of RASMCs in 96 well plates were incubated culture medium 
in the absence (Control) and presence of LPS (100 µg) and IFN-γ (100 U/ml) for at 
least 21 hours prior to exposure to FBS-free culture medium containing increasing 
concentrations of H2O2 for periods of 5 (Panel a), 15 (Panel B), 30 (Panel C), 60 
(Panel D) and 180 (Panel E) minutes. Cell viability was monitored as described in 
the methods (Section 2.8). The data represents one single experiment with at least 3 
replicates. 
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Figure 3.13. Time and concentration dependent effects of H2O2 on L-arginine 
transport in control and activated RASMCs in media without phenol red. 
Confluent monolayers of RASMCs in 96 well plates were incubated in culture 
medium in the absence (Controls) and presence of LPS (100 µg) and IFN-γ (100 
U/ml) for at least 21 hours prior to exposure to phenol red-free culture medium 
containing increasing concentrations of H2O2 for periods of 5 (Panel A), 15 (Panel B), 
30 (Panel C), 60 (Panel D) and 180 (Panel E) minutes. Transport of [3H]L-arginine 
was initiated and monitored as described in the methods (Section 2.6). The data 
represents the mean ± S.E.M. of at least 3 separate experiments with 3 replicates in 
each.
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Figure 3.14. Time and concentration dependent effects of H2O2 on L-arginine 
transport in control and activated RASMCs in media without FBS or phenol 
red. 
Confluent monolayers of RASMCs in 96 well plates were incubated in culture 
medium in the absence (Controls) and presence of LPS (100 µg) and IFN-γ (100 
U/ml) for at least 21 hours prior to exposure to increasing concentrations of H2O2 for 
periods of 5 (Panel A), 15 (Panel B), 30 (Panel C), 60 (Panel D) and 180 (Panel E) 
minutes, in media without FBS and phenol red. Transport of [3H]L-arginine was 
initiated and monitored as described in the methods (Section 2.6). The data 
represents the mean ± S.E.M. of at least 3 separate experiments with 3 replicates in 
each. 
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The marginal effects with H2O2 would indicate that neither NO production nor 
L-arginine transport may be strongly regulated by OS. To confirm this, further studies 
were carried inducing OS using either antimycin A, an antibiotic that blocks electron 
transfer flow in Complex III in the mitochondrial respiratory chain (Izzo et al. 1978; 
Pietrobon et al. 1981), or DEM, an electrophile that alkylates the sulfhydryl group of 
glutathione, thereby blocking its function (Miccadei et al. 1988). 
As in the previous experiments, cells were induced with LPS (100 µg) and 
IFN-γ (100 U/ml) for at least 21 hours prior to the incubation with either antimycin A 
(100 µM) or DEM (5 µM) for periods ranging from 5 minutes to 180 minutes. 
Transport of L-arginine was subsequently performed as described on section 2.6. 
Under these conditions neither antimycin A nor DEM caused any significant changes 
on L-arginine transport in control and activated cells (Figure 3.15 and Figure 3.16). 
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Figure 3.15. Effect of antimycin A on L-arginine transport in control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were incubated in culture 
medium in the absence (Controls) and presence of LPS (100 µg) and IFN-γ (100 
U/ml) for at least 21 hours prior to exposure to antimycin A (100 µM) for the time 
points shown on the graph. Transport of [3H]L-arginine was initiated and monitored 
as described in the methods (Section 2.6). The data represents the mean ± S.E.M. 
of at least 3 separate experiments with 3 replicates in each. 
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Figure 3.16. Effect of DEM on L-arginine transport in control and activated 
RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were either incubated in culture 
medium in the absence (Controls) and presence of LPS (100 µg) and IFN-γ (100 
U/ml) for at least 21 hours prior to exposure to DEM 5 µM during the time points (5, 
15, 30, 60 and 180 minutes). Transport of [3H]L-arginine was initiated and monitored 
as described in the methods (Section 2.6). The data represents the mean ± S.E.M. 
of at least 3 separate experiments with 3 replicates in each. 
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3.5.2 . Effects of chronic exposure to oxidative stress inducers 
 
In parallel with the above studies, additional experiments were carried out 
examining whether prolonged pre-exposure to H2O2, antimycin A or DEM would alter 
transporter activity. For these studies, H2O2 was used at a concentration of 300 µM 
which may regulate L-arginine transport without causing marked cytotoxicity (Figure 
3.19), and was pre-incubated with RASMCs for 30 minutes prior to incubation with 
complete medium alone or with medium containing LPS (100 µg/ml) and IFN-γ (100 
U/ml) for 24 hours. Under these conditions H2O2 caused a slight decrease in 
accumulated nitrite levels (Figure 3.17) and only marginally reduced induced L-
arginine transport rates (Figure 3.18). A lower concentration of 100 µM was without 
effect (data not shown). Experiments with higher concentrations were not carried out 
due to cytotoxicity cause at 1 mM and above. In parallel with H2O2, pre-incubation of 
cells with antimycin A (25 µM -150 µM) or DEM (1 µM - 25 µM) caused a 
concentration dependent inhibition of induced NO synthesis which was virtually 
abolished with 150 µM antimycin A (Figure 3.20) or 25 µM DEM (Figure 3.22). Both 
compounds also concentration-dependently inhibited induced transporter activity, 
reducing the latter back to the control non-activated levels at ≥100 µM. Basal 
transport rates remained virtually unaltered (Figure 3.21 and Figure 3.23) and neither 
compound showed any cytotoxicity even at the highest concentrations used (Figure 
3.24 and Figure 3.25). It is worth noting that the inhibition of induced L-arginine 
transport by DEM occurred at concentrations much higher than those required to 
inhibit NO synthesis (Figure 3.23). This would suggest that induced transporter 
activity may be less sensitive to DEM. Alternatively, DEM may be mediating these 
 115
effects (i.e. inhibition of NO synthesis and induced transporter activity) via different 
mechanisms which are yet to be determined.  
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Figure 3.17. Effect of H2O2 on nitrite production in control and activated 
RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with H2O2 at the concentrations shown on the graph. 
Cells were subsequently incubated in complete culture medium alone (Controls) or in 
medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 24 hours. Nitrite 
production was monitored as described in the methods (Section 2.4). The data 
represents the mean ± S.E.M. of at least 3 separate experiments with 3 replicates in 
each. 
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Figure 3.18. Effect of H2O2 on L-arginine transport in control and activated 
RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with H2O2 at the concentrations shown on the graph. 
Cells were subsequently incubated in complete culture medium alone (Controls) or in 
medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 24 hours. 
Transport of [3H]L-arginine was determined in the cell monolayer as described in the 
methods (Section 2.6). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. 
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Figure 3.19. Effect of H2O2 on viability in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with H2O2 at the concentrations shown on the graph. 
Cells were subsequently incubated in complete culture medium alone (Controls) or in 
medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 24 hours. Cell 
viability was monitored as described in the methods (Section 2.8). The data 
represents the mean ± S.E.M. of at least 3 separate experiments with 3 replicates in 
each. 
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Figure 3.20. Effect of antimycin A on nitrite production in control and activated 
RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with antimycin A at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours. Nitrite production was monitored as described in the methods (Section 
2.4). The data represents the mean ± S.E.M. of at least 3 separate experiments with 
3 replicates in each. *denotes p<0.05 when compared to the activated control. 
*
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Figure 3.21. Effect of antimycin A on L-arginine transport in control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with antimycin A at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours Transport of [3H]L-arginine was determined in the cell monolayer as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. *denotes p<0.05 when 
compared to the activated control. 
*
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Figure 3.22. Effect of DEM on nitrite production in control and activated 
RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with DEM at the concentrations shown on the graph. 
Cells were subsequently incubated in complete culture medium alone (Controls) or in 
medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 24 hours. Nitrite 
production was monitored as described in the methods (Section 2.4). The data 
represents the mean ± S.E.M. of at least 3 separate experiments with 3 replicates in 
each. *denotes p<0.05 when compared to the activated control. 
*
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Figure 3.23. Effect of DEM on L-arginine transport in control and activated 
RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with DEM at the concentrations shown on the graph. 
Cells were subsequently incubated in complete culture medium alone (Controls) or in 
medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 24 hours. 
Transport of [3H]L-arginine was determined in the cell monolayer as described in the 
methods (Section 2.6). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. *denotes p<0.05 when compared to the 
activated control. 
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Figure 3.24. Effect of antimycin A on viability in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with antimycin A at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours. Cell viability was monitored as described in the methods (Section 2.8). The 
data represents the mean ± S.E.M. of at least 3 separate experiments with 3 
replicates in each. 
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Figure 3.25. Effect of DEM on viability in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with DEM at the concentrations shown on the graph. 
Cells were subsequently incubated in complete culture medium alone (Controls) or in 
medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 24 hours. Cell 
viability was monitored as described in the methods (Section 2.8). The data 
represents the mean ± S.E.M. of at least 3 separate experiments with 3 replicates in 
each. 
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3.5.3 . Does the regulation of NO synthesis and/or L-arginine 
transport by antimycin A or DEM occur at the functional or 
expression levels? 
 
To determine whether the effects described above were mediated via direct 
inhibition or through regulation of the induction of either NOS and/or transporter 
activity, additional experiments were carried out exposing cells to antimycin A (150 
µM) or DEM (150 µM) either 30 minutes prior to, or at different time points (3, 6, 9 
and 18 hours) after activation with LPS (100 µg) and IFN-γ (100 U/ml). Changes in 
NO production and in L-arginine transport were assessed 24 hours after activation. 
As shown in Figure 3.26, addition of antimycin A for 30 minutes prior to or for up to 3 
hours after activation of cells resulted in a marked inhibition of NO synthesis. In 
contrast, when added at 6 hours or later, antimycin A failed to cause any statistically 
significant change in NO production (Figure 3.26). By comparison, L-arginine 
transport remained suppressed unless when antimycin A was added 18 hours after 
exposure of cells to LPS (100 µg) and IFN-γ (100 U/ml) (Figure 3.27). Similarly, 
addition of DEM 18 hours after activation of cells failed to inhibit NO synthesis 
(Figure 3.28) or L-arginine transport (Figure 3.29) but caused marked inhibition of 
both processes when added at the earlier time points where the iNOS and CAT 
genes may not have been fully induced. Nitric oxide production after exposure to 
DEM was affected by concentrations as low as 1 µM (Figure 3.22) but L-arginine 
transport was less susceptible and only affected by concentrations higher than 100 
µM in induced cells (Figure 3.23). Initially, NO production was also examined using 
DEM at 25 µM to 150 µM (data not shown) and was completely inhibited even at the 
 126
25 μM concentration. The expression of iNOS on the other hand decreased in a 
concentration dependent manner from 25 µM and was completely abolished at 150 
µM (Figure 3.32). 
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Figure 3.26. Time dependent effects of antimycin A on nitrite production in 
control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were incubated for 24 hours 
either in culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml). When applied, antimycin A (150 µM) was added at the time points 
shown on the graph. Nitrite production was monitored as described in the methods 
(Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. *denotes p<0.05 when compared to the 
activated control. 
*
 128
 
 
C -0.5 0 3 6 9 18
0
50
100
150
200
Control
LPS & IFN-γ
Time points (hours)
[3
H
]L
-a
rg
in
in
e 
tr
an
sp
or
t
(%
 o
f C
on
tr
ol
)
 
 
 
Figure 3.27. Time dependent effects of antimycin A on L-arginine transport in 
control and activated RASMC. 
Confluent monolayers of RASMCs in 96 well plates were incubated for 24 hours 
either in culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml). When applied, antimycin A (150 µM) was added at the time points 
shown on the graph. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. *denotes p<0.05 when 
compared to the activated control. 
*
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Figure 3.28. Time dependent effects of DEM on nitrite production in control 
and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were incubated for 24 hours 
either in culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml). When applied, DEM (150 µM) was added at the time points shown 
on the graph. Nitrite production was monitored as described in the methods (Section 
2.4). The data represents the mean ± S.E.M. of at least 3 separate experiments with 
3 replicates in each. *denotes p<0.05 when compared to the activated control. 
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Figure 3.29. Time dependent effects of DEM on L-arginine transport in control 
and activated RASMC. 
Confluent monolayers of RASMCs in 96 well plates were incubated for 24 hours 
either in culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml). When applied, DEM (150 µM) was added at the time points shown 
on the graph. Transport of [3H]L-arginine was initiated and monitored as described in 
the methods (Section 2.6). The data represents the mean ± S.E.M. of at least 3 
separate experiments with 3 replicates in each. *denotes p<0.05 when compared to 
the activated control. 
*
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3.6 . Effects of oxidative stress inducers on iNOS protein 
 
As a follow on to the time-course studies, experiments were carried out 
investigating changes in iNOS protein expression in order to confirm that the actions 
described for the oxidative stress inducers were in fact mediated via suppression of 
the expression of this enzyme. Studies looking at the CATs were not carried out as 
specific antibodies against these proteins are currently not commercially available. 
There was no detectable expression of iNOS in control non-activated cells. 
Exposure to LPS and IFN-γ did however cause a marked increase in the expression 
of iNOS which was inhibited by about 50 % in the presence of H2O2 at a 
concentration of 300 µM (Figure 3.30). This contrasts with the effects of H2O2 on NO 
production where only marginal inhibitions were observed. Antimycin A also 
suppressed iNOS protein expression but this was only significant at 150 µM. 
Although partial inhibitions were seen with the lower concentrations, these were not 
concentration dependent nor significantly different from the control activated samples 
(Figure 3.31). These results do not correlate well with the concentration dependent 
decrease in NO production reported for the functional studies above (Figure 3.20). 
Exposure of cells to DEM concentration-dependently suppressed iNOS expression 
but, unlike the changes seen with NO production (Figure 3.22), iNOS expression 
was not abolished except at concentrations ≥100 μM (Figure 3.32). The reasons for 
the discrepancies between the effects of these compounds on NO production and 
iNOS expression are currently not known but it is likely that the action of some 
compounds on NO production may not only reside in blocking the induction of iNOS 
but potentially also in regulating the function of the expressed enzyme. 
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Figure 3.30. Effect of H2O2 on expression of inducible NOS in control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 6 well plates were pre-treated for 30 minutes 
with H2O2 at the concentrations shown on the graph prior to activation with LPS (100 
µg) and IFN-γ (100 U/ml) for 24 hours. Lysates were generated and analysed by 
western blotting as described in the Methods (Section 2.7). The lanes represent: 1: 
control and 2: H2O2 300 µM. Panel A is one representative blot from three separate 
experiments and Panel B is the densitometric analysis of the blots ± S.E.M. *denotes 
p<0.05. 
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Figure 3.31. Effect of antimycin A on expression of inducible NOS in control 
and activated RASMCs. 
Confluent monolayers of RASMCs in 6 well plates were treated with antimycin A at 
the concentrations shown for 30 minutes prior to activation with LPS (100 µg) and 
IFN-γ (100 U/ml) for 24 hours. Lysates were generated and analysed by western 
blotting as described in the Methods (Section 2.7). The lanes represent: 1: control; 2: 
antimycin A at 25 µM; 3: antimycin A at 50 µM; 4: antimycin A at 100 µM and 5: 
antimycin A at 150 µM. Panel A is one representative blot from 3 separate 
experiments and Panel B is the densitometric analysis of the 3 blots represented as 
the mean ± S.E.M. * denotes p<0.05. 
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Figure 3.32. Effect of DEM on expression of inducible NOS in control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 6 well plates were treated with DEM at the 
concentrations shown for 30 minutes prior to activation with LPS (100 µg) and IFN-γ 
(100 U/ml) for 24 hours. Lysates were generated and analysed by western blotting 
as described in the Methods (Section 2.7). The lanes represent: 1: control; 2: DEM 
25 µM; 3: DEM 50 µM; 4: DEM 100 µM and 5: DEM 150 µM. Panel A is one 
representative blot from 3 separate experiments and Panel B is the densitometric 
analysis of the 3 blots represented as the mean ± S.E.M. * denotes p<0.05. 
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3.7 . Effect of oxidative stress inducers on Heme-Oxygenase-1 
expression in rat cultured aortic smooth muscle cells 
 
The HO-1 protein is a stress protein, expressed in response to oxidative 
stress. In these studies, cells were pre-treated with each compound individually prior 
to exposure to either medium alone (Control) or medium containing LPS (100 µg) 
and IFN-γ (100 U/ml) for 24 hours. The western blots of lysates generated did not 
show any detectable or significant expression of HO-1 in controls or in cells treated 
with H2O2 (Figure 3.33). Antimycin A on the other hand induced a 32 kDa protein that 
was detectable with an anti-HO-1 specific antibody. The expression was however 
identified only at 150 µM in induced cells (Figure 3.34). Interestingly, in the series of 
experiments with DEM, HO-1 was detected in lysates from LPS (100 µg) and IFN-γ 
(100 U/ml) treated cells and this was increased in a concentration-dependent 
manner by DEM, reaching a maximum at 150 µM (Figure 3.35). The reason for the 
induction of HO-1 by LPS (100 µg) and IFN-γ (100 U/ml) in this series of experiments 
but not in the others is unclear. It is possible however that this reflects the degree of 
stress that may have been induced on the cells at any given time. Should this be 
higher in the experiments carried out with DEM then this would perhaps account for 
the detectable levels of HO-1. 
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Figure 3.33. Effect of H2O2 on expression of heme-oxygenase-1 in control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 6 well plates were treated with H2O2 at the 
concentrations shown for 30 minutes prior to activation with LPS (100 µg) and IFN-γ 
(100 U/ml) or incubated in medium alone without LPS and IFN-γ (Control) for 24 
hours. Lysates were generated and analysed by western blotting as described in the 
Methods (Section 2.7). The lanes represent: 1: control; 2: H2O at 300 µM. One 
representative blot from 3 separate experiments. 
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Figure 3.34. Effect of antimycin A on expression of heme-oxygenase-1 in 
control and activated RASMCs. 
Confluent monolayers of RASMCs in 6 well plates were treated with antimycin A at 
the concentrations shown for 30 minutes prior to activation with LPS (100 µg) and 
IFN-γ (100 U/ml) or incubated in medium alone without LPS and IFN-γ (Control) for 
24 hours. Lysates were generated and analysed by western blotting as described in 
the Methods (Section 2.7). The lanes represent: 1: control; 2: antimycin A 25 µM; 3: 
antimycin A 50 µM; 4: antimycin A 100 µM and 5: antimycin A150 µM. One 
representative blot from 3 separate experiments. 
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Figure 3.35. Effect of DEM on expression of heme-oxygenase-1 in control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 6 well plates were treated with DEM at the 
concentrations shown for 30 minutes prior to activation with LPS (100 µg) and IFN-γ 
(100 U/ml) or incubated in medium alone without LPS and IFN-γ (Control) for 24 
hours. Lysates were generated and analysed by western blotting as described in the 
Methods (Section 2.7). The lanes represent: 1: control; 2: DEM 25 µM; 3: DEM 50 
µM; 4: DEM 100 µM and 5: DEM 150 µM. One representative blot from 3 separate 
experiments. 
 
Control 
LPS & IFN-γ 
Lane number 1 2 3 4 5
HO-1 32 kDa 
HO-1 32 kDa 
 142
3.8 . Effect of statins on nitrite production and L-arginine transport 
in rat cultured aortic smooth muscle cells 
 
As highlighted in the introduction chapter, statins are now known to exert a 
diverse range of actions which are not simply restricted to cholesterol lowering. We 
have therefore initiated studies to determine the effects of statins on the expression 
and function of the L-arginine-NO pathway in RASMCs. Studies have been carried 
out using atorvastatin, simvastatin and pravastatin, which are widely administered to 
patients with coronary artery disease to lower their blood cholesterol levels 
(Bauersachs et al. 2006; Chapidze et al. 2006). In our experiments, cells were pre-
incubated with increasing concentrations of statins (1-100 µM) for 30 minutes prior to 
activation with LPS (100 µg/ml) and IFN-γ (100 U/ml) for 24 hours. Changes in nitrite 
production and L-arginine transport were subsequently determined. 
Atorvastatin caused a bell-shaped response on LPS and IFN-γ induced NO 
synthesis, initially increasing this in a concentration-dependent manner up to 10 µM 
and decreasing thereafter. Even at a 100 µM atorvastatin, the amount of nitrite 
detected, although lower than that measured with 10 µM, was still higher than the 
levels detected with LPS and IFN-γ alone (Figure 3.36). Basal nitrite levels remained 
undetectable and unaffected by the drug (Figure 3.36). As with atorvastatin, 
simvastatin also produced a bell-shaped response curve on NO production which 
was enhanced at 3 µM to 10 µM, declining to just below those detected with LPS 
and IFN-γ at 100 µM (Figure 3.37). In contrast to the previous two statins, pravastatin 
failed to cause any significant change in NO production even at concentrations of up 
 143
to 100 µM (Figure 3.38). None of the drugs showed any cytotoxicity at any of the 
concentrations used (Figure 3.39, Figure 3.40 and Figure 3.41). 
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Figure 3.36. Concentration dependent effect of atorvastatin on nitrite 
production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in complete 
culture medium for 30 minutes with atorvastatin at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours. Nitrite production was monitored as described in the methods (Section 
2.4). The data represents the mean ± S.E.M. of at least 3 separate experiments with 
3 replicates in each. *denotes p<0.05 when compared to the activated control. 
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Figure 3.37. Concentration dependent effect of simvastatin on nitrite 
production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with simvastatin at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours. Nitrite production was monitored as described in the methods (Section 
2.4). The data represents the mean ± S.E.M. of at least 3 separate experiments with 
3 replicates in each. *denotes p<0.05 when compared to the activated control. 
*
*
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Figure 3.38. Concentration dependent effect of pravastatin on nitrite 
production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with pravastatin at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours. Nitrite production was monitored as described in the methods (Section 
2.4). The data represents the mean ± S.E.M. of at least 3 separate experiments with 
3 replicates in each. 
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Figure 3.39. Effect of atorvastatin on viability in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with atorvastatin at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours. Cell viability was monitored as described in the methods (Section 2.8). The 
data represents the mean ± S.E.M. of at least 3 separate experiments with 3 
replicates in each. 
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Figure 3.40. Effect of simvastatin on viability in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with simvastatin at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours. Cell viability was monitored as described in the methods (Section 2.8). The 
data represents the mean ± S.E.M. of at least 3 separate experiments with 3 
replicates in each. 
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Figure 3.41. Effect of pravastatin on viability in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with pravastatin at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours. Cell viability was monitored as described in the methods (Section 2.8). The 
data represents the mean ± S.E.M. of at least 3 separate experiments with 3 
replicates in each. 
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Consistent with its effects on induced NO synthesis, atorvastatin also 
enhanced L-arginine transport. However, this did not appear to be concentration 
dependent in that the increases observed were virtually comparable at all 
concentrations used except for 100 µM which inhibited transport rates, albeit 
marginally, in both control and activated cells (Figure 3.42). In contrast to 
atorvastatin, simvastatin did not alter L-arginine transport (Figure 3.43), contrasting 
with its effects on NO production. Pravastatin also failed to modify transporter activity 
in either control or activated cells (Figure 3.44) which is consistent with its lack of 
effects on induced NO synthesis. 
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Figure 3.42. Effect of atorvastatin on L-arginine transport in control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with atorvastatin at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours Transport of [3H]L-arginine was determined in the cell monolayer as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. *denotes p<0.05 when 
compared to the activated control. 
*
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Figure 3.43. Effect of simvastatin on L-arginine transport in control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with simvastatin at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours Transport of [3H]L-arginine was determined in the cell monolayer as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. 
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Figure 3.44. Effect of pravastatin on L-arginine transport in control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-treated in normal 
culture medium for 30 minutes with pravastatin at the concentrations shown on the 
graph. Cells were subsequently incubated in complete culture medium alone 
(Controls) or in medium containing LPS (100 µg) and IFN-γ (100 U/ml) for a further 
24 hours Transport of [3H]L-arginine was determined in the cell monolayer as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. 
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3.9 . Effects of statins on iNOS protein expression 
 
In order to determine whether the changes induced by atorvastatin and 
simvastatin on nitrite production were associated with changes in the induction of 
iNOS, western blot analysis of the enzyme was carried out under identical conditions 
to those described above. In these studies, atorvastatin clearly enhanced iNOS 
expression in activated cells. More importantly, the enhancements correlated well 
with the changes seen in NO production (Figure 3.36) in that 10 µM and 30 µM 
atorvastatin produced the maximum increase in enzyme protein expression with 100 
µM decreasing the latter (Figure 3.45). Simvastatin also appeared to enhance iNOS 
expression (Figure 3.46) over the concentration range that increased NO production 
(Figure 3.37) while pravastatin failed to cause any significant change in iNOS 
induction (Figure 3.47). 
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Figure 3.45. Effect of atorvastatin on expression of inducible NOS in control 
and activated RASMCs. 
Confluent monolayers of RASMCs in 6 well plates were treated with atorvastatin at 
the concentrations shown for 30 minutes prior to activation with LPS (100 µg) and 
IFN-γ (100 U/ml) for 24 hours. Lysates were generated and analysed by western 
blotting as described in the Methods (Section 2.7). The lanes represent: 1: control; 2: 
atorvastatin 1 µM; 3: atorvastatin 3 µM; 4: atorvastatin 10 µM, 5: atorvastatin 30 µM 
and 6: atorvastatin 100 µM. Panel A is one representative blot from 3 separate 
experiments and Panel B the densitometry of ± S.E.M. of at least 3 separate 
experiments.
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Figure 3.46. Effect of simvastatin on expression of inducible NOS in control 
and activated RASMCs. 
Confluent monolayers of RASMCs in 6 well plates were treated with simvastatin at 
the concentrations shown for 30 minutes prior to activation with LPS (100 µg) and 
IFN-γ (100 U/ml) for 24 hours. Lysates were generated and analysed by western 
blotting as described in the Methods (Section 2.7). The lanes represent: 1: control; 2: 
simvastatin 1 µM; 3: simvastatin 3 µM; 4: simvastatin 10 µM, 5: simvastatin 30 µM 
and 6: simvastatin 100 µM. Panel A is one representative blot from 3 separate 
experiments and Panel B the densitometry of ± S.E.M. of at least 3 separate 
experiments. 
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Figure 3.47. Effect of pravastatin on expression of inducible NOS in control 
and activated RASMCs. 
Confluent monolayers of RASMCs in 6 well plates were treated with pravastatin at 
the concentrations shown for 30 minutes prior to activation with LPS (100 µg) and 
IFN-γ (100 U/ml) for 24 hours. Lysates were generated and analysed by western 
blotting as described in the Methods (Section 2.7). The lanes represent: 1: control; 2: 
pravastatin 1 µM; 3: pravastatin 3 µM; 4: pravastatin 10 µM, 5: pravastatin 30 µM 
and 6: pravastatin 100 µM. Panel A is one representative blot from 3 separate 
experiments and Panel B the densitometry of ± S.E.M. of at least 3 separate 
experiments. 
Lane number
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3.10 . Effect of statins on oxidative stress induced changes in NO 
synthesis and L-arginine transport in rat cultured aortic 
smooth muscle cells 
 
In view of the effects described above for atorvastatin and simvastatin, studies 
with these compounds were extended to determine whether they could reverse or 
counteract the actions of the OS inducers described earlier (Section 3.5). In these 
studies experiments were performed by incubating cultured RASMCs with 
atorvastatin, simvastatin or pravastatin at the concentration ranging from 1 to 100 µM 
30 minutes prior to the co-incubation with antimycin A (100 µM) or DEM (5 or 100 
µM) for a further 30 minutes before activation with LPS (100 µg) and IFN-γ (100 
U/ml) for 24 hours. Controls were incubated in culture medium alone and another 
control was used incubating cells with the oxidative stress inducer only. 
Consistent with the original observations, antimycin A at 100 µM significantly 
inhibited NO production as shown in Figure 3.20. More importantly, pre-incubating 
cells with atorvastatin concentration-dependently reversed these inhibitions with 1 
µM virtually restoring levels to those seen with LPS and IFN-γ alone. Moreover, 
higher concentrations of up to 30 µM caused further potentiation of accumulated 
nitrite levels which is consistent with the effects observed previously with the statin 
alone. At 100 µM, atorvastatin suppressed NO production back to the activated 
control values (Figure 3.48). In contrast, simvastatin (Figure 3.49) and pravastatin 
(Figure 3.50) modestly recovered the inhibitions of NO production caused by 
antimycin A but these effects did not appear to be statistically different to the 
inhibited values. Moreover, neither compound enhanced NO production beyond the 
 159
induced values. Furthermore, none of the statins altered the blockage of L-arginine 
transport seen with antimycin A (Figure 3.51, Figure 3.52 and Figure 3.53). 
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Figure 3.48. Concentration dependent effect of atorvastatin on antimycin A-
induced suppression of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of atorvastatin for 30 minutes before co-incubation with antimycin A 
(100 µM) for a further 30 minutes. Cells were subsequently incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. *denotes p<0.05 when compared to all the 
other conditions. 
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Figure 3.49. Concentration dependent effect of simvastatin on antimycin A-
induced suppression of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of simvastatin for 30 minutes before co-incubation with antimycin A 
(100 µM) for a further 30 minutes. Cells were subsequently incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. * denotes p<0.05 when compared with control.  
 
 
*
 162
 
 
C 0 1 3 10 30 100
0
25
50
75
100
125
Control
LPS & IFN-γ
          Pravastatin (μM)
          Antimycin A (100 μM)
N
itr
ite
 p
ro
du
ct
io
n
(%
 o
f C
on
tr
ol
-L
PS
 &
 IF
N
- γ)
 
 
 
Figure 3.50. Concentration dependent effect of pravastatin on antimycin A-
induced suppression of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of pravastatin for 30 minutes before co-incubation with antimycin A 
(100 µM) for a further 30 minutes. Cells were subsequently incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. * denotes p<0.05 when compared with control. 
*
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Figure 3.51. Concentration dependent effect of atorvastatin on antimycin A-
induced suppression of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of atorvastatin for 30 minutes before co-incubation with antimycin A 
100 µM for a further 30 minutes. Cells were subsequently incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and 
monitored as described in the methods (Section 2.6). The data represents the mean 
± S.E.M. of at least 3 separate experiments with 3 replicates in each. *denotes 
p<0.05 when the values in activated cells (black bars) are compared to the activated 
control. 
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Figure 3.52. Concentration dependent effect of simvastatin on antimycin A-
induced suppression of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to simvastatin 
increasing concentrations for 30 minutes before co-incubation with antimycin A 100 
µM for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. *denotes p<0.05 when the 
values in activated cells (black bars) are compared to the activated control. 
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Figure 3.53. Concentration dependent effect of pravastatin on antimycin A-
induced suppression of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to pravastatin 
increasing concentrations for 30 minutes before co-incubation with antimycin A 100 
µM for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. 
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3.11 . Effect of statins on DEM-induced changes in NO synthesis 
and L-arginine transport in rat cultured aortic smooth muscle 
cells 
 
As with antimycin A, studies were carried out investigating the effects of 
statins on DEM-induced changes in both NO synthesis and L-arginine transport. Two 
concentrations of DEM were selected for these experiments, one at 100 µM, and the 
other at 5 µM. The higher concentration was selected to ensure changes in L-
arginine transport could be observed and at this concentration, DEM completely 
abolished nitrite accumulation and inhibited induced L-arginine transport back to the 
basal control levels. Higher concentrations of atorvastatin (≥30 μM) together with the 
100 μM DEM appear to suppress transport rates in both control and activated cells 
below the basal values (Figure 3.57). At 5 µM, DEM selectively but only partially, 
inhibited NO production with no significant effects on transport. When applied, 
atorvastatin was able to reverse the inhibition of NO synthesis in the presence of 5 
µM DEM (Figure 3.60). Simvastatin (Figure 3.61) and pravastatin (Figure 3.62) did 
not cause any significant changes in the inhibitions produced by 5 µM DEM and all 
three statins failed to reverse the abrogation of NO synthesis in the presence of DEM 
100 µM (Figure 3.54, Figure 3.55 and Figure 3.56 respectively for atorvastatin, 
simvastatin and pravastatin). 
The inhibitions of L-arginine transport induced by DEM at 100 µM were not 
altered by any of the statins (Figure 3.57, Figure 3.58 and Figure 3.59). 
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Figure 3.54. Concentration dependent effect of atorvastatin on DEM-induced 
suppression of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of atorvastatin for 30 minutes before co-incubation with DEM (100 
µM) for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. *denotes p<0.005 when the values in 
activated cells (black bars) are compared to the activated control. 
*
 168
 
 
C 0 1 3 10 30 100
0
25
50
75
100
LPS & IFN-γ
Control
       Simvastatin (μM)
        DEM (100 μM)
N
itr
ite
 p
ro
du
ct
io
n
(%
 o
f C
on
tr
ol
-L
PS
 &
 IF
N
- γ)
 
 
 
Figure 3.55. Concentration dependent effect of simvastatin on DEM-induced 
suppression of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of simvastatin for 30 minutes before co-incubation with DEM (100 
µM) for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. *denotes p<0.005 when the values in 
activated cells (black bars) are compared to the activated control. 
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Figure 3.56. Concentration dependent effect of pravastatin on DEM-induced 
suppression of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of pravastatin for 30 minutes before co-incubation with DEM (100 µM) 
for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. *denotes p<0.005 when the values in 
activated cells (black bars) are compared to the activated control. 
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Figure 3.57. Concentration dependent effect of atorvastatin on DEM-induced 
suppression of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of atorvastatin for 30 minutes before co-incubation with DEM (100 
µM) for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. *denotes p<0.05 when the 
values in activated cells (black bars) are compared to the activated control. 
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Figure 3.58. Concentration dependent effect of simvastatin on DEM-induced 
suppression of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of simvastatin for 30 minutes before co-incubation with DEM (100 
µM) for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. *denotes p<0.05 when 
compared to the activated control. 
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Figure 3.59. Concentration dependent effect of pravastatin on DEM-induced 
suppression of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of pravastatin for 30 minutes before co-incubation with DEM (100 µM) 
for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. *denotes p<0.05 when 
compared to the activated control. 
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Figure 3.60. Concentration dependent effect of atorvastatin on DEM-induced 
suppression of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of atorvastatin for 30 minutes before co-incubation with DEM (5 µM) 
for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. * denotes p<0.05 when compared with the 
activated control. 
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Figure 3.61. Concentration dependent effect of simvastatin on DEM-induced 
suppression of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of simvastatin for 30 minutes before co-incubation with DEM (5 µM) 
for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. *denotes p<0.05 when compared to the 
activated control. 
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Figure 3.62. Concentration dependent effect of pravastatin on DEM-induced 
suppression of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of pravastatin for 30 minutes before co-incubation with DEM (5 µM) 
for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. *denotes p<0.05 when compared to the 
activated control. 
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Figure 3.63. Concentration dependent effect of atorvastatin on DEM-induced 
suppression of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of atorvastatin for 30 minutes before co-incubation with DEM (5 µM) 
for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. 
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Figure 3.64. Concentration dependent effect of simvastatin on DEM-induced 
suppression of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of simvastatin for 30 minutes before co-incubation with DEM (5 µM) 
for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. *denotes p<0.05 when 
compared to the activated control. 
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Figure 3.65. Concentration dependent effect of pravastatin on DEM-induced 
suppression of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of pravastatin for 30 minutes before co-incubation with DEM (5 µM) 
for a further 30 minutes. Cells were subsequently incubated either in complete 
culture medium alone (Controls) or in medium containing LPS (100 µg) and IFN-γ 
(100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and monitored as 
described in the methods (Section 2.6). The data represents the mean ± S.E.M. of at 
least 3 separate experiments with 3 replicates in each. 
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3.12 . Effect of mevalonate on statins induced changes in NO 
synthesis and/or L-arginine transport in rat cultured rat aortic 
smooth muscle cells 
 
Statins inhibit the HMG-CoA reductase enzymes and may deplete cells of 
mevalonic acid as a consequence. Mevalonate is the product of the reduction of 
HMG-CoA by the HMG-CoA reductase enzyme and inhibition of its production would 
ultimately inhibit cholesterol synthesis. To determine whether the effects observed in 
our studies with the statins are directly related to HMG-CoA inhibition, experiments 
were carried out supplementing the culture medium with mevalonate at 50 µM and 
100 µM. Mevalonate was administered to cultured cells prior to addition of each 
statin, following induction with LPS and IFN-γ as described previously. Consistent 
with our earlier observations, induction of NO synthesis was enhanced by 
atorvastatin at a concentration of 10 µM and by simvastatin at the same 
concentration. When present, mevalonate appeared to modify the effects of the both 
atorvastatin and simvastatin (Figure 3.66 and Figure 3.67), reducing at least the 
simvastatin enhancement of nitrite production back to the LPS and IFN-γ stimulated 
levels. It is worth noting however that simvastatin did not cause a very marked 
enhancement in this series of experiments. Interestingly, the responses observed for 
transport appear to show differences with the statins. Atorvastatin induced 
transporter activity albeit marginally, and these effects were inhibited by mevalonate 
(Figure 3.68). When co-incubated simvastatin and mevalonate, the transporter 
activity was unaffected (Figure 3.69). When applied alone, mevalonate had no 
distinct effects on either nitrite levels (Figure 3.70) or L-arginine transport (Figure 
 180
3.71). Cell viability assays for mevalonate suggest that non cytotoxic concentrations 
were used (Figure 3.72). 
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Figure 3.66. Concentration dependent effect of mevalonate on atorvastatin-
induced enhancement of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of mevalonate for 30 minutes before co-incubation with 10 µM 
atorvastatin for a further 30 minutes. Cells were subsequently incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. 
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Figure 3.67. Concentration dependent effect of mevalonate on simvastatin-
induced enhancement of nitrite production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of mevalonate for 30 minutes before co-incubation with 10 µM 
simvastatin for a further 30 minutes. Cells were subsequently incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. 
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Figure 3.68. Concentration dependent effect of mevalonate on atorvastatin-
induced enhancement of L-arginine transport in control and activated 
RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of mevalonate for 30 minutes before co-incubation with 10 µM 
atorvastatin for a further 30 minutes. Cells were subsequently incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and 
monitored as described in the methods (Section 2.6). The data represents the mean 
± S.E.M. of at least 3 separate experiments with 3 replicates in each. 
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Figure 3.69. Concentration dependent effect of mevalonate on simvastatin 
induced of L-arginine transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of mevalonate for 30 minutes before co-incubation with 10 µM 
simvastatin for a further 30 minutes. Cells were subsequently incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and 
monitored as described in the methods (Section 2.6). The data represents the mean 
± S.E.M. of at least 3 separate experiments with 3 replicates in each. 
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Figure 3.70. Concentration dependent effect of mevalonate on nitrite 
production in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of mevalonate for 30 minutes before cells were incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Nitrite production was monitored as described in the 
methods (Section 2.4). The data represents the mean ± S.E.M. of at least 3 separate 
experiments with 3 replicates in each. 
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Figure 3.71. Concentration dependent effect of mevalonate on L-arginine 
transport in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of mevalonate for 30 minutes before cells were incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Transport of [3H]L-arginine was initiated and 
monitored as described in the methods (Section 2.6). The data represents the mean 
± S.E.M. of at least 3 separate experiments with 3 replicates in each. 
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Figure 3.72. Effect of mevalonate on viability in control and activated RASMCs. 
Confluent monolayers of RASMCs in 96 well plates were pre-exposed to increasing 
concentrations of mevalonate for 30 minutes before cells were incubated either in 
complete culture medium alone (Controls) or in medium containing LPS (100 µg) and 
IFN-γ (100 U/ml), for 24 hours. Cell viability was monitored as described in the 
methods (Section 2.8). The data represents the mean of 2 separate experiments 
with 3 replicates in each.  
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4 . Discussion 
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The studies outlined in this thesis were carried out to determine whether NOS 
and CATs expression and function may be regulated under conditions of oxidative 
stress (OS). The studies were initially planned for endothelial cells, where the 
constitutive NOS pathway exists; and for smooth muscle cells where the expression 
of the inducible enzyme can be initiated. These two cell types play a critical role in 
regulating vascular tone under normal physiological conditions and are targets for 
OS induced impairment of vascular function. Disruption of NO synthesis in 
endothelial cells is characteristic of OS-induced impairment of vascular relaxation, 
and is a process that may involve an inhibition in eNOS expression, function or even 
sequestration of eNOS derived NO by ROS generated during an OS insult. Although 
conclusive evidence is lacking, the latter may also alter L-arginine transport into 
cells, thereby restricting NO synthesis.  
This however requires vital proof and studies aimed at addressing this issue 
were originally planned in endothelial cells cultured from porcine aorta. Moreover, as 
with the investigations in SMCs, the effects of statins were also going to be 
examined in PAECs in order to establish if this group of lipid lowering drugs protect 
L-arginine transport and NO synthesis and bioavailability under conditions of OS. 
Such an effect would highlight an additional mechanism of action for these 
compounds which may contribute towards their beneficial therapeutic actions in man. 
However difficulties encountered with tissue supply (see discussion below) meant 
the experiments in endothelial cells could not be carried out. 
For the studies in smooth muscle cells, the aim was to determine what role 
iNOS and CATs play in diseases associated with OS and further determine if the 
actions of OS on these proteins could be modulated by statins. These studies are 
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timely and pertinent to the focus of this thesis, especially because of the existing 
controversy over the role of iNOS in diseases, such atherosclerosis, where 
controversial data suggest both deleterious and protective actions for this enzyme. 
iNOS-derived NO has been implicated in the ensuing inflammatory response and 
has been suggested to influence the pathologic features of the disease through 
various actions, including the induction of nitrosative stress and enhancing levels of 
lipoperoxides (Beckman et al. 1990; Graham et al. 1993; Hogg et al. 1993; Huang et 
al. 1999). In contrast to these reports, iNOS-induced NO has been shown to reduce 
oxidative modification of LDL (Jessup and Dean 1993; Malo-Ranta et al. 1994; 
Rikitake et al. 1998; Hemmrich et al. 2003) and attenuate atherosclerotic lesions 
after immune injury in in vivo models of the disease (Russell et al. 1995; Koglin et al. 
1998; Koglin 2000). Thus it is clear that iNOS and the NO derived from it can, under 
certain conditions, be beneficial. We hypothesised in this thesis that the deleterious 
actions of OS may be mediated, in part, through suppression of the expression 
and/or activity of iNOS, and potentially L-arginine transport which mediates substrate 
supply to the enzyme. Such effects would abolish the protective actions of the 
inducible L-arginine-NO pathway, contributing to the pathogenesis of disease states. 
This is a rather controversial notion but with emerging evidence in support; and with 
a fascinating potential of generating new data which may lead to novel ideas for 
treatment of OS-mediated pathologies such as atherosclerosis. The latter, as already 
highlighted in the introduction, is a progressive disease which can be initiated as 
early as in the first decade of life with the identification of “fatty streaks” in vessels 
such as the coronary artery and abdominal aorta (McMahan et al. 2006). The 
disease develops at different stages and by the second decade of life, the “fatty 
streak lesions” may become evident  in coronary artery spreading to the cerebral 
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arteries by the third and fourth decade of life (Bonomini et al. 2008). The early 
formation of atherosclerotic plaque starts with injury caused to the endothelium 
(Chester et al. 1990; Creager et al. 1990; Braddock et al. 1998). This in turn results 
in structural, functional and biochemical changes in the affected vessel with 
accumulation of macrophage and lipid formed foam cells, smooth muscle cell, 
cholesterol crystals and other cell debris accumulating in what is referred to as a 
fibrous plaque (Pulido et al. 2004; Antohe 2006; Crouse 2006; Saam et al. 2007). 
One of the other fundamental changes that occur is the increased production of ROS 
and initiation of an inflammatory response which contribute to the progression of the 
disease state.   
In the vessel wall, the major sources of ROS are NADPH oxidase, xanthine 
oxidase, enzymes from the mitochondrial respiratory chain and dysfunctional NOS 
(Figure 4.1). (Hattori et al. 2004; Inagi 2006; Elahi et al. 2007; Seddon et al. 2007; 
Forstermann 2008). Of these, the NADPH oxidase system appears to contribute the 
largest amount of ROS in smooth muscle, endothelial cells and fibroblast (Bengtsson 
et al. 2003; Herkert et al. 2004; Ushio-Fukai and Alexander 2004; Escobales and 
Crespo 2005; Rouhanizadeh et al. 2008; Selemidis et al. 2008). The NADPH 
oxidase enzyme is composed of six subunits including a GTPase (Rho guanosine 
triphosphatase: usually Rac1 or Rac2 - Rac stands for Rho-related C3 botulinum 
toxin substrate); p40phox; p47phox; p67phox; p22phox and gp91. The latter is 
barely detectable in VSMCs, and is believed to be replaced by its homologous 
proteins nox1 and nox4 together with nox2 (Wassmann et al. 2002; Higashi et al. 
2003; Ushio-Fukai 2006).  
Nox proteins are prominent sources of vascular reactive oxygen species. 
These proteins are differentially expressed depending on the cell type and may have 
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diverse functions such as mediating cellular activation, differentiation, proliferation 
and angiogenesis, as well as contributing to signal transduction and gene expression 
(Lambeth 2007). Excessive formation of nox-dependent reactive oxygen species 
may be associated with pathologies such as atherosclerosis where 60 % of the ROS 
generated are from nox enzymes (Lambeth 2007) (Figure 4.1). In other conditions 
such as hypertension, hyperlipidemia or diabetes, nox-derived ROS may also 
contribute to vascular dysfunction resulting in defective angiogenesis and activation 
of the inflammatory process (Maytin et al. 1999; Cave et al. 2006; Selemidis et al. 
2008). Inhibition of nox proteins may therefore provide a novel approach in 
preventing and treating cardiovascular diseases (Cave et al. 2006; Brandes and 
Schroder 2008). 
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Figure 4.1. Sources of ROS in the vasculature. 
Adapted from (Seddon et al. 2007; Forstermann 2008). 
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 The initial studies conducted for this thesis were aimed at identifying and 
characterising the transport system(s) for L-arginine in aortic endothelial cells with a 
view to understanding how these carriers may be regulated by OS and further 
exploring what the consequence would be in modulating NO production. However, 
only limited experiments were carried out because of the disruption in supply of 
porcine aortae. The latter were obtained from a link with GlaxoSmithKline as there is 
no abattoir close to the University that supplied porcine aorta. The supply by 
GlaxoSmithKline was restricted to limited periods when their studies were being 
conducted and this eventually ceased when their studies were concluded. Thus, the 
further experiments planed with PAECs had to be abandoned. However, in the 
limited studies carried out, it was demonstrated that uptake of L-arginine into these 
cells was linear for up to 10 minutes, saturating thereafter reaching a plateau at 60 
minutes. In addition, the limited kinetics experiments showed transport did not obey 
saturable Michaelis-Menten kinetics. The later would suggest the expression of a 
high capacity but low affinity carrier. This however requires further investigation by 
PCR analysis. Furthermore, cross-inhibition studies with select substrate amino 
acids are also required to check the selectivity of the transporter(s) expressed.  
It is worth noting that previous investigations have shown that L-arginine 
transport into endothelial cells may be mediated through a high affinity carrier which, 
under normal physiological conditions, may be CAT-1. In other studies in porcine 
pulmonary aortic endothelial cells, it appears that L-arginine may be transported 
through a Na+-independent system that resembles system y+ (around 70 % of the 
uptake) (Greene et al. 1993; Bogle et al. 1996) and a Na+-dependent system that is 
characteristic of B0,+ (Greene et al. 1993). Thus, it is likely that several transporters 
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may be associated with uptake of L-arginine into the endothelium, but with system y+ 
constituting the predominant carrier system. 
In addition to the time course and kinetic experiments, limited studies were 
also conducted investigating the effects of H2O2 on L-arginine transport. This 
molecule is believed to be produced under conditions of OS and to be one of the 
major reactive oxygen intermediates that can activate many of the pathways 
associated with stress. In our studies, H2O2 was without significant effect even when 
applied at different concentrations and in the absence of FBS which is believed to 
quench the pro-oxidant actions of H2O2. Where changes were observed (such as at 
1 mM), this was often associated with cytotoxicity and therefore reflect a non-specific 
action of the compound. These findings indicate that L-arginine transport in PAECs 
is not susceptible to modification by OS. Alternatively, it is possible that H2O2 did not 
induce stress under the conditions used but this needs further clarification by, for 
instance, determining whether ROS production was in fact induced following H2O2 
treatment. Changes in expression of stress proteins such as HO-1 could also be 
determined as performed to RASMCs (discussed below).  
It is worth pointing out that H2O2 has indeed been shown to induce OS in 
several cell types including leukocytes (Arendt et al. 2005), chinese hamster ovary 
cells (Borradaile et al. 2006), H9c2 cells (Pesant et al. 2006), endothelial cells 
(Haendeler et al. 2005), hepatic cells (Itagaki et al. 2005), adipocytes (Kamigaki et 
al. 2006), HeLa epithelial-like cells and Human lens epithelial B-3 cells (Adachi et al. 
2004; Narayan et al. 2005; Seomun et al. 2005), cardiomyocytes (Pesant et al. 2006) 
and SMCs (Adachi et al. 2004; Lee et al. 2004; Ryer et al. 2005). These were 
observed over the same concentration range used in this thesis. Thus, the 
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concentrations of H2O2 employed in our studies should have induced some degree 
of OS and the reasons why this was not the case is unclear. 
In parallel with the PAECs, RASMCs were exploited as the second cellular 
model, and used specifically to determine how the inducible L-arginine-NO pathway 
may be regulated under conditions of OS. As pointed out in the introduction, iNOS-
induced NO has been widely reported to exert detrimental effects in various 
inflammatory conditions, inducing deleterious effects largely through its interaction 
with ROS to generate highly reactive intermediate species such as ONOO-. 
The L-arginine-NO pathway in RASMCs had already been characterised 
previously by the group (Wileman et al. 1995) and the current studies conducted 
using these cells relied on the previous data already generated. For instance, the 
expression of iNOS and up-regulation of L-arginine transport rates were routinely 
induced by exposing cells to LPS (100 µg/ml) and IFN-γ (100U/ml). These agents 
have already been shown to cause consistent and sustained induction of these 
processes (Wileman et al. 1995). As in previous studies (MacNaul and Hutchinson 
1993; Wileman et al. 1995; Wileman et al. 2003), this combination of LPS and IFN-γ 
up-regulated iNOS-induced NO production and enhanced L-arginine transport, 
increasing the latter above the basal rates seen in control non activated cells. 
The effects of OS on both iNOS expression and enhanced L-arginine 
transport in RASMCs were investigated using two approaches in which cells were 
either activated and then exposed to the OS inducers or pre-exposed to these 
agents before activating with LPS and IFN-γ. In the former studies, exposure of 
RASMCs to OS inducers was preceded by induction with LPS and IFN-γ for 21 hours 
and activation was always confirmed by the Griess assay. These cells were 
subsequently exposed to H2O2 at different concentrations and time points prior to 
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monitoring L-arginine transport. Over these shorter incubation periods, H2O2 
suppressed L-arginine transport but only when used at 1 mM and exposed to cells 
for periods of up to 180 minutes in complete culture medium. Lower incubation times 
and concentrations were without significant effect. This may reflect the amount of 
free radicals generated over this period and may indicate that high amounts of free 
radicals are required over prolonged periods to suppress L-arginine uptake. 
Alternatively, since there was some degree of cytotoxicity seen at the extreme 
conditions, it is likely that the inhibition of transport rates may in fact reflect 
cytotoxicity. 
It was considered that the lack of significant effect with H2O2 in complete 
medium may be due to the presence of phenol red and FBS, which both have 
antioxidant potentials (Zheng et al. 2006; Lewinska et al. 2007). To eliminate this 
possibility, further experiments were carried out omitting these from the culture 
medium during incubation of cells with H2O2. In these studies, there were no 
significant changes in either basal or induced transport rates at any of the 
concentrations of H2O2 used or time points examined. These observations indicate 
clearly that the lack of effects seen with H2O2 in complete medium was in fact not 
due to any of the antioxidant actions of either phenol red of FBS but perhaps due to 
H2O2 not being able to modify transport, al least in acute incubations (<180 minutes). 
Similar to the findings with short term treatments, chronic exposure of RASMCs to 
H2O2 did not result in any marked changes in basal or induced transporter activities. 
Accordingly, induced NO synthesis was also not significantly affected by H2O2. Since 
H2O2 was added prior to inducing cells with LPS and IFN-γ, it is clear therefore that 
the induction process associated with enhanced L-arginine transport or NO 
production were not modified by H2O2. Taken together, the data in RASMCs is 
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consistent with the preliminary findings in PAECs in that neither the induction of 
iNOS-induced NO synthesis nor the up-regulation in L-arginine transport appeared to 
be susceptible to H2O2. As already discussed for PAECs, it is not clear whether this 
is because OS was not induced or whether these processes (iNOS-induced NO 
synthesis and L-arginine transport) may in fact be insensitive to the oxidant actions 
of H2O2. Unfortunately it was not possible to determine the production of ROS due to 
the facilities not being available in the laboratory. However, the effects of H2O2 on 
HO-1 expression were determined and this is discussed below.  
In other studies where H2O2 has been employed, experiments were carried 
out in PBS or media with low FBS (0.1 %) (Adachi et al. 2004; Lee et al. 2004) and 
with higher concentrations of H2O2 (≥1 mM) to induce apoptosis (Borradaile et al. 
2006). Moreover, these studies revealed the effects of H2O2 at 72 hours incubation in 
low FBS medium. Our experiments were however limited to a maximum of 24 hours 
incubation because of decreased cell viability over prolonged exposure time points. 
Our aim was not to induce apoptosis but rather to induce OS and maintain cell 
viability without any adverse apoptotic actions being evident. In addition, the focus of 
our studies was to determine how OS may regulate the function and/or induction of 
iNOS/L-arginine transport. This needed to be examined over the period where the 
induction takes place; and for iNOS this is reported to start at 3 hours reaching a 
peak at 18 hours (Boughton-Smith et al. 1993). 
One other issue worth noting is the fact that there may be differences in the 
ability of various systems to cope with OS and this may reflect differences in their 
antioxidant capacities. For instance, it is reported that endothelial and VSMCs from 
humans contain low levels of catalase activity and as a result, these cells are more 
susceptible to the effects of H2O2 (Shingu et al. 1985; Lin et al. 2007). The fact that 
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the same is not true in RASMCs may additionally reflect, perhaps, species 
differences. 
The protection of tissue and cells against OS is provided by anti-oxidative and 
phase 2 enzymes (Li et al. 2006). In RASMCs the antioxidant defence triggers a  
time and concentration dependent increase of cellular antioxidants and phase 2 
enzymes including SOD, catalase, glutathione, glutathione reductase, glutathione 
peroxidase, glutathione S-transferase (GST), and NADPH:quinone oxidoreductase-1 
(NOQ1) (Li et al. 2006). Studies in SMCs show that when exposed to oxidative 
stress or oxLDL, these cells respond by inducing the expression of stress proteins 
like HO-1 and MSP23, as a cytoprotective mechanism (Siow et al. 1995). Although 
the induction of HO-1 is important under OS, this protein has a crucial role in 
preventing atherosclerosis as described in a study where a HO-1 deficient child had 
severe atherosclerotic lesions (Kawashima et al. 2002). The transcription factor 
Nuclear Factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) regulates phase 2 
antioxidant response by binding to the antioxidant response elements (ARE) in the 
promoter region of genes like HO-1, GPx and GSH enzymes (Nguyen et al. 2003). In 
a study with spontaneously hypertensive rats (SHR) the GSH system was impaired 
in aortic SMCs further contributing to OS (Wu and Juurlink 2001). 
The lack of effect with H2O2 in our systems is rather unexpected not least 
because of the discussion in the paragraph above but also because H2O2 has been 
shown to have many physiological functions and is reported to regulate cell 
proliferation, differentiation, and migration. It can also act as a second messenger 
modulating the growth of SMCs and fibroblasts and regulating the expression of 
inflammatory mediators (Schleicher and Friess 2007). Moreover, H2O2 may be able 
to activate many signalling pathways, inducing the phosphorylation and activation of 
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proteins such as c-Jun N-terminal Kinases (JNK), extracellular signal regulated 
kinases (ERK)1/2, protein kinase B (PKB) and p38 MAPK in vascular cells (Ushio-
Fukai et al. 1998; Chevalier et al. 2000; Blanc et al. 2004). These proteins, and in 
particular the p38 MAPK, may play a significant role in regulating both induced NO 
synthesis and L-arginine transport (Baydoun et al. 1999).  
Because of the moderate effects of H2O2 in RASMCs, our studies were 
extended to other inducers of OS in order to determine conclusively whether OS 
regulated the inducible L-arginine–NO pathway. The additional compounds used 
were antimycin A and DEM. Antimycin A is produced by Streptomyces sp. bacteria 
and exerts its effects by blocking the flow of electrons from semiquinone to 
ubiquinone in the Q-cycle of complex III in mitochondrial oxidative phosphorylation. 
By disrupting the proton gradient across the inner membrane, antimycin A prevents 
the production of adenosine 5'-triphosphate (ATP) as protons are unable to flow 
through the ATP synthase complex. The inhibition of Complex III by antimycin A 
results in the formation of large quantities of the toxic free radical (O2.- ) augmenting 
intracellular OS (Bundy et al. 2005). In cells such as the As4.1 from pigeons hearts, 
H2O2 may be one of the products generated by antimycin A (Boveris and Chance 
1973; Boveris et al. 1976; Han et al. 2007). The effects of antimycin A on  
mitochondria may also contribute largely to the increases in peroxynitrite production 
which is promoted by the reaction between NO and superoxide from mitochondria 
(Packer et al. 1996). 
As with H2O2, studies using either antimycin A or DEM examined both acute 
(5 minutes to 180 minutes) and chronic effects (24 hours) of these compounds on L-
arginine transport in control and activated cells. Consistent with the H2O2 data, 
neither antimycin A nor DEM altered transport rates when exposed to cells acutely 
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and after activation with LPS and IFN-γ. It can be concluded therefore that OS, or at 
least the OS inducers used in the studies, do not regulate the function of the 
transporters for L-arginine in RASMCs. This would however contradict at least one 
other report in the literature which has suggested that L-arginine transport in porcine 
pulmonary aortic endothelial cells may be regulated under conditions of OS (Patel et 
al. 1996). This is thought to occur through S-nytrosilation of the transporters by 
sulfhydryl agents that modify protein thiol groups thereby reducing the function of the 
carriers and thus L-arginine transport (Patel et al. 1996). 
In the 24 hours exposure studies, both antimycin A and DEM treatment 
resulted in a concentration dependent inhibition of both nitrite accumulation and L-
arginine transport. Interestingly, the latter was affected only in activated cells with the 
enhanced transporter activity being reduced back to control levels but with basal 
rates remaining virtually unaltered. Moreover, the inhibitions on induced L-arginine 
transport were more apparent at lower concentrations of antimycin A when 
compared to suppression of NO synthesis where 150 µM of the drug was required to 
virtually abolish the response. By comparison, 100 µM antimycin A was sufficient to 
reverse induced L-arginine transport back to basal levels. This suggests that the 
transporter(s) may be more sensitive to regulation by OS or at least by antimycin A.  
The precise mechanism via which these effects of antimycin A are mediated 
remain to be determined. However, the fact that both induced NO production and L-
arginine transport were abolished without affecting controls suggests that antimycin 
A may be acting at the induction level, potentially inhibiting these processes. Since 
antimycin A can deplete ATP levels due to the disruption of oxidative 
phosphorylation, it would not be unreasonable to suggest that its ability to suppress 
both NO production and L-arginine transport may, in part, be through this 
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mechanism. Indeed, cellular models of inflammation are known to require higher 
energy production for gene transcription and de novo protein synthesis (Berg et al. 
2003). Thus inhibition of ATP generation would inevitably disrupt these processes. 
Also of significance to transport is the fact that it is an energy dependent process 
which may be suppressed significantly if cells are depleted of ATP. This would be an 
effect that directly affects the functioning of the transporter rather than their 
induction. Such a mechanism would however be contradicted by the fact that 
antimycin A was without effect on basal transporter activity which should also be 
dependent on cellular ATP. Thus the more likely explanation for the actions of 
antimycin A may be that the compound is influencing cellular signalling pathways 
that are responsible for the induction of iNOS and the CATs. This in turn leads, 
potentially, to a suppression of gene transcription and translation and thus reduced 
protein expression which is reflected in a decrease in function. Unfortunately, 
because of the constraints of time, gene analysis studies could not be carried out 
and these studies are clearly needed. Expression of iNOS protein was however 
monitored and this is discussed further below. Changes in CAT proteins could not be 
determined because of lack of appropriate available antibodies. 
As with antimycin A, prolonged incubation of cells with DEM also inhibited NO 
production and induced L-arginine transport. However, the latter appeared less 
susceptible to DEM when compared to NO production because transport remained 
virtually unaltered at concentrations of DEM (25 µM) that virtually abolished NO 
synthesis. This shows a clear differential regulation of transport and NO synthesis by 
DEM and may highlight differences in the mechanisms associated with the induction 
of these processes. 
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The inhibition of NO production by DEM in RASMCs is consistent with its 
reported effects in hepatocytes where it has been shown to decreases levels of 
nitrite and iNOS expression (Kang et al. 1999; Tirmenstein et al. 2000). Although we 
have not addressed the underlying mechanisms of action of DEM in our studies, it is 
possible that this may be linked to its ability to deplete glutathione levels which in 
turn induces OS (Boyland and Chasseaud 1967; Miccadei et al. 1988; Russo et al. 
1995). DEM possesses an electrophilic core that interacts with the glutathione S-
transferase system, modifying thiol groups, albeit non specifically, and reducing  
GSH levels to 50 % when used at concentrations ranging from 125 µM to 250 µM 
(Boyland and Chasseaud 1967; Yang et al. 2004). These reductions could have 
detrimental consequences and in a rat animal model, the depletion of GSH induced 
hypertension, decreased NO bioavailability and may contribute to the pathogenesis 
of atherosclerosis (Vaziri et al. 2000).  
It has been demonstrated in other studies that administration of 
concentrations ≤100 µM of DEM in fibroblasts enhanced GSH content and induced 
transport of its precursor L-cysteine, but L-cystine transport declines when higher 
concentrations (up to 1 mM) are used (Bannai 1984). The increase in L-cysteine may 
be a cell protective response to OS against electrophiles (Ruiz et al. 2003) and 
interestingly, DEM has been used as a therapeutic agent to prevent organ damage 
in extreme inflammatory conditions such as septic shock (Jones et al. 1999). In such 
conditions, there is an overproduction of NO which could lead to marked hypotension 
and eventually end on organ failure. In such a state, DEM may conceivably reduce 
NO production and bioavailability, thereby reducing the chance of organs collapse. 
The underlying mechanism is likely to involve the generation of free radicals which 
uncouple NOS and blunt NO produced. In addition, signalling events that lead to the 
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induction of iNOS may potentially be inhibited leading to a decrease of iNOS 
expression and potentially L-arginine transport. Moreover, ROS may also oxidise 
BH4 and uncouple NOS (Landmesser et al. 2003; Bevers et al. 2006; Tang et al. 
2007; Sweazea and Walker 2008; Zhang et al. 2008). In the absence of sufficient 
BH4, NOS changes its functional profile and instead of oxidising L-arginine, oxygen 
is reduced to superoxide. In these conditions, the flux of superoxide will be higher 
due to the increased activity of iNOS (Loscalzo 2000). Disruption of NADPH, 
associated with oxidation of L-arginine by iNOS, may lead to an interruption in NO 
production and further perpetuating superoxide production (Vasquez-Vivar et al. 
1997; Vasquez-Vivar et al. 1997; Vasquez-Vivar et al. 1998; Panda et al. 2004). It is 
worth noting that should this process go unchecked it could result in detrimental 
consequences. 
The different profiles of inhibition of iNOS-induced NO and L-arginine 
transport caused by antimycin A and DEM may well reflect their different actions in 
terms of the actual cellular targets regulated by these compounds or their products. 
However, since the effects are only visible following pre-treatment of cells prior to 
activation, it is likely that both compounds act through inhibition of the induction 
process rather than affecting the actual direct activity of either the transporters or 
iNOS. What has not been established in this thesis is whether the actions of 
antimycin A or DEM are indeed mediated through ROS generation, which these 
compounds are clearly well documented to do, or through other mechanisms 
independent of ROS generation. What is clear however is the fact that the literature 
supports that antimycin A and DEM (and indeed H2O2) induce OS at the 
concentrations used. This cannot therefore be ruled out as a potential factor in the 
effects reported in the thesis. Studies measuring changes in levels of ROS produced 
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are clearly required to further develop the studies and these should be part of the 
future work planned. 
As an alternative to ROS generation, changes in the expression of the stress 
protein HO-1 was monitored as an index of the induction of OS. Heme oxygenase-1 
is a stress protective protein induced under oxidative imbalance. The products of its 
catabolism are carbon monoxide (CO), biliverdin (which is rapidly converted to 
bilirubin) and free iron (which leads to the induction of ferritin, an iron-binding 
protein). The actions of these products could be valuable physiological and 
therapeutic agents. For instance, CO like NO modulates intracellular cGMP levels, 
platelet aggregation and smooth muscle relaxation, but has a much lower affinity for 
sGC than NO (Siow et al. 1999). Similarly, bilirubin acts as a potent cellular 
antioxidant by rapid interconversion to biliverdin, removing ROS at up to 30,000 
times its concentration (Siow et al. 1999; Otterbein et al. 2003). Contrasting with 
these beneficial effects, it is reported that under certain conditions, CO may have 
detrimental effects if produced inappropriately. One example where this may be the 
case is in chronic hypoxia where generation of ROS and the production of CO by 
induced HO-1 is reported to lead to vasoconstriction of mesenteric arteries 
(Sweazea and Walker 2008). 
In our studies, experiments were carried out exploring the changes in 
expression of HO-1 under control conditions and in cells exposed to the OS 
inducers. The data obtained to date show that HO-1, which is not expressed in 
controls, is induced following exposure to DEM. Surprisingly, antimycin A had a less 
pronounced effect which was only evident at the highest concentration used (150 
µM) while H2O2 was virtually without effect. These studies suggest a difference in the 
mechanism of actions of the three compounds and indicate that effects of H2O2 and, 
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potentially, antimycin A may be independent of an action on HO-1 expression. It is 
possible that with DEM, the depletion of glutathione may account for the expression 
of HO-1 and also for its effects on both NO production and L-arginine transport which 
may all be linked to the induction of OS. 
Oxidative stress can regulate several signalling events as already highlighted. 
One of its targets in cells is NF-кB (Sen and Packer 1996; Chakraborti and 
Chakraborti 1998) which is implicated in the induction of not only iNOS (Xie et al. 
1994; Katsuyama et al. 1999; Matsumura et al. 2001; Zhang et al. 2001; Pingle et al. 
2003) but also L-arginine transport (Hammermann et al. 2000; Visigalli et al. 2004). 
This transcription factor is normally maintained in the inactive state by the inhibitory 
protein IκB. Its activation and subsequent translocation to the nucleus is preceded by 
the phosphorylation of IкB kinases (IKK) which phosphorylate IкB, resulting in 
ubiquitination, dissociation and proteasomal degradation of NF-κB. The latter next 
migrates from the cytoplasm to the nucleus and stimulates gene transcription 
(Zapolska-Downar et al. 2004). The ability of DEM to regulate NF-κB by down-
regulating its activation could therefore account for its effects in suppressing induced 
NO synthesis and L-arginine transport in RASMCs (Jones et al. 1999; Vos et al. 
1999; Szaszi et al. 2005; Lou and Kaplowitz 2007). 
 To confirm that the inhibitions of NO synthesis were associated with a 
suppression of iNOS expression, western blotting was performed on lysates 
generated from cells treated chronically with either antimycin A or DEM. Studies with 
the maximum non-cytotoxic concentration (300 μM) of H2O2 were also performed for 
completion even though it was found not to have any significant effect on NO 
production. In these studies, antimycin A and DEM suppressed iNOS expression as 
did H2O2 which, interestingly, did not significantly alter NO synthesis. The reason for 
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this discrepancy with H2O2 is currently unclear. The inhibition was however only 
partial and it is possible that the expressed enzyme protein may be sufficient to 
sustain NO production. This is however only a hypothesis. 
The inhibitions caused by antimycin A, unlike its effects on NO production, 
were not concentration dependent. In contrast, DEM caused a concentration-
dependent reduction in iNOS protein expression but this was only evident at 
concentrations well above those required to completely block NO synthesis. The 
latter was seen with 25 μM DEM, a concentration which only partially suppressed 
iNOS expression. From these observations, it is feasible to suggest that DEM may 
be exerting a dual effect where both the function and expression of iNOS may be 
inhibited. As already indicated earlier, parallel studies examining changes in CAT 
protein expressions could not be conducted because of lack of appropriate 
antibodies to the carriers. Although analysis of gene expression was planned the 
restricted timescale towards the end of the project meant these studies could not be 
conducted either but are again essential in developing the project further. 
 In conjunction with the above, further experiments were carried out examining 
the time dependent inhibition of NO production and L-arginine transport by either 
antimycin A or DEM. In these studies, cells were either pre-exposed to the drugs for 
30 minutes prior to, or added together with or at various time points from 3 hours to 
18 hours after activation with LPS and IFN-γ. This is the time period over which the 
induction of both iNOS and CATs genes were expected to occur, reaching a peak at 
18 hours. When added prior to activation, antimycin A and DEM inhibited both NO 
production and induced L-arginine transport rates. The inhibitions with antimycin A 
became less pronounced when the compound was added several hours after 
activation of cells. In fact there did not appear to be any significant difference 
 208
between the levels of nitrite detected in activated controls when compared to those 
where antimycin A was added ≥6 hours after activation. In contrast, L-arginine 
transport in activated cells was suppressed at all the time points except when 
antimycin A was added 18 hours after activation. Whether this reflects that CAT 
gene induction occur over a much delayed time period or whether their activity could 
be affected directly is not clear at present. However, since direct exposure of 
induced transporters to antimycin A did not alter transporter activity in our ‘acute’ 
exposure studies, it is likely that the inhibitions reflect an effect of antimycin A at the 
induction level. Quantitative PCR analysis of gene expression is again required to 
confirm this suggestion. 
Similar experiments conducted with DEM were carried out using a 
concentration of 150 μM to ensure changes in L-arginine transport could also be 
determined. This concentration was however supra-maximal for inhibition of NO 
synthesis and as such the inhibitions observed in the time course studies were much 
more prolonged. No nitrite was detected in samples obtained from cells treated 
either before or for up to 3 hours after activation but was virtually restored in samples 
where DEM was added 18 hours after LPS and IFN-γ. Similarly, induced L-arginine 
transport was back to the control activated levels when cells were exposed to DEM 
18 hours after activation but remained suppressed at all other time points. Taken 
together, these results again highlight that DEM, as with antimycin A, suppressed 
both processes by potentially inhibition the induction of either iNOS or CATs. 
 The second part of this thesis focused on establishing the effects of statins on 
both iNOS and L-arginine transport, and on the changes in these processes induced 
by antimycin A and DEM. Statins are amongst the drugs used for lowering 
cholesterol (Endo et al. 1976; Endo et al. 1977), and, as already stated, inhibit the 
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rate limiting HMG-CoA reductases in the cholesterol synthetic pathway (Goldstein 
and Brown 1990; Chong et al. 2001). These statins are either lipophilic or hydrophilic 
and can be naturally occurring or synthetic. A vast majority of studies distinguish 
between these compounds according to their lipophilicity which correlates with their 
pleiotropic effects. Lipophilic statins can enter cells by passive diffusion in contrast to 
hydrophilic molecules such as pravastatin that are unable to penetrate the plasma 
membrane of most cells (Turner et al. 2007). Certain cells such as hepatocytes have 
specific transporters to hydrophilic drugs and can therefore easily take up these 
compounds (Turner et al. 2007).  
Statins are increasingly prescribed due to their efficiency in lowering 
cholesterol and in protecting patients from cardiovascular events (Kronmann et al. 
2007; Bartholomeeusen et al. 2008). Some of these effects are however not 
exclusively related to their cholesterol lowering actions. Statins pleiotropic effects 
comprise anti-inflammatory properties, improvement of endothelial function, 
stabilizing atherosclerotic plaque, inhibiting platelet aggregation and vascular SMC 
proliferation (Nakagami et al. 2003; Chandrasekar et al. 2006; Greenwood and 
Mason 2007; Jasinska et al. 2007; Kronmann et al. 2007; Bersano et al. 2008; Shaw 
et al. 2009). The pharmacology of these drugs is also influential for patient’s 
treatment; therefore the plasma concentration, half-life and lipophilicity are 
determinant to the outcomes both on lowering cholesterol and on their pleiotropic 
effects. The statins used in this study differ in these parameters. Pravastatin for 
instance is a selective hydrophilic inhibitor. Its oral absorption is 34 % and its 
bioavailability is 17 % (Pan 1991). In patients, the maximum plasma concentrations 
is proportional to the doses administered and this drug, although binding 45 % to 
plasma proteins, shows no evidence of drug accumulation (Pan 1991). Up to 95 % of 
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lipophilic statins such as simvastatin and atorvastatin may bind to plasma proteins 
(Neuvonen et al. 2008).  
The mean plasma concentration of pravastatin may vary from 60 µM to 140 
µM while simvastatin reaches 10 µM after administration of a single dose of 40 mg 
(Neuvonen et al. 1998; Neuvonen et al. 2008). Plasma concentrations of atorvastatin 
after the administration of single doses of 40 and 80 mg could reach concentration of 
up to 28.6 µM and 66.2 µM respectively (Lins et al. 2003). In our studies the 
concentrations used range was from 1 to 100 µM, correlating with the human plasma 
concentrations found in patients given statins. Lipophilic statins like simvastatin and 
atorvastatin are however thought to be accumulated in cells and tissues, further 
propagating their pleiotropic effects (Turner et al. 2007). 
Statins demonstrate beneficial effects not only in patients with high 
cholesterol, but also in other pathologies. For instance, in patients with diabetes and 
normal LDL levels statins may improve vascular dysfunction by NADPH inhibition 
(Gao and Mann 2009). 
They may act on specific signalling molecules, regulating their activity, and in 
doing so alter the cellular processes which the molecules regulate. Some of these 
processes include regulation of iNOS gene transcription and thus expression and 
subsequent NO synthesis which has a direct bearing to the thesis. 
For our studies, three satins were used, including the synthetic compound 
atorvastatin which is commonly known as Zarator®. The other two are simvastatin or 
Zocor®, a synthetic derivate of a fermentation product of Aspergillus terreus, and 
pravastatin or Pravachol®, originally identified in a bacterium called Nocardia 
autotrophica. The data obtained with these compounds shows marked differences in 
their ability to regulate NO production and L-arginine transport. Atorvastatin, for 
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instance, produced a concentration-dependent bell shaped response on NO 
production with the maximal increase observed at 10 µM and represented a 6 fold 
increase when compared to the levels seen with LPS and IFN-γ alone. Even though 
these levels decreased thereafter, the amounts of nitrite detected in the presence of 
30 µM and 100 µM were still higher than those in the activated controls. Atorvastatin 
also enhanced L-arginine transport but only in induced cells where the activated 
rates were further enhanced in the presence of the drug. In this case the increase at 
1 µM to 30 µM appeared similar with no obvious concentration difference but the rate 
of transport declined back to the activated control levels with 100 µM. It is evident 
therefore that induction of NO synthesis was more susceptible than the transporters 
to regulation by atorvastatin. This trend was more evident with simvastatin which 
selectively enhanced induced NO synthesis without regulating L-arginine transport in 
either controls or activated cells. Moreover, pravastatin was without significant effect 
on either process. Although all three compounds inhibit HMG-CoA reductases and 
lower cholesterol, they do not appear to regulate the inducible L-arginine-NO 
pathway in a consistent similar manner, highlighting for the first time, differences in 
the alternative actions of these compounds. The results on NO production are 
corroborated by data from western blots in which iNOS protein expression was 
enhanced by both atorvastatin and simvastatin and over the concentration range that 
induced the increases in nitrite accumulation. Pravastatin again failed to cause any 
obvious significant change in iNOS expression. The reasons for the lack of effect 
with pravastatin are as yet undefined but as it is hydrophilic, it is possible that its 
penetration into RASMCs may be limited. There is however no data to indicate 
whether this may be the case or whether RASMCs actually lack the specific 
transporters required to internalising this compound.  
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In reviewing the literature, the following effects of statins on the NOS 
pathways were identified: simvastatin administered to endotoxic rat in vivo reduced 
iNOS expression in endothelial cells but not in SMCs (Giusti-Paiva et al. 2004; 
Alvarez de Sotomayor et al. 2008). Both eNOS and iNOS are up-regulated by 
atorvastatin in brain and aorta of hypertensive rats (Kishi et al. 2003). Simvastatin 
significantly increase eNOS but decrease iNOS mRNA and protein expression in rat 
hearts after ischemia-reperfusion (Di Napoli et al. 2001). Statins also consistently 
improve endothelium-dependent vasorelaxation in hyperlipidemic patients by 
increased NO bioavailability (Egashira et al. 1994; Treasure et al. 1995; Jiang et al. 
2004; Landmesser et al. 2004). Interestingly, simvastatin has been shown to cause 
relaxation of contracted arteries in the absence of endothelium (Perez-Guerrero et 
al. 2005) suggesting that not all its actions are endothelium dependent. Statins such 
as cerivastatin and fluvastatin have been shown to have little effect on NO 
production when added after the induction of iNOS, suggesting that these 
compounds do not regulate the activity of the enzyme once induced (Yamamoto et 
al. 2003). 
Currently, there is little or no information on the effects of statins on L-arginine 
transport and the data presented in this thesis, is to our knowledge, the only 
information currently available. What is important from the data is the clear 
discrimination between the statins in terms of their ability to regulate iNOS 
expression and the induced transporter activity and also the fact that the three 
statins selected for our studies demonstrated quite a completely different profile, 
when examined against NO production and L-arginine transport.  
Differences in the profile of actions of statins have been highlighted from 
clinical data with atorvastatin being more effective in reducing circulating cholesterol 
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levels with patients requiring 10 mg/day to achieve this. By comparison, patients on 
simvastatin required 40 mg/day to achieve the same effectiveness (Doggrell 2006). 
Atorvastatin is also reported to be more efficient than simvastatin and pravastatin in 
lowering both LDL and CRP and TNF-α levels (Ridker et al. 2002; Ridker et al. 2005; 
Doggrell 2006). In contrast, HDL levels are apparently increased more effectively by 
simvastatin and pravastatin with atorvastatin causing a less prominent effect in 
patients with diabetes or metabolic syndrome, except when combined with fibrates 
(Doggrell 2006). A more potent drug, rosuvastatin, depletes LDL levels more 
drastically than atorvastatin with rosuvastatin at 10, 20 and 40 mg/day reducing LDL 
by 46, 52 and 55 % while atorvastatin at 20, 40 and 80 mg/day lowered LDL-
cholesterol by 34, 45 and 51 % respectively. Atorvastatin at 20 mg/day is reported to 
reduce intimal thickness over 12 months and stabilised the process at lower 
concentrations. In contrast, simvastatin did not alter intimal thickening but the latter 
was reversed if patients were switched to atorvastatin (Doggrell 2006; Rubba 2007; 
Turner et al. 2007; Yu et al. 2007).  
Further analysis of the actions of the hydrophilic pravastatin revealed that the 
incidences of cardiovascular events were consistently lower when using this statin in 
patients with a history of myocardial infarction, than when using atorvastatin or 
simvastatin, where the benefits were more modest (Paciaroni et al. 2007). Similarly, 
in a model of pulmonary hypertension, pravastatin but not atorvastatin, significantly 
reduced hypertension and right ventricular pressure even though both drugs were 
used at equal concentrations (Rakotoniaina et al. 2006). In this study, pravastatin 
was reported to also diminished apoptosis at the same time that it up-regulated 
eNOS. By comparison, atorvastatin caused only modest changes (Rakotoniaina et 
al. 2006). These selected examples highlight the differences in the actions and 
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effectiveness of statins and suggests exercising some caution in not generalising 
their expected actions either in man or in experimental models. 
The mechanisms that regulate the effects of atorvastatin or simvastatin were 
not examined in this thesis because of lack of time but clearly warrant investigation. 
Speculating on potential mechanisms, it is likely that these compounds may act 
through cellular targets such as the small GTPase Rho. The latter is known to be 
negatively coupled to iNOS induction and its inhibition by statins, a common action 
widely reported (Chen et al. 2000; Muniyappa et al. 2000; Chen et al. 2001; Ikeda et 
al. 2001; Yamamoto et al. 2003; Madonna et al. 2005), may prevent the ability of 
Rho to repress iNOS gene expression, thereby resulting in a potentiation of iNOS 
protein and thus NO synthesis. Evidence in support of such actions was obtained 
with fluvastatin which apparently increased iNOS mRNA through the blockade of the 
Rho/Rho kinase pathway in rat VSMCs (Yamamoto et al. 2003). However, in 
embryonic cardiac myoblasts challenged with IL-1 or TNF-α, simvastatin inhibited 
iNOS expression and mRNA levels (Madonna et al. 2005). Whether this is a Rho 
mediated effect or simply reflecting differences in the cellular actions of statins is 
unclear. Interestingly, and of relevance to the findings in this thesis, pravastatin was 
unable to blunt Rho activity in SMCs (Yamanouchi et al. 2005) highlighting perhaps 
why it was ineffective in the RASMCs used in our studies. 
Additional mechanisms of actions could potentially include regulation of NOS 
gene transcription and in this regard, the transcriptional activity of the iNOS promoter 
has been shown to be augmented by atorvastatin in human VSMCs (Kolyada et al. 
2001). This statin is claimed to stabilise eNOS mRNA, increasing its half-life from 14 
up to 27 hours and this was considered to be responsible for the increase in NO 
bioavailability (Laufs et al. 1998; Laufs and Liao 1998). Additional to the above 
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actions, lipophilic statins such as cerivastatin and fluvastatin increase the cellular 
content of BH4 (Hattori et al. 2002) and this could also enhance the production of NO 
by coupled iNOS.  
Some reports have indicate statins may negatively couple with NF-κB and 
simvastatin has been shown to inhibit TNF-α stimulated activation of NF-κB, as 
demonstrated by elevated levels of p65 in the cytosol of TNF-α-stimulated 
endothelial cells (Zapolska-Downar et al. 2004). Simvastatin has also been shown to 
reduce NF-κB activation in epithelial cells (Sakoda et al. 2006) while atorvastatin 
exerted the same effect in SMCs and monocytes stimulated with TNF-α (Ortego et 
al. 1999). Simvastatin and atorvastatin both inhibited the activation of NF-κB in 
response to oxidized LDL in human umbilical vein endothelial cells and rat ischemic 
model (Sironi et al. 2006; Singh et al. 2008). In a rabbit model of atherosclerosis, 
atorvastatin also reduced the activity of NF-κB in vascular macrophages and SMCs 
(Bustos et al. 1998). These reports clearly implicating NF-κB in the actions of statins 
provide another potential pathway through which these compounds could regulate 
not only the induction of iNOS but also L-arginine transport as these are also NF-κB 
dependent as already discussed earlier. However, the studies carried out in this 
thesis show clearly that atorvastatin and simvastatin enhance induction of iNOS and 
NO synthesis. The negative coupling of these statins to NF-κB would therefore be at 
odds with these findings. Thus it would be essential to established whether statins 
are able to regulate induced NO production and L-arginine transport through 
regulation of NF-κB activation in RASMCs.  
Amongst the growing profile of actions exerted by statins, their ability to act as 
antioxidants has a direct influence in regulating OS induced modification of cellular 
processes. In a trial with diabetic patients, characterised by high ROS levels, 
 216
atorvastatin was able to prevent cardiovascular events (Collins et al. 2003) and in 
hyperglycaemic model it induced the re-coupling of eNOS through inhibition of 
NADPH oxidase expression (Wenzel et al. 2008). Furthermore, atorvastatin has 
been reported to induce several other antioxidant effects including: (i) increase 
catalase mRNA expression and activity (Wassmann et al. 2002), (ii) reducing ROS 
generation in a rat hypertensive model (Mondo et al. 2006) and (iii) down-regulating 
angiotensin II (AT1) receptor expression, consequently decreasing p22phox and 
exerting an antioxidant effect in endothelial cells (Wassmann et al. 2001; Zhou et al. 
2004). The antioxidant effects of statins have also been attributed to the inhibition of 
the Rho-kinase pathway and inhibition of the latter using the potent Rho-kinase 
inhibitor, farsudil, was able to deplete NADPH oxidase subunit (nox1, nox4, 
gp91phox and p22phox) expression in VSMCs thereby diminishing OS in these cells 
(Higashi et al. 2003).  
In view of the potential antioxidant properties of statins, studies were extended 
to include an examination of the effects of these compounds on the responses 
induced by antimycin A and DEM. As shown in the results section, atorvastatin 
restored NO production when applied in the presence of either antimycin A or DEM, 
reversing the inhibitory actions of these compounds. Moreover, atorvastatin 
potentiated levels of accumulated nitrite beyond those seen with LPS and IFN-γ, 
showing a similar bell-shaped response to that seen when atorvastatin was applied 
alone. By comparison, simvastatin and pravastatin were much less effective in 
overcoming the effects of antimycin A or DEM when compared to atorvastatin. None 
of the statins recovered the inhibition of induced L-arginine transport, further 
indicating that these processes may be regulated differentially. 
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The first product blocked by statins in the mevalonate pathway is mevalonic 
acid which is produced by the rate limiting enzyme HMG-CoA reductase. Because of 
this, additional studies were conducted examining the effects of mevalonate on 
induced NO synthesis and L-arginine transport. Moreover, the ability of mevalonate 
to modulate the actions of statins was also investigated. On its own, mevalonate was 
without significant effect on either nitrite production or L-arginine transport but 
appeared to inhibit the increments in NO production caused by atorvastatin and 
simvastatin. In contrast, the effects of the latter on L-arginine transport remained 
unaffected while the enhancements caused by atorvastatin were blocked. This is a 
novel finding which has not been reported before and again indicate that atorvastatin 
and simvastatin may regulate these processes via different mechanisms which have 
not as yet been fully elucidated. It would appear however that the actions of both 
statins on NO production may be mediated via the Rho pathway and would be 
consistent with published literature as discussed earlier. It is also possible that the 
effects of atorvastatin on transport may potentially involve Rho because of its 
susceptibility to mevalonate but this needs to be confirmed and an alternative 
mechanism of action cannot be ruled out. In this regard, a study in neuronal cells 
and macrophages, where statins inhibited iNOS and pro-inflammatory cytokines, co-
incubation with cholesterol or ubiquinone, the end products of the mevalonate 
pathway, did not reverse the actions of statins (Pahan et al. 1997). 
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4.1 . Summary and conclusions 
 
The data generated in this thesis has highlighted some important differences 
in the regulation of the inducible L-arginine-NO pathway in cultured vascular smooth 
muscle cells by OS inducers and thus potentially OS. One of the key findings is the 
fact that H2O2, a key OS inducer and intermediate in the process of OS, was without 
effect while antimycin A and DEM both regulated induced NO synthesis and L-
arginine transport. The data with the latter two confirm that the inducible L-arginine-
NO pathway can be down-regulated by OS inducers and this may contribute to the 
deleterious effects observed in disease states associated with OS. However, 
antimycin A and DEM exhibited different profiles of action and only DEM induced 
HO-1 expression indicating perhaps that the effects of antimycin A were not related 
to the induction of OS.  
In the second half of the studies, statins were found to regulate both induced 
NO production and L-arginine transport but the effects produced depended on the 
statin used and unlike their cholesterol lowering actions, not all statins may have the 
ability to regulate the inducible L-arginine-NO pathway. A good illustration of this is 
the fact that pravastatin was without effect in our system while atorvastatin and 
simvastatin both enhanced iNOS expression and NO synthesis. Only atorvastatin 
regulated L-arginine transport, elevating the latter in LPS and IFN-γ treated cells but 
not in controls. Moreover, atorvastatin reversed the inhibition of NO production 
caused by either antimycin A or DEM but the inhibitions of L-arginine transport 
caused by OS inducers were unaffected by statins.  
Taken together, the data highlighting the effects of statins (especially 
atorvastatin) on NO production and L-arginine transport are encouraging if we 
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consider the original hypothesis proposed which is the deleterious effect of OS may 
be mediated in part through suppression of iNOS induced NO production whereby 
the protective and beneficial effects of the latter are lost, contributing to the 
pathogenesis of atherosclerosis. The ability of statins such as atorvastatin to restore 
NO production in the presence of OS inducers could contribute to the cardio-
protective actions of these compounds and the data from this thesis may help further 
in understanding how these drugs act. 
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5 . Future work 
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The limited experiments with PAECs raise questions about which carrier 
would be involved on L-arginine transport under the conditions presented. Further 
studies on kinetics, amino acid cross-inhibitions studies to verify the transporter 
selectivity and ultimately investigation by PCR analysis are necessary. 
 
 There is need to confirm the presence of ROS and determine the levels 
released under the different experimental conditions especially when using pro-
oxidants. Inflammation is also a source of ROS and their detection should be 
measured in the presence of LPS and IFN-γ alone or/and together with pro-oxidants 
(Javesghani et al. 2003). The presence and amount of ROS formed during the 
incubation periods would also allow us to infer more accurately if the effects are 
actually due to the free radicals generation or other mechanisms. The detection of 
ROS could be carried out by chemiluminescence using lucigenin (Javesghani et al. 
2003). 
 
 Quantitative PCR analysis of iNOS and CATs induction or lack of it in the 
presence of antimycin A or DEM (and possibly H2O2) is required to confirm whether 
the changes some of the effects observed are related to a change in gene 
expression of either iNOS and/or CATs.  
 
The effects observed with OS inducers and/or statins are most likely affecting 
signalling pathways and studies looking at key signalling molecules known to 
regulate iNOS expression and/or CATs should be conducted following treatment of 
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cells under the different conditions investigated. Some of the pathways could include 
Rho, the P38 MAPKs, PI3K and the transcription factor NF-kB.  
 223
 
 
 
 
 
 
 
 
6 . References 
 
 224
 
Abu-Soud, Rousseau, et al. (1996). "Nitric oxide binding to the heme of neuronal 
nitric-oxide synthase links its activity to changes in oxygen tension." J Biol 
Chem 271(51): 32515-8. 
Adachi, Pimentel, et al. (2004). "S-glutathiolation of Ras mediates redox-sensitive 
signaling by angiotensin II in vascular smooth muscle cells." J Biol Chem 
279(28): 29857-62. 
Adam-Vizi (2005). "Production of reactive oxygen species in brain mitochondria: 
contribution by electron transport chain and non-electron transport chain 
sources." Antioxid Redox Signal 7(9-10): 1140-9. 
Adam and Laufs (2008). "Antioxidative effects of statins." Arch Toxicol 82(12): 885-
92. 
Ago and Sadoshima (2006). "Thioredoxin and ventricular remodeling." J Mol Cell 
Cardiol 41(5): 762-73. 
Alderton, Cooper, et al. (2001). "Nitric oxide synthases: structure, function and 
inhibition." Biochem J 357(Pt 3): 593-615. 
Aldieri, Riganti, et al. (2008). "Classical inhibitors of NOX NAD(P)H oxidases are not 
specific." Curr Drug Metab 9(8): 686-96. 
Alp and Channon (2004). "Regulation of endothelial nitric oxide synthase by 
tetrahydrobiopterin in vascular disease." Arterioscler Thromb Vasc Biol 24(3): 
413-20. 
Alvarez de Sotomayor, Vega, et al. (2008). "Effects of HMG-CoA reductase inhibition 
by simvastatin on vascular dysfunction induced by lipopolysaccharide in rats." 
Pharmacology 82(2): 89-96. 
 225
Amezcua-Guerra, Springall del Villar, et al. (2007). "[C-reactive protein: 
cardiovascular issues of an acute-phase protein]." Arch Cardiol Mex 77(1): 
58-66. 
Antohe (2006). "Endothelial cells and macrophages, partners in atherosclerotic 
plaque progression." Arch Physiol Biochem 112(4-5): 245-53. 
Arendt, Ellinger, et al. (2005). "Single and repeated moderate consumption of native 
or dealcoholized red wine show different effects on antioxidant parameters in 
blood and DNA strand breaks in peripheral leukocytes in healthy volunteers: a 
randomized controlled trial (ISRCTN68505294)." Nutr J 4: 33. 
Arnaboldi, Guzzetta, et al. (2007). "Serum from hypercholesterolemic patients 
treated with atorvastatin or simvastatin inhibits cultured human smooth 
muscle cell proliferation." Pharmacol Res 56(6): 503-8. 
Assreuy and Moncada (1992). "A perfusion system for the long term study of 
macrophage activation." Br J Pharmacol 107(2): 317-21. 
Aviram, Rosenblat, et al. (1998). "Atorvastatin and gemfibrozil metabolites, but not 
the parent drugs, are potent antioxidants against lipoprotein oxidation." 
Atherosclerosis 138(2): 271-80. 
Bannai (1984). "Induction of cystine and glutamate transport activity in human 
fibroblasts by diethyl maleate and other electrophilic agents." J Biol Chem 
259(4): 2435-40. 
Bartholomeeusen, Vandenbroucke, et al. (2008). "Trends in total cholesterol 
screening and in prescribing lipid-lowering drugs in general practice in the 
period 1994-2003." BMC Fam Pract 9: 39. 
 226
Bauch, Forster, et al. (2003). "Functional cooperation of epithelial heteromeric amino 
acid transporters expressed in madin-darby canine kidney cells." J Biol Chem 
278(2): 1316-22. 
Bauersachs, Hiss, et al. (2006). "Simvastatin improves left ventricular function after 
myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory 
effects." Cardiovasc Res 72(3): 438-46. 
Baydoun, Bertran, et al. (2006). "y+ LAT-1 mediates transport of the potent and 
selective iNOS inhibitor, GW274150, in control J774 macrophages." Amino 
Acids 31(2): 101-9. 
Baydoun, Emery, et al. (1990). "Substrate-dependent regulation of intracellular 
amino acid concentrations in cultured bovine aortic endothelial cells." 
Biochem Biophys Res Commun 173(3): 940-8. 
Baydoun and Mann (1994). "Selective targeting of nitric oxide synthase inhibitors to 
system y+ in activated macrophages." Biochem Biophys Res Commun 
200(2): 726-31. 
Baydoun, Wileman, et al. (1999). "Transmembrane signalling mechanisms regulating 
expression of cationic amino acid transporters and inducible nitric oxide 
synthase in rat vascular smooth muscle cells." Biochem J 344 Pt 1: 265-72. 
Beckman, Beckman, et al. (1990). "Apparent hydroxyl radical production by 
peroxynitrite: implications for endothelial injury from nitric oxide and 
superoxide." Proc Natl Acad Sci U S A 87(4): 1620-4. 
Bengtsson, Gulluyan, et al. (2003). "Novel isoforms of NADPH oxidase in vascular 
physiology and pathophysiology." Clin Exp Pharmacol Physiol 30(11): 849-54. 
 227
Bentzon, Weile, et al. (2006). "Smooth muscle cells in atherosclerosis originate from 
the local vessel wall and not circulating progenitor cells in ApoE knockout 
mice." Arterioscler Thromb Vasc Biol 26(12): 2696-702. 
Berg, Sappington, et al. (2003). "Proinflammatory cytokines increase the rate of 
glycolysis and adenosine-5'-triphosphate turnover in cultured rat enterocytes." 
Crit Care Med 31(4): 1203-12. 
Bernatova, Pechanova, et al. (2002). "Wine polyphenols improve cardiovascular 
remodeling and vascular function in NO-deficient hypertension." Am J Physiol 
Heart Circ Physiol 282(3): H942-8. 
Bersano, Ballabio, et al. (2008). "Statins and stroke." Curr Med Chem 15(23): 2380-
92. 
Bevers, Braam, et al. (2006). "Tetrahydrobiopterin, but not L-arginine, decreases NO 
synthase uncoupling in cells expressing high levels of endothelial NO 
synthase." Hypertension 47(1): 87-94. 
Bickers and Athar (2006). "Oxidative stress in the pathogenesis of skin disease." J 
Invest Dermatol 126(12): 2565-75. 
Blanc, Pandey, et al. (2004). "Distinct roles of Ca2+, calmodulin, and protein kinase 
C in H2O2-induced activation of ERK1/2, p38 MAPK, and protein kinase B 
signaling in vascular smooth muscle cells." Antioxid Redox Signal 6(2): 353-
66. 
Boaz, Smetana, et al. (2000). "Secondary prevention with antioxidants of 
cardiovascular disease in endstage renal disease (SPACE): randomised 
placebo-controlled trial." Lancet 356(9237): 1213-8. 
 228
Bogle, Baydoun, et al. (1996). "Regulation of L-arginine transport and nitric oxide 
release in superfused porcine aortic endothelial cells." J Physiol 490 (Pt 1): 
229-41. 
Bogle, Baydoun, et al. (1992). "L-arginine transport is increased in macrophages 
generating nitric oxide." Biochem J 284 (Pt 1): 15-8. 
Bogle, Coade, et al. (1991). "Bradykinin and ATP stimulate L-arginine uptake and 
nitric oxide release in vascular endothelial cells." Biochem Biophys Res 
Commun 180(2): 926-32. 
Bonomini, Tengattini, et al. (2008). "Atherosclerosis and oxidative stress." Histol 
Histopathol 23(3): 381-90. 
Borradaile, Buhman, et al. (2006). "A critical role for eukaryotic elongation factor 1A-
1 in lipotoxic cell death." Mol Biol Cell 17(2): 770-8. 
Boughton-Smith, Evans, et al. (1993). "The induction of nitric oxide synthase and 
intestinal vascular permeability by endotoxin in the rat." Br J Pharmacol 
110(3): 1189-95. 
Boveris, Cadenas, et al. (1976). "Role of ubiquinone in the mitochondrial generation 
of hydrogen peroxide." Biochem J 156(2): 435-44. 
Boveris and Chance (1973). "The mitochondrial generation of hydrogen peroxide. 
General properties and effect of hyperbaric oxygen." Biochem J 134(3): 707-
16. 
Boyland and Chasseaud (1967). "Enzyme-catalysed conjugations of glutathione with 
unsaturated compounds." Biochem J 104(1): 95-102. 
Boyle (2005). "Macrophage activation in atherosclerosis: pathogenesis and 
pharmacology of plaque rupture." Curr Vasc Pharmacol 3(1): 63-8. 
 229
Braddock, Schwachtgen, et al. (1998). "Fluid Shear Stress Modulation of Gene 
Expression in Endothelial Cells." News Physiol Sci 13: 241-246. 
Brandes and Schroder (2008). "Differential vascular functions of Nox family NADPH 
oxidases." Curr Opin Lipidol 19(5): 513-8. 
Briante, Febbraio, et al. (2003). "Antioxidant properties of low molecular weight 
phenols present in the mediterranean diet." J Agric Food Chem 51(24): 6975-
81. 
Broer, Wagner, et al. (2000). "The heterodimeric amino acid transporter 
4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine." Biochem 
J 349 Pt 3: 787-95. 
Bundy, Hoare, et al. (2005). "Redox regulation of p38 MAPK activation and 
expression of ICAM-1 and heme oxygenase-1 in human alveolar epithelial 
(A549) cells." Antioxid Redox Signal 7(1-2): 14-24. 
Bustos, Hernandez-Presa, et al. (1998). "HMG-CoA reductase inhibition by 
atorvastatin reduces neointimal inflammation in a rabbit model of 
atherosclerosis." J Am Coll Cardiol 32(7): 2057-64. 
Buttery, Springall, et al. (1996). "Inducible nitric oxide synthase is present within 
human atherosclerotic lesions and promotes the formation and activity of 
peroxynitrite." Lab Invest 75(1): 77-85. 
Calabrese, Butterfield, et al. (2006). "Redox regulation of heat shock protein 
expression by signaling involving nitric oxide and carbon monoxide: relevance 
to brain aging, neurodegenerative disorders, and longevity." Antioxid Redox 
Signal 8(3-4): 444-77. 
 230
Calderon Guzman, Barragan Mejia, et al. (2006). "Effect of nutritional status and 
ozone exposure on some biomarkers of oxidative stress in rat brain regions." 
Nutr Cancer 55(2): 195-200. 
Campbell and Campbell (1993). "Culture techniques and their applications to studies 
of vascular smooth muscle." Clin Sci (Lond) 85(5): 501-13. 
Cave, Brewer, et al. (2006). "NADPH oxidases in cardiovascular health and 
disease." Antioxid Redox Signal 8(5-6): 691-728. 
Chakraborti and Chakraborti (1998). "Oxidant-mediated activation of mitogen-
activated protein kinases and nuclear transcription factors in the 
cardiovascular system: a brief overview." Cell Signal 10(10): 675-83. 
Chandrasekar, Mummidi, et al. (2006). "Interleukin-18-induced human coronary 
artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-
mediated matrix metalloproteinase-9 expression and is inhibited by 
atorvastatin." J Biol Chem 281(22): 15099-109. 
Chapidze, Kapanadze, et al. (2006). "[Combination treatment with coenzyme Q10 
and simvastatin in patients with coronary atherosclerosis]." Kardiologiia 46(8): 
11-3. 
Chen, Ikeda, et al. (2000). "Fluvastatin upregulates inducible nitric oxide synthase 
expression in cytokine-stimulated vascular smooth muscle cells." 
Hypertension 36(6): 923-8. 
Chen, Kuhlencordt, et al. (2003). "Effects of chronic treatment with L-arginine on 
atherosclerosis in apoE knockout and apoE/inducible NO synthase double-
knockout mice." Arterioscler Thromb Vasc Biol 23(1): 97-103. 
Chen, Niroomand, et al. (2006). "Expression of nitric oxide related enzymes in 
coronary heart disease." Basic Res Cardiol 101(4): 346-53. 
 231
Chen, Xing, et al. (2001). "Lovastatin increases nitric oxide synthesis in IL-1 beta-
stimulated smooth muscle cells." Chin Med J (Engl) 114(11): 1123-7. 
Chester, O'Neil, et al. (1990). "Low basal and stimulated release of nitric oxide in 
atherosclerotic epicardial coronary arteries." Lancet 336(8720): 897-900. 
Chevalier, Thorin, et al. (2000). "Simultaneous measurement of ERK, p38, and JNK 
MAP kinase cascades in vascular smooth muscle cells." J Pharmacol Toxicol 
Methods 44(2): 429-39. 
Chiarugi and Fiaschi (2007). "Redox signalling in anchorage-dependent cell growth." 
Cell Signal 19(4): 672-82. 
Chin-Dusting, Willems, et al. (2007). "L-arginine transporters in cardiovascular 
disease: a novel therapeutic target." Pharmacol Ther 116(3): 428-36. 
Chong, Seeger, et al. (2001). "Clinically relevant differences between the statins: 
implications for therapeutic selection." Am J Med 111(5): 390-400. 
Chu, Tsai, et al. (2005). "NF-kappaB inhibitors significantly attenuate the 
transcription of high affinity type-2 cationic amino acid transporter in LPS-
stimulated rat kidney." Acta Anaesthesiol Taiwan 43(1): 23-32. 
Chuang, Chan, et al. (2007). "The effect of urban air pollution on inflammation, 
oxidative stress, coagulation, and autonomic dysfunction in young adults." Am 
J Respir Crit Care Med 176(4): 370-6. 
Closs, Albritton, et al. (1993). "Identification of a low affinity, high capacity transporter 
of cationic amino acids in mouse liver." J Biol Chem 268(10): 7538-44. 
Closs, Boissel, et al. (2006). "Structure and function of cationic amino acid 
transporters (CATs)." J Membr Biol 213(2): 67-77. 
Closs, Borel Rinkes, et al. (1993). "Retroviral infection and expression of cationic 
amino acid transporters in rodent hepatocytes." J Virol 67(4): 2097-102. 
 232
Closs, Lyons, et al. (1993). "Characterization of the third member of the MCAT family 
of cationic amino acid transporters. Identification of a domain that determines 
the transport properties of the MCAT proteins." J Biol Chem 268(28): 20796-
800. 
Closs and Mann (1999). "Identification of carrier systems in plasma membranes of 
mammalian cells involved in transport of L-arginine." Methods Enzymol 301: 
78-91. 
Collins, Armitage, et al. (2003). "MRC/BHF Heart Protection Study of cholesterol-
lowering with simvastatin in 5963 people with diabetes: a randomised 
placebo-controlled trial." Lancet 361(9374): 2005-16. 
Cook-Mills (2006). "Hydrogen peroxide activation of endothelial cell-associated 
MMPs during VCAM-1-dependent leukocyte migration." Cell Mol Biol (Noisy-
le-grand) 52(4): 8-16. 
Cooke and Davidge (2002). "Peroxynitrite increases iNOS through NF-kappaB and 
decreases prostacyclin synthase in endothelial cells." Am J Physiol Cell 
Physiol 282(2): C395-402. 
Cooper and Magwere (2008). "Nitric oxide-mediated pathogenesis during nicotine 
and alcohol consumption." Indian J Physiol Pharmacol 52(1): 11-8. 
Coughlan, Cooper, et al. (2007). "Renal microvascular injury in diabetes: RAGE and 
redox signaling." Antioxid Redox Signal 9(3): 331-42. 
Creager, Cooke, et al. (1990). "Impaired vasodilation of forearm resistance vessels 
in hypercholesterolemic humans." J Clin Invest 86(1): 228-34. 
Cross and Segal (2004). "The NADPH oxidase of professional phagocytes--
prototype of the NOX electron transport chain systems." Biochim Biophys 
Acta 1657(1): 1-22. 
 233
Crouse (2006). "Thematic review series: patient-oriented research. Imaging 
atherosclerosis: state of the art." J Lipid Res 47(8): 1677-99. 
D'Autreaux and Toledano (2007). "ROS as signalling molecules: mechanisms that 
generate specificity in ROS homeostasis." Nat Rev Mol Cell Biol 8(10): 813-
24. 
Dall'Asta, Bussolati, et al. (2000). "Arginine transport through system y(+)L in 
cultured human fibroblasts: normal phenotype of cells from LPI subjects." Am 
J Physiol Cell Physiol 279(6): C1829-37. 
Dalton, Shertzer, et al. (1999). "Regulation of gene expression by reactive oxygen." 
Annu Rev Pharmacol Toxicol 39: 67-101. 
Davidson (2000). "Does differing metabolism by cytochrome p450 have clinical 
importance?" Curr Atheroscler Rep 2(1): 14-9. 
Davies (1995). "Oxidative stress: the paradox of aerobic life." Biochem Soc Symp 
61: 1-31. 
Delbosc, Cristol, et al. (2002). "Simvastatin prevents angiotensin II-induced cardiac 
alteration and oxidative stress." Hypertension 40(2): 142-7. 
Delbosc, Morena, et al. (2002). "Statins, 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors, are able to reduce superoxide anion production by 
NADPH oxidase in THP-1-derived monocytes." J Cardiovasc Pharmacol 
40(4): 611-7. 
Dennery (2004). "Introduction to serial review on heme oxygenase in human 
disease." Free Radic Biol Med 37(8): 1095-6. 
Deves and Boyd (1998). "Transporters for cationic amino acids in animal cells: 
discovery, structure, and function." Physiol Rev 78(2): 487-545. 
 234
Di Napoli, Antonio Taccardi, et al. (2001). "Simvastatin reduces reperfusion injury by 
modulating nitric oxide synthase expression: an ex vivo study in isolated 
working rat hearts." Cardiovasc Res 51(2): 283-93. 
Diouf, Garcon, et al. (2006). "Environmental lead exposure and its relationship to 
traffic density among Senegalese children: a cross-sectional study." Hum Exp 
Toxicol 25(11): 637-44. 
Doggrell (2006). "Is atorvastatin superior to other statins? Analysis of the clinical 
trials with atorvastatin having cardiovascular endpoints." Rev Recent Clin 
Trials 1(2): 143-53. 
Doran, Meller, et al. (2008). "Role of smooth muscle cells in the initiation and early 
progression of atherosclerosis." Arterioscler Thromb Vasc Biol 28(5): 812-9. 
Durante (2001). "Regulation of L-arginine transport and metabolism in vascular 
smooth muscle cells." Cell Biochem Biophys 35(1): 19-34. 
Durante, Liao, et al. (1995). "Differential regulation of L-arginine transport and 
inducible NOS in cultured vascular smooth muscle cells." Am J Physiol 268(3 
Pt 2): H1158-64. 
Durante, Liao, et al. (1995). "Differential regulation of L-arginine transport and 
inducible NOS in cultured vascular smooth muscle cells." Am.J.Physiol.Heart 
Circ.Physiol. 268: H1158-H1164. 
Egashira, Hirooka, et al. (1994). "Reduction in serum cholesterol with pravastatin 
improves endothelium-dependent coronary vasomotion in patients with 
hypercholesterolemia." Circulation 89(6): 2519-24. 
Elahi, Naseem, et al. (2007). "Nitric oxide in blood. The nitrosative-oxidative 
disequilibrium hypothesis on the pathogenesis of cardiovascular disease." 
Febs J 274(4): 906-23. 
 235
Endo, Kuroda, et al. (1976). "ML-236A, ML-236B, and ML-236C, new inhibitors of 
cholesterogenesis produced by Penicillium citrinium." J Antibiot (Tokyo) 
29(12): 1346-8. 
Endo, Tsujita, et al. (1977). "Inhibition of cholesterol synthesis in vitro and in vivo by 
ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase." Eur J Biochem 77(1): 31-6. 
Escobales and Crespo (2005). "Oxidative-nitrosative stress in hypertension." Curr 
Vasc Pharmacol 3(3): 231-46. 
Farombi and Surh (2006). "Heme oxygenase-1 as a potential therapeutic target for 
hepatoprotection." J Biochem Mol Biol 39(5): 479-91. 
Feron, Dessy, et al. (2001). "Hydroxy-methylglutaryl-coenzyme A reductase 
inhibition promotes endothelial nitric oxide synthase activation through a 
decrease in caveolin abundance." Circulation 103(1): 113-8. 
Fialkow, Wang, et al. (2007). "Reactive oxygen and nitrogen species as signaling 
molecules regulating neutrophil function." Free Radic Biol Med 42(2): 153-64. 
Fleming and Busse (1999). "NO: the primary EDRF." J Mol Cell Cardiol 31(1): 5-14. 
Fleming and Busse (1999). "Signal transduction of eNOS activation." Cardiovasc 
Res 43(3): 532-41. 
Fleming, Hecker, et al. (1994). "Intracellular alkalinization induced by bradykinin 
sustains activation of the constitutive nitric oxide synthase in endothelial 
cells." Circ Res 74(6): 1220-6. 
Forstermann (2006). "Janus-faced role of endothelial NO synthase in vascular 
disease: uncoupling of oxygen reduction from NO synthesis and its 
pharmacological reversal." Biol Chem 387(12): 1521-33. 
 236
Forstermann (2008). "Oxidative stress in vascular disease: causes, defense 
mechanisms and potential therapies." Nat Clin Pract Cardiovasc Med 5(6): 
338-49. 
Forstermann and Munzel (2006). "Endothelial nitric oxide synthase in vascular 
disease: from marvel to menace." Circulation 113(13): 1708-14. 
Furchgott (1993). "Introduction to EDRF research." J Cardiovasc Pharmacol 22 
Suppl 7: S1-2. 
Furchgott and Vanhoutte (1989). "Endothelium-derived relaxing and contracting 
factors." Faseb J 3(9): 2007-18. 
Furchgott and Zawadzki (1980). "The obligatory role of endothelial cells in the 
relaxation of arterial smooth muscle by acetylcholine." Nature 288(5789): 373-
6. 
Gao and Mann (2009). "Vascular NAD(P)H oxidase activation in diabetes: a double-
edged sword in redox signalling." Cardiovasc Res 82(1): 9-20. 
Geiszt (2006). "NADPH oxidases: new kids on the block." Cardiovasc Res 71(2): 
289-99. 
Ghosh and Stuehr (1995). "Macrophage NO synthase: characterization of isolated 
oxygenase and reductase domains reveals a head-to-head subunit 
interaction." Biochemistry 34(3): 801-7. 
Gill, Low, et al. (1996). "Interleukin-1beta and tumor necrosis factor-alpha stimulate 
the cat-2 gene of the L-arginine transporter in cultured vascular smooth 
muscle cells." Journal of Biological Chemistry 271: 11280-11283. 
Girona, La Ville, et al. (1999). "Simvastatin decreases aldehyde production derived 
from lipoprotein oxidation." Am J Cardiol 83(6): 846-51. 
 237
Giusti-Paiva, Martinez, et al. (2004). "Simvastatin decreases nitric oxide 
overproduction and reverts the impaired vascular responsiveness induced by 
endotoxic shock in rats." Shock 21(3): 271-5. 
Goldstein and Brown (1990). "Regulation of the mevalonate pathway." Nature 
343(6257): 425-30. 
Graham, Hogg, et al. (1993). "Peroxynitrite modification of low-density lipoprotein 
leads to recognition by the macrophage scavenger receptor." FEBS Lett 
330(2): 181-5. 
Granger, Hibbs, et al. (1990). "Metabolic fate of L-arginine in relation to 
microbiostatic capability of murine macrophages." J Clin Invest 85(1): 264-73. 
Granger, Vowinkel, et al. (2004). "Modulation of the inflammatory response in 
cardiovascular disease." Hypertension 43(5): 924-31. 
Green, Wagner, et al. (1982). "Analysis of nitrate, nitrite, and [15N]nitrate in 
biological fluids." Anal Biochem 126(1): 131-8. 
Greene, Pacitti, et al. (1993). "Characterization of L-arginine transport by pulmonary 
artery endothelial cells." Am J Physiol 264(4 Pt 1): L351-6. 
Greenwood and Mason (2007). "Statins and the vascular endothelial inflammatory 
response." Trends Immunol 28(2): 88-98. 
Griffiths (2005). "ROS as signalling molecules in T cells--evidence for abnormal 
redox signalling in the autoimmune disease, rheumatoid arthritis." Redox Rep 
10(6): 273-80. 
Groves, Wang, et al. (2005). "Two distinct phenotypes of rat vascular smooth muscle 
cells: growth rate and Production of tumor necrosis factor-alpha." Am Surg 
71(7): 546-50; discussion 550-1. 
 238
Grzelak, Rychlik, et al. (2001). "Light-dependent generation of reactive oxygen 
species in cell culture media." Free Radic Biol Med 30(12): 1418-25. 
Gupte (2008). "Glucose-6-phosphate dehydrogenase: a novel therapeutic target in 
cardiovascular diseases." Curr Opin Investig Drugs 9(9): 993-1000. 
Haendeler, Popp, et al. (2005). "Cathepsin D and H2O2 stimulate degradation of 
thioredoxin-1: implication for endothelial cell apoptosis." J Biol Chem 280(52): 
42945-51. 
Hagenbuch and Meier (2003). "The superfamily of organic anion transporting 
polypeptides." Biochim Biophys Acta 1609(1): 1-18. 
Hammermann, Dreissig, et al. (2000). "Nuclear factor-kappaB mediates 
simultaneous induction of inducible nitric-oxide synthase and Up-regulation of 
the cationic amino acid transporter CAT-2B in rat alveolar macrophages." Mol 
Pharmacol 58(6): 1294-302. 
Han, Kim, et al. (2007). "The changes of intracellular H2O2 are an important factor 
maintaining mitochondria membrane potential of antimycin A-treated As4.1 
juxtaglomerular cells." Biochem Pharmacol 73(6): 863-72. 
Hansson and Libby (2006). "The immune response in atherosclerosis: a double-
edged sword." Nat Rev Immunol 6(7): 508-19. 
Harrison (1997). "Endothelial function and oxidant stress." Clin Cardiol 20(11 Suppl 
2): II-11-7. 
Hattori, Kasai, et al. (1999). "Cationic amino acid transporter gene expression in 
cultured vascular smooth muscle cells and in rats." Am J Physiol 276(6 Pt 2): 
H2020-8. 
 239
Hattori, Kasai, et al. (2004). "NO suppresses while peroxynitrite sustains NF-kappaB: 
a paradigm to rationalize cytoprotective and cytotoxic actions attributed to 
NO." Cardiovasc Res 63(1): 31-40. 
Hattori, Nakanishi, et al. (2002). "Statin enhances cytokine-mediated induction of 
nitric oxide synthesis in vascular smooth muscle cells." Cardiovasc Res 54(3): 
649-58. 
Hayashi, Esaki, et al. (2006). "Modulating role of estradiol on arginase II expression 
in hyperlipidemic rabbits as an atheroprotective mechanism." Proc Natl Acad 
Sci U S A 103(27): 10485-90. 
Hemmrich, Suschek, et al. (2003). "iNOS activity is essential for endothelial stress 
gene expression protecting against oxidative damage." J Appl Physiol 95(5): 
1937-46. 
Herkert, Djordjevic, et al. (2004). "Insights into the redox control of blood coagulation: 
role of vascular NADPH oxidase-derived reactive oxygen species in the 
thrombogenic cycle." Antioxid Redox Signal 6(4): 765-76. 
Hernandez-Perera, Perez-Sala, et al. (1998). "Effects of the 3-hydroxy-3-
methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the 
expression of endothelin-1 and endothelial nitric oxide synthase in vascular 
endothelial cells." J Clin Invest 101(12): 2711-9. 
Higashi, Shimokawa, et al. (2003). "Long-term inhibition of Rho-kinase suppresses 
angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on 
endothelial NAD(P)H oxidase system." Circ Res 93(8): 767-75. 
Hofnagel, Luechtenborg, et al. (2006). "Pravastatin inhibits expression of lectin-like 
oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable 
 240
hyperlipidemic rabbits: a new pleiotropic effect of statins." Arterioscler Thromb 
Vasc Biol 26(3): 604-10. 
Hofnagel, Luechtenborg, et al. (2007). "Statins and foam cell formation: impact on 
LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors." 
Biochim Biophys Acta 1771(9): 1117-24. 
Hogg, Darley-Usmar, et al. (1993). "Peroxynitrite and atherosclerosis." Biochem Soc 
Trans 21(2): 358-62. 
Hogue, Lamarche, et al. (2008). "Differential effect of atorvastatin and fenofibrate on 
plasma oxidized low-density lipoprotein, inflammation markers, and cell 
adhesion molecules in patients with type 2 diabetes mellitus." Metabolism 
57(3): 380-6. 
Hosokawa, Sawamura, et al. (1997). "Cloning and characterization of a brain-specific 
cationic amino acid transporter." J Biol Chem 272(13): 8717-22. 
Hsiang, Zhu, et al. (1999). "A novel human hepatic organic anion transporting 
polypeptide (OATP2). Identification of a liver-specific human organic anion 
transporting polypeptide and identification of rat and human 
hydroxymethylglutaryl-CoA reductase inhibitor transporters." J Biol Chem 
274(52): 37161-8. 
Huang, Li, et al. (1999). "Lipid hydroperoxides inhibit nitric oxide production in 
RAW264.7 macrophages." Free Radic Biol Med 26(5-6): 526-37. 
Huang, Tsai, et al. (2004). "Pulmonary transcription of CAT-2 and CAT-2B but not 
CAT-1 and CAT-2A were upregulated in hemorrhagic shock rats." 
Resuscitation 63(2): 203-12. 
Ignarro (1990). "Biosynthesis and metabolism of endothelium-derived nitric oxide." 
Annu Rev Pharmacol Toxicol 30: 535-60. 
 241
Ignarro (1999). "Nitric oxide: a unique endogenous signaling molecule in vascular 
biology." Biosci Rep 19(2): 51-71. 
Ignarro (2002). "Wei Lun Visiting Professorial Lecture: Nitric oxide in the regulation of 
vascular function: an historical overview." J Card Surg 17(4): 301-6. 
Ikeda, Shimpo, et al. (2001). "Lipophilic statins augment inducible nitric oxide 
synthase expression in cytokine-stimulated cardiac myocytes." J Cardiovasc 
Pharmacol 38(1): 69-77. 
Inagi (2006). "Oxidative stress in cardiovascular disease: a new avenue toward 
future therapeutic approaches." Recent Patents Cardiovasc Drug Discov 1(2): 
151-9. 
Itagaki, Shimizu, et al. (2005). "Opposing effects of oestradiol and progesterone on 
intracellular pathways and activation processes in the oxidative stress induced 
activation of cultured rat hepatic stellate cells." Gut 54(12): 1782-9. 
Ito and Groudine (1997). "A new member of the cationic amino acid transporter 
family is preferentially expressed in adult mouse brain." J Biol Chem 272(42): 
26780-6. 
Izzo, Guerrieri, et al. (1978). "On the mechanism of inhibition of the respiratory chain 
by 2-heptyl-4-hydroxyquinoline-N-oxide." FEBS Lett 93(2): 320-2. 
Jasinska, Owczarek, et al. (2007). "Statins: a new insight into their mechanisms of 
action and consequent pleiotropic effects." Pharmacol Rep 59(5): 483-99. 
Javesghani, Hussain, et al. (2003). "Superoxide production in the vasculature of 
lipopolysaccharide-treated rats and pigs." Shock 19(5): 486-93. 
Jessup and Dean (1993). "Autoinhibition of murine macrophage-mediated oxidation 
of low-density lipoprotein by nitric oxide synthesis." Atherosclerosis 101(2): 
145-55. 
 242
Ji (2007). "Antioxidant signaling in skeletal muscle: a brief review." Exp Gerontol 
42(7): 582-93. 
Jialal and Devaraj (2003). "Antioxidants and atherosclerosis: don't throw out the 
baby with the bath water." Circulation 107(7): 926-8. 
Jiang, Jiang, et al. (2004). "Effect of simvastatin on endothelium-dependent vaso-
relaxation and endogenous nitric oxide synthase inhibitor." Acta Pharmacol 
Sin 25(7): 893-901. 
Jin, Caldwell, et al. (2007). "Homocysteine induces endothelial dysfunction via 
inhibition of arginine transport." J Physiol Pharmacol 58(2): 191-206. 
Jones, Fan, et al. (1999). "Redox manipulation using the thiol-oxidizing agent diethyl 
maleate prevents hepatocellular necrosis and apoptosis in a rodent 
endotoxemia model." Hepatology 30(3): 714-24. 
Jones, Kafonek, et al. (1998). "Comparative dose efficacy study of atorvastatin 
versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with 
hypercholesterolemia (the CURVES study)." Am J Cardiol 81(5): 582-7. 
Kagemann, Sies, et al. (2007). "Limited availability of L-arginine increases DNA-
binding activity of NF-kappaB and contributes to regulation of iNOS 
expression." J Mol Med 85(7): 723-32. 
Kakuda, Sweet, et al. (1999). "CAT2-mediated L-arginine transport and nitric oxide 
production in activated macrophages." Biochem J 340 (Pt 2): 549-53. 
Kamigaki, Sakaue, et al. (2006). "Oxidative stress provokes atherogenic changes in 
adipokine gene expression in 3T3-L1 adipocytes." Biochem Biophys Res 
Commun 339(2): 624-32. 
 243
Kang, Pak, et al. (1999). "Diethylmaleate and buthionine sulfoximine, glutathione-
depleting agents, differentially inhibit expression of inducible nitric oxide 
synthase in endotoxemic mice." Nitric Oxide 3(3): 265-71. 
Katsuyama, Shichiri, et al. (1999). "Differential inhibitory actions by glucocorticoid 
and aspirin on cytokine-induced nitric oxide production in vascular smooth 
muscle cells." Endocrinology 140(5): 2183-90. 
Kawashima, Oda, et al. (2002). "Heme oxygenase-1 deficiency: the first autopsy 
case." Hum Pathol 33(1): 125-30. 
Kelly and Smith (1996). "Nitric oxide and nitrovasodilators: similarities, differences, 
and interactions." Am J Cardiol 77(13): 2C-7C. 
Kishi, Hirooka, et al. (2003). "Atorvastatin causes depressor and sympatho-inhibitory 
effects with upregulation of nitric oxide synthases in stroke-prone 
spontaneously hypertensive rats." J Hypertens 21(2): 379-86. 
Kishida and Klann (2007). "Sources and targets of reactive oxygen species in 
synaptic plasticity and memory." Antioxid Redox Signal 9(2): 233-44. 
Kitamura, Matsuoka, et al. (1998). "Induction of inducible nitric oxide synthase and 
heme oxygenase-1 in rat glial cells." Life Sci 62(17-18): 1717-21. 
Kivisto and Niemi (2007). "Influence of drug transporter polymorphisms on 
pravastatin pharmacokinetics in humans." Pharm Res 24(2): 239-47. 
Knopp, Paramsothy, et al. (2008). "Comprehensive lipid management versus 
aggressive low-density lipoprotein lowering to reduce cardiovascular risk." Am 
J Cardiol 101(8A): 48B-57B. 
Koesling, Russwurm, et al. (2004). "Nitric oxide-sensitive guanylyl cyclase: structure 
and regulation." Neurochem Int 45(6): 813-9. 
 244
Koglin (2000). "Pathogenetic mechanisms of cardiac allograft vasculopathy--impact 
of nitric oxide." Z Kardiol 89 Suppl 9: IX/24-7. 
Koglin, Glysing-Jensen, et al. (1998). "Exacerbated transplant arteriosclerosis in 
inducible nitric oxide-deficient mice." Circulation 97(20): 2059-65. 
Kohnen, Mouithys-Mickalad, et al. (2001). "Oxidation of tetrahydrobiopterin by 
peroxynitrite or oxoferryl species occurs by a radical pathway." Free Radic 
Res 35(6): 709-21. 
Kolyada, Fedtsov, et al. (2001). "3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors upregulate inducible NO synthase expression and activity in 
vascular smooth muscle cells." Hypertension 38(5): 1024-9. 
Konig, Seithel, et al. (2006). "Pharmacogenomics of human OATP transporters." 
Naunyn Schmiedebergs Arch Pharmacol 372(6): 432-43. 
Korantzopoulos, Kolettis, et al. (2006). "The role of oxidative stress in the 
pathogenesis and perpetuation of atrial fibrillation." Int J Cardiol. 
Kronmann, Hatfield, et al. (2007). "Statin therapy: not just used to lower cholesterol?" 
Crit Care Nurs Q 30(2): 154-60. 
Kuo, Schroeder, et al. (1997). "Nitric oxide and acetaminophen-mediated oxidative 
injury: modulation of interleukin-1-induced nitric oxide synthesis in cultured rat 
hepatocytes." J Pharmacol Exp Ther 282(2): 1072-83. 
Kureishi, Luo, et al. (2000). "The HMG-CoA reductase inhibitor simvastatin activates 
the protein kinase Akt and promotes angiogenesis in normocholesterolemic 
animals." Nat Med 6(9): 1004-10. 
Kuzkaya, Weissmann, et al. (2003). "Interactions of peroxynitrite, tetrahydrobiopterin, 
ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide 
synthase." J Biol Chem 278(25): 22546-54. 
 245
Lambeth (2007). "Nox enzymes, ROS, and chronic disease: an example of 
antagonistic pleiotropy." Free Radic Biol Med 43(3): 332-47. 
Lamon and Hajjar (2008). "Inflammation at the molecular interface of atherogenesis: 
an anthropological journey." Am J Pathol 173(5): 1253-64. 
Landmesser, Dikalov, et al. (2003). "Oxidation of tetrahydrobiopterin leads to 
uncoupling of endothelial cell nitric oxide synthase in hypertension." J Clin 
Invest 111(8): 1201-9. 
Landmesser, Engberding, et al. (2004). "Statin-induced improvement of endothelial 
progenitor cell mobilization, myocardial neovascularization, left ventricular 
function, and survival after experimental myocardial infarction requires 
endothelial nitric oxide synthase." Circulation 110(14): 1933-9. 
Langer and Gawaz (2008). "Platelet-vessel wall interactions in atherosclerotic 
disease." Thromb Haemost 99(3): 480-6. 
Lau, Okochi, et al. (2006). "Pharmacokinetics of atorvastatin and its hydroxy 
metabolites in rats and the effects of concomitant rifampicin single doses: 
relevance of first-pass effect from hepatic uptake transporters, and intestinal 
and hepatic metabolism." Drug Metab Dispos 34(7): 1175-81. 
Laufs, La Fata, et al. (1998). "Upregulation of endothelial nitric oxide synthase by 
HMG CoA reductase inhibitors." Circulation 97(12): 1129-35. 
Laufs and Liao (1998). "Post-transcriptional regulation of endothelial nitric oxide 
synthase mRNA stability by Rho GTPase." J Biol Chem 273(37): 24266-71. 
Laursen, Somers, et al. (2001). "Endothelial regulation of vasomotion in apoE-
deficient mice: implications for interactions between peroxynitrite and 
tetrahydrobiopterin." Circulation 103(9): 1282-8. 
 246
Lee, Chang, et al. (2004). "Simvastatin induces heme oxygenase-1: a novel 
mechanism of vessel protection." Circulation 110(10): 1296-302. 
Lee and Hirani (2006). "Role of interleukin-4 in atherosclerosis." Arch Pharm Res 
29(1): 1-15. 
Lee, Lim, et al. (2004). "Antiproliferative mechanisms of raxofelast (IRFI-016) in 
H2O2-stimulated rat aortic smooth muscle cells." Eur J Pharmacol 484(2-3): 
119-25. 
Lee, Lim, et al. (2008). "A combination of Lox-1 and Nox1 regulates TLR9-mediated 
foam cell formation." Cell Signal 20(12): 2266-75. 
Leopold and Loscalzo (2005). "Oxidative enzymopathies and vascular disease." 
Arterioscler Thromb Vasc Biol 25(7): 1332-40. 
Lewinska, Wnuk, et al. (2007). "Total anti-oxidant capacity of cell culture media." Clin 
Exp Pharmacol Physiol 34(8): 781-6. 
Li, Cao, et al. (2006). "Upregulation of endogenous antioxidants and phase 2 
enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth 
muscle cells leads to cytoprotection against oxidative and electrophilic stress." 
Pharmacol Res 53(1): 6-15. 
Lin, Liu, et al. (2005). "Lovastatin reduces nuclear factor kappaB activation induced 
by C-reactive protein in human vascular endothelial cells." Biol Pharm Bull 
28(9): 1630-4. 
Lin, Shyue, et al. (2007). "Superoxide dismutase and catalase inhibit oxidized low-
density lipoprotein-induced human aortic smooth muscle cell proliferation: role 
of cell-cycle regulation, mitogen-activated protein kinases, and transcription 
factors." Atherosclerosis 190(1): 124-34. 
 247
Linares, Perales, et al. (2006). "Nutritional control, gene regulation, and 
transformation of vascular smooth muscle cells in atherosclerosis." 
Cardiovasc Hematol Disord Drug Targets 6(3): 151-68. 
Lins, Matthys, et al. (2003). "Pharmacokinetics of atorvastatin and its metabolites 
after single and multiple dosing in hypercholesterolaemic haemodialysis 
patients." Nephrol Dial Transplant 18(5): 967-76. 
Lopez, Hernandez, et al. (2007). "Changes in antioxidant enzymes in humans with 
long-term exposure to pesticides." Toxicol Lett 171(3): 146-53. 
Loscalzo (2000). "What we know and don't know about L-arginine and NO." 
Circulation 101(18): 2126-9. 
Lou and Kaplowitz (2007). "Glutathione depletion down-regulates tumor necrosis 
factor alpha-induced NF-kappaB activity via IkappaB kinase-dependent and -
independent mechanisms." J Biol Chem 282(40): 29470-81. 
Luscher (1991). "Endothelium-derived nitric oxide: the endogenous nitrovasodilator 
in the human cardiovascular system." Eur Heart J 12 Suppl E: 2-11. 
Lynch and Price (2007). "The effect of cytochrome P450 metabolism on drug 
response, interactions, and adverse effects." Am Fam Physician 76(3): 391-6. 
Maack, Kartes, et al. (2003). "Oxygen free radical release in human failing 
myocardium is associated with increased activity of rac1-GTPase and 
represents a target for statin treatment." Circulation 108(13): 1567-74. 
MacNaul and Hutchinson (1993). "Differential expression of iNOS and cNOS mRNA 
in human vascular smooth muscle cells and endothelial cells under normal 
and inflammatory conditions." Biochem Biophys Res Commun 196(3): 1330-4. 
Madamanchi, Tchivilev, et al. (2006). "Genetic markers of oxidative stress and 
coronary atherosclerosis." Curr Atheroscler Rep 8(3): 177-83. 
 248
Madonna, Di Napoli, et al. (2005). "Simvastatin attenuates expression of cytokine-
inducible nitric-oxide synthase in embryonic cardiac myoblasts." J Biol Chem 
280(14): 13503-11. 
Maines (1988). "Heme oxygenase: function, multiplicity, regulatory mechanisms, and 
clinical applications." Faseb J 2(10): 2557-68. 
Maines (1997). "The heme oxygenase system: a regulator of second messenger 
gases." Annu Rev Pharmacol Toxicol 37: 517-54. 
Maines and Gibbs (2005). "30 some years of heme oxygenase: from a "molecular 
wrecking ball" to a "mesmerizing" trigger of cellular events." Biochem Biophys 
Res Commun 338(1): 568-77. 
Malo-Ranta, Yla-Herttuala, et al. (1994). "Nitric oxide donor GEA 3162 inhibits 
endothelial cell-mediated oxidation of low density lipoprotein." FEBS Lett 
337(2): 179-83. 
Mangat, Agarwal, et al. (2007). "Do statins lower blood pressure?" J Cardiovasc 
Pharmacol Ther 12(2): 112-23. 
Mann, Niehueser-Saran, et al. (2007). "Nrf2/ARE regulated antioxidant gene 
expression in endothelial and smooth muscle cells in oxidative stress: 
implications for atherosclerosis and preeclampsia." Sheng Li Xue Bao 59(2): 
117-27. 
Mann, Rowlands, et al. (2007). "Activation of endothelial nitric oxide synthase by 
dietary isoflavones: role of NO in Nrf2-mediated antioxidant gene expression." 
Cardiovasc Res 75(2): 261-74. 
Manzoni and Rollini (2002). "Biosynthesis and biotechnological production of statins 
by filamentous fungi and application of these cholesterol-lowering drugs." Appl 
Microbiol Biotechnol 58(5): 555-64. 
 249
Matsumura, Kakishita, et al. (2001). "Dexamethasone suppresses iNOS gene 
expression by inhibiting NF-kappaB in vascular smooth muscle cells." Life Sci 
69(9): 1067-77. 
Maytin, Leopold, et al. (1999). "Oxidant stress in the vasculature." Curr Atheroscler 
Rep 1(2): 156-64. 
Maziere and Maziere (2008). "Activation of transcription factors and gene expression 
by oxidized low-density lipoprotein." Free Radic Biol Med. 
McCoubrey, Huang, et al. (1997). "Isolation and characterization of a cDNA from the 
rat brain that encodes hemoprotein heme oxygenase-3." Eur J Biochem 
247(2): 725-32. 
McMahan, Gidding, et al. (2006). "Pathobiological determinants of atherosclerosis in 
youth risk scores are associated with early and advanced atherosclerosis." 
Pediatrics 118(4): 1447-55. 
McMillan and Masters (1995). "Prokaryotic expression of the heme- and flavin-
binding domains of rat neuronal nitric oxide synthase as distinct polypeptides: 
identification of the heme-binding proximal thiolate ligand as cysteine-415." 
Biochemistry 34(11): 3686-93. 
McTaggart, Buckett, et al. (2001). "Preclinical and clinical pharmacology of 
Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitor." Am J Cardiol 87(5A): 28B-32B. 
McTavish and Sorkin (1991). "Pravastatin. A review of its pharmacological properties 
and therapeutic potential in hypercholesterolaemia." Drugs 42(1): 65-89. 
Mendes Ribeiro, Brunini, et al. (2001). "Abnormalities in L-arginine transport and 
nitric oxide biosynthesis in chronic renal and heart failure." Cardiovasc Res 
49(4): 697-712. 
 250
Miccadei, Kyle, et al. (1988). "Toxic consequence of the abrupt depletion of 
glutathione in cultured rat hepatocytes." Arch Biochem Biophys 265(2): 311-
20. 
Mitchell, Hecker, et al. (1990). "Cultured endothelial cells maintain their L-arginine 
level despite the continuous release of EDRF." Eur J Pharmacol 182(3): 573-
6. 
Moncada, Palmer, et al. (1988). "The discovery of nitric oxide as the endogenous 
nitrovasodilator." Hypertension 12(4): 365-72. 
Moncada, Palmer, et al. (1991). "Nitric oxide: physiology, pathophysiology, and 
pharmacology." Pharmacol Rev 43(2): 109-42. 
Mondo, Yang, et al. (2006). "Anti-oxidant effects of atorvastatin in dexamethasone-
induced hypertension in the rat." Clin Exp Pharmacol Physiol 33(11): 1029-34. 
Moreira, Santos, et al. (2007). "Alzheimer's disease: a lesson from mitochondrial 
dysfunction." Antioxid Redox Signal 9(10): 1621-30. 
Morrison, Rahman, et al. (2006). "Permeability, inflammation and oxidant status in 
airspace epithelium exposed to ozone." Respir Med 100(12): 2227-34. 
Mosmann (1983). "Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays." J Immunol Methods 65(1-
2): 55-63. 
Motterlini, Clark, et al. (2002). "Carbon monoxide-releasing molecules: 
characterization of biochemical and vascular activities." Circ Res 90(2): E17-
24. 
Muniyappa, Xu, et al. (2000). "Inhibition of Rho protein stimulates iNOS expression 
in rat vascular smooth muscle cells." Am J Physiol Heart Circ Physiol 278(6): 
H1762-8. 
 251
Nakagami, Jensen, et al. (2003). "A novel pleiotropic effect of statins: prevention of 
cardiac hypertrophy by cholesterol-independent mechanisms." Ann Med 
35(6): 398-403. 
Nakamura, Sasaki, et al. (2008). "Statin prevents plaque disruption in apoE-knockout 
mouse model through pleiotropic effect on acute inflammation." 
Atherosclerosis. 
Nakata, Tsutsui, et al. (2007). "Statin treatment upregulates vascular neuronal nitric 
oxide synthase through Akt/NF-kappaB pathway." Arterioscler Thromb Vasc 
Biol 27(1): 92-8. 
Nakatsu and Diamond (1989). "Role of cGMP in relaxation of vascular and other 
smooth muscle." Can J Physiol Pharmacol 67(4): 251-62. 
Nanetti, Taffi, et al. (2007). "Reactive oxygen species plasmatic levels in ischemic 
stroke." Mol Cell Biochem 303(1-2): 19-25. 
Narayan, Stadel, et al. (2005). "Redox response of the endogenous calcineurin 
inhibitor Adapt 78." Free Radic Biol Med 39(6): 719-27. 
Neuvonen, Backman, et al. (2008). "Pharmacokinetic comparison of the potential 
over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." 
Clin Pharmacokinet 47(7): 463-74. 
Neuvonen, Kantola, et al. (1998). "Simvastatin but not pravastatin is very susceptible 
to interaction with the CYP3A4 inhibitor itraconazole." Clin Pharmacol Ther 
63(3): 332-41. 
Nguyen, Sherratt, et al. (2003). "Regulatory mechanisms controlling gene expression 
mediated by the antioxidant response element." Annu Rev Pharmacol Toxicol 
43: 233-60. 
 252
Nicholson, Manner, et al. (2001). "Sustained nitric oxide production in macrophages 
requires the arginine transporter CAT2." J Biol Chem 276(19): 15881-5. 
Niess and Simon (2007). "Response and adaptation of skeletal muscle to exercise--
the role of reactive oxygen species." Front Biosci 12: 4826-38. 
Noakes, Thomas, et al. (2007). "Association of maternal smoking with increased 
infant oxidative stress at 3 months of age." Thorax 62(8): 714-7. 
Noris, Todeschini, et al. (2004). "L-arginine depletion in preeclampsia orients nitric 
oxide synthase toward oxidant species." Hypertension 43(3): 614-22. 
Ohtawa, Masuda, et al. (1999). "Cellular uptake of fluvastatin, an inhibitor of HMG-
CoA reductase, by rat cultured hepatocytes and human aortic endothelial 
cells." Br J Clin Pharmacol 47(4): 383-9. 
Orlandi, Ferlosio, et al. (2005). "Phenotypic heterogeneity influences the behavior of 
rat aortic smooth muscle cells in collagen lattice." Exp Cell Res 311(2): 317-
27. 
Ortego, Bustos, et al. (1999). "Atorvastatin reduces NF-kappaB activation and 
chemokine expression in vascular smooth muscle cells and mononuclear 
cells." Atherosclerosis 147(2): 253-61. 
Ortego, Gomez-Hernandez, et al. (2005). "HMG-CoA reductase inhibitors reduce I 
kappa B kinase activity induced by oxidative stress in monocytes and vascular 
smooth muscle cells." J Cardiovasc Pharmacol 45(5): 468-75. 
Otterbein, Soares, et al. (2003). "Heme oxygenase-1: unleashing the protective 
properties of heme." Trends Immunol 24(8): 449-55. 
Pacher, Beckman, et al. (2007). "Nitric oxide and peroxynitrite in health and 
disease." Physiol Rev 87(1): 315-424. 
 253
Paciaroni, Hennerici, et al. (2007). "Statins and stroke prevention." Cerebrovasc Dis 
24(2-3): 170-82. 
Packer, Porteous, et al. (1996). "Superoxide production by mitochondria in the 
presence of nitric oxide forms peroxynitrite." Biochem Mol Biol Int 40(3): 527-
34. 
Pahan, Sheikh, et al. (1997). "Lovastatin and phenylacetate inhibit the induction of 
nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and 
macrophages." J Clin Invest 100(11): 2671-9. 
Palacin, Estevez, et al. (1998). "Molecular biology of mammalian plasma membrane 
amino acid transporters." Physiol Rev 78(4): 969-1054. 
Pan (1991). "Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA 
reductase." Eur J Clin Pharmacol 40 Suppl 1: S15-8. 
Panda, Adak, et al. (2004). "A conserved aspartate (Asp-1393) regulates NADPH 
reduction of neuronal nitric-oxide synthase: implications for catalysis." J Biol 
Chem 279(18): 18323-33. 
Parker, Huang, et al. (2003). "Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) reductase inhibitors on endothelial nitric oxide synthase and the 
formation of oxidants in the vasculature." Atherosclerosis 169(1): 19-29. 
Patel, Abeles, et al. (1996). "Nitric oxide exposure and sulfhydryl modulation alter L-
arginine transport in cultured pulmonary artery endothelial cells." Free Radic 
Biol Med 20(5): 629-37. 
Pentikainen, Saraheimo, et al. (1992). "Comparative pharmacokinetics of lovastatin, 
simvastatin and pravastatin in humans." J Clin Pharmacol 32(2): 136-40. 
 254
Pereira and Borba (2008). "The role of inflammation, humoral and cell mediated 
autoimmunity in the pathogenesis of atherosclerosis." Swiss Med Wkly 
138(37-38): 534-9. 
Peretz, Peck, et al. (2007). "Diesel exhaust inhalation and assessment of peripheral 
blood mononuclear cell gene transcription effects: an exploratory study of 
healthy human volunteers." Inhal Toxicol 19(14): 1107-19. 
Perez-Guerrero, Marquez-Martin, et al. (2005). "Regulation of vascular tone from 
spontaneously hypertensive rats by the HMG-CoA reductase inhibitor, 
simvastatin." Pharmacology 74(4): 209-15. 
Pesant, Sueur, et al. (2006). "Peroxisome proliferator-activated receptor delta 
(PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-
induced apoptosis." Cardiovasc Res 69(2): 440-9. 
Pfeiffer, Rossier, et al. (1999). "Amino acid transport of y+L-type by heterodimers of 
4F2hc/CD98 and members of the glycoprotein-associated amino acid 
transporter family." Embo J 18(1): 49-57. 
Pietrobon, Azzone, et al. (1981). "Effect of funiculosin and antimycin A on the redox-
driven H+-pumps in mitochondria: on the nature of "leaks'." Eur J Biochem 
117(2): 389-94. 
Pingle, Sanchez, et al. (2003). "Hypertonicity inhibits lipopolysaccharide-induced 
nitric oxide synthase expression in smooth muscle cells by inhibiting nuclear 
factor kappaB." Mol Pharmacol 63(6): 1238-47. 
Popa, Netea, et al. (2007). "The role of TNF-alpha in chronic inflammatory 
conditions, intermediary metabolism, and cardiovascular risk." J Lipid Res 
48(4): 751-62. 
 255
Pulido, Angiolillo, et al. (2004). "Imaging of atherosclerotic plaque." Int J Cardiovasc 
Imaging 20(6): 553-9. 
Quinn and Gauss (2004). "Structure and regulation of the neutrophil respiratory burst 
oxidase: comparison with nonphagocyte oxidases." J Leukoc Biol 76(4): 760-
81. 
Rakotoniaina, Guerard, et al. (2006). "The protective effect of HMG-CoA reductase 
inhibitors against monocrotaline-induced pulmonary hypertension in the rat 
might not be a class effect: comparison of pravastatin and atorvastatin." 
Naunyn Schmiedebergs Arch Pharmacol 374(3): 195-206. 
Ravalli, Albala, et al. (1998). "Inducible nitric oxide synthase expression in smooth 
muscle cells and macrophages of human transplant coronary artery disease." 
Circulation 97(23): 2338-45. 
Ray and Shah (2005). "NADPH oxidase and endothelial cell function." Clin Sci 
(Lond) 109(3): 217-26. 
Reade, Clark, et al. (2002). "Increased cationic amino acid flux through a newly 
expressed transporter in cells overproducing nitric oxide from patients with 
septic shock." Clin Sci (Lond) 102(6): 645-50. 
Richards and Marletta (1994). "Characterization of neuronal nitric oxide synthase 
and a C415H mutant, purified from a baculovirus overexpression system." 
Biochemistry 33(49): 14723-32. 
Ridker, Cannon, et al. (2005). "C-reactive protein levels and outcomes after statin 
therapy." N Engl J Med 352(1): 20-8. 
Ridker, Rifai, et al. (2002). "Comparison of C-reactive protein and low-density 
lipoprotein cholesterol levels in the prediction of first cardiovascular events." N 
Engl J Med 347(20): 1557-65. 
 256
Rikitake, Hirata, et al. (1998). "Inhibitory effect of inducible type nitric oxide synthase 
on oxidative modification of low density lipoprotein by vascular smooth muscle 
cells." Atherosclerosis 136(1): 51-7. 
Risom, Moller, et al. (2005). "Oxidative stress-induced DNA damage by particulate 
air pollution." Mutat Res 592(1-2): 119-37. 
Rosenson and Tangney (1998). "Antiatherothrombotic properties of statins: 
implications for cardiovascular event reduction." Jama 279(20): 1643-50. 
Ross (1993). "The pathogenesis of atherosclerosis: a perspective for the 1990s." 
Nature 362(6423): 801-9. 
Ross (1995). "Cell biology of atherosclerosis." Annu Rev Physiol 57: 791-804. 
Rotoli, Bussolati, et al. (2005). "The transport of cationic amino acids in human 
airway cells: expression of system y+L activity and transepithelial delivery of 
NOS inhibitors." Faseb J 19(7): 810-2. 
Rouhanizadeh, Takabe, et al. (2008). "Monitoring oxidative stress in vascular 
endothelial cells in response to fluid shear stress: from biochemical analyses 
to micro- and nanotechnologies." Methods Enzymol 441: 111-50. 
Rubba (2007). "Effects of atorvastatin on the different phases of atherogenesis." 
Drugs 67 Suppl 1: 17-27. 
Rueckschloss, Galle, et al. (2001). "Induction of NAD(P)H oxidase by oxidized low-
density lipoprotein in human endothelial cells: antioxidative potential of 
hydroxymethylglutaryl coenzyme A reductase inhibitor therapy." Circulation 
104(15): 1767-72. 
Ruiz, Siow, et al. (2003). "Vitamin C inhibits diethylmaleate-induced L-cystine 
transport in human vascular smooth muscle cells." Free Radic Biol Med 34(1): 
103-10. 
 257
Ruperez, Rodrigues-Diez, et al. (2007). "HMG-CoA reductase inhibitors decrease 
angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK 
pathways." Hypertension 50(2): 377-83. 
Russell, Wallace, et al. (1995). "Upregulation and modulation of inducible nitric oxide 
synthase in rat cardiac allografts with chronic rejection and transplant 
arteriosclerosis." Circulation 92(3): 457-64. 
Russo, Zambrano, et al. (1995). "A p53-independent pathway for activation of 
WAF1/CIP1 expression following oxidative stress." J Biol Chem 270(49): 
29386-91. 
Ryer, Sakakibara, et al. (2005). "Protein kinase C delta induces apoptosis of 
vascular smooth muscle cells through induction of the tumor suppressor p53 
by both p38-dependent and p38-independent mechanisms." J Biol Chem 
280(42): 35310-7. 
Ryoo, Gupta, et al. (2008). "Endothelial arginase II: a novel target for the treatment 
of atherosclerosis." Circ Res 102(8): 923-32. 
Ryoo, Lemmon, et al. (2006). "Oxidized low-density lipoprotein-dependent 
endothelial arginase II activation contributes to impaired nitric oxide signaling." 
Circ Res 99(9): 951-60. 
Saam, Hatsukami, et al. (2007). "The vulnerable, or high-risk, atherosclerotic plaque: 
noninvasive MR imaging for characterization and assessment." Radiology 
244(1): 64-77. 
Saini, Xu, et al. (2005). "Pharmacological basis of different targets for the treatment 
of atherosclerosis." J Cell Mol Med 9(4): 818-39. 
Sakoda, Yamamoto, et al. (2006). "Simvastatin decreases IL-6 and IL-8 production in 
epithelial cells." J Dent Res 85(6): 520-3. 
 258
Salerno, Harris, et al. (1997). "An autoinhibitory control element defines calcium-
regulated isoforms of nitric oxide synthase." J Biol Chem 272(47): 29769-77. 
San Jose, Fortuno, et al. (2008). "NADPH oxidase CYBA polymorphisms, oxidative 
stress and cardiovascular diseases." Clin Sci (Lond) 114(3): 173-82. 
Sauer and Wartenberg (2005). "Reactive oxygen species as signaling molecules in 
cardiovascular differentiation of embryonic stem cells and tumor-induced 
angiogenesis." Antioxid Redox Signal 7(11-12): 1423-34. 
Schachter (2005). "Chemical, pharmacokinetic and pharmacodynamic properties of 
statins: an update." Fundam Clin Pharmacol 19(1): 117-25. 
Schleicher and Friess (2007). "Oxidative stress, AGE, and atherosclerosis." Kidney 
Int Suppl(106): S17-26. 
Schott, Vetrovsky, et al. (1993). "Cationic amino acids inhibit the effects of L-arginine 
in rat aorta exposed to lipopolysaccharide." Eur.J.Pharmacol. 236: 155-157. 
Schroecksnadel, Frick, et al. (2006). "Crucial role of interferon-gamma and 
stimulated macrophages in cardiovascular disease." Curr Vasc Pharmacol 
4(3): 205-13. 
Schwartz, Schwartz, et al. (2003). "Differential regulation of glomerular arginine 
transporters (CAT-1 and CAT-2) in lipopolysaccharide-treated rats." Am J 
Physiol Renal Physiol 284(4): F788-95. 
Seddon, Looi, et al. (2007). "Oxidative stress and redox signalling in cardiac 
hypertrophy and heart failure." Heart 93(8): 903-7. 
Selemidis, Sobey, et al. (2008). "NADPH oxidases in the vasculature: molecular 
features, roles in disease and pharmacological inhibition." Pharmacol Ther 
120(3): 254-91. 
 259
Sen and Packer (1996). "Antioxidant and redox regulation of gene transcription." 
Faseb J 10(7): 709-20. 
Seomun, Kim, et al. (2005). "Induction of p21Cip1-mediated G2/M arrest in H2O2-
treated lens epithelial cells." Mol Vis 11: 764-74. 
Shaw, Fildes, et al. (2009). "Pleiotropic effects and cholesterol-lowering therapy." 
Cardiology 112(1): 4-12. 
Sheeran and Pepe (2006). "Energy deficiency in the failing heart: linking increased 
reactive oxygen species and disruption of oxidative phosphorylation rate." 
Biochim Biophys Acta 1757(5-6): 543-52. 
Shen and Liu (2006). "JNK signaling pathway is a key modulator in cell death 
mediated by reactive oxygen and nitrogen species." Free Radic Biol Med 
40(6): 928-39. 
Shingu, Yoshioka, et al. (1985). "Human vascular smooth muscle cells and 
endothelial cells lack catalase activity and are susceptible to hydrogen 
peroxide." Inflammation 9(3): 309-20. 
Sies (1991). "Role of reactive oxygen species in biological processes." Klin 
Wochenschr 69(21-23): 965-8. 
Silver (1985). "Regulation of contractile activity in vascular smooth muscle by protein 
kinases." Rev Clin Basic Pharm 5(3-4): 341-95. 
Simmons, Closs, et al. (1996). "Cytokines and insulin induce cationic amino acid 
transporter (CAT) expression in cardiac myocytes. Regulation of L-arginine 
transport and no production by CAT-1, CAT-2A, and CAT-2B." J Biol Chem 
271(20): 11694-702. 
 260
Singh, Devaraj, et al. (2008). "Comparison effect of atorvastatin (10 versus 80 mg) 
on biomarkers of inflammation and oxidative stress in subjects with metabolic 
syndrome." Am J Cardiol 102(3): 321-5. 
Siow, Ishii, et al. (2007). "Modulation of antioxidant gene expression by 4-
hydroxynonenal: atheroprotective role of the Nrf2/ARE transcription pathway." 
Redox Rep 12(1): 11-5. 
Siow, Ishii, et al. (1995). "Induction of the antioxidant stress proteins heme 
oxygenase-1 and MSP23 by stress agents and oxidised LDL in cultured 
vascular smooth muscle cells." FEBS Lett 368(2): 239-42. 
Siow, Li, et al. (2007). "Cardiovascular targets for estrogens and phytoestrogens: 
transcriptional regulation of nitric oxide synthase and antioxidant defense 
genes." Free Radic Biol Med 42(7): 909-25. 
Siow, Sato, et al. (1999). "Heme oxygenase-carbon monoxide signalling pathway in 
atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide?" 
Cardiovasc Res 41(2): 385-94. 
Sironi, Banfi, et al. (2006). "Activation of NF-kB and ERK1/2 after permanent focal 
ischemia is abolished by simvastatin treatment." Neurobiol Dis 22(2): 445-51. 
Skalli, Ropraz, et al. (1986). "A monoclonal antibody against alpha-smooth muscle 
actin: a new probe for smooth muscle differentiation." J Cell Biol 103(6 Pt 2): 
2787-96. 
Sobrevia, Cesare, et al. (1995). "Diabetes-induced activation of system y+ and nitric 
oxide synthase in human endothelial cells: association with membrane 
hyperpolarization." J Physiol 489 (Pt 1): 183-92. 
Sorescu, Szocs, et al. (2001). "NAD(P)H oxidases and their relevance to 
atherosclerosis." Trends Cardiovasc Med 11(3-4): 124-31. 
 261
Sperandeo, Borsani, et al. (1998). "The gene encoding a cationic amino acid 
transporter (SLC7A4) maps to the region deleted in the velocardiofacial 
syndrome." Genomics 49(2): 230-6. 
Stamler, Singel, et al. (1992). "Biochemistry of nitric oxide and its redox-activated 
forms." Science 258(5090): 1898-902. 
Stocker and Keaney (2005). "New insights on oxidative stress in the artery wall." J 
Thromb Haemost 3(8): 1825-34. 
Stone and Marletta (1994). "Soluble guanylate cyclase from bovine lung: activation 
with nitric oxide and carbon monoxide and spectral characterization of the 
ferrous and ferric states." Biochemistry 33(18): 5636-40. 
Sugino (2007). "The role of oxygen radical-mediated signaling pathways in 
endometrial function." Placenta 28 Suppl A: S133-6. 
Suschek, Schnorr, et al. (2003). "Critical role of L-arginine in endothelial cell survival 
during oxidative stress." Circulation 107(20): 2607-14. 
Sweazea and Walker (2008). "Antioxidant and Vasodilatory Effects of Heme 
Oxygenase on Mesenteric Vasoreactivity Following Chronic Hypoxia." 
Microcirculation: 1-11. 
Szaszi, Jones, et al. (2005). "Glutathione depletion inhibits lipopolysaccharide-
induced intercellular adhesion molecule 1 synthesis." Free Radic Biol Med 
38(10): 1333-43. 
Tan, Forbes, et al. (2007). "AGE, RAGE, and ROS in diabetic nephropathy." Semin 
Nephrol 27(2): 130-43. 
Tang, Leung, et al. (2007). "Calcium and reactive oxygen species increase in 
endothelial cells in response to releasers of endothelium-derived contracting 
factor." Br J Pharmacol 151(1): 15-23. 
 262
Tardif, Gregoire, et al. (2008). "Effects of the antioxidant succinobucol (AGI-1067) on 
human atherosclerosis in a randomized clinical trial." Atherosclerosis 197(1): 
480-6. 
Terblanche, Almog, et al. (2007). "Statins and sepsis: multiple modifications at 
multiple levels." Lancet Infect Dis 7(5): 358-68. 
Tirmenstein, Nicholls-Grzemski, et al. (2000). "Glutathione-dependent regulation of 
nitric oxide production in isolated rat hepatocyte suspensions." Antioxid Redox 
Signal 2(4): 767-77. 
Torrents, Estevez, et al. (1998). "Identification and characterization of a membrane 
protein (y+L amino acid transporter-1) that associates with 4F2hc to encode 
the amino acid transport activity y+L. A candidate gene for lysinuric protein 
intolerance." J Biol Chem 273(49): 32437-45. 
Treasure, Klein, et al. (1995). "Beneficial effects of cholesterol-lowering therapy on 
the coronary endothelium in patients with coronary artery disease." N Engl J 
Med 332(8): 481-7. 
Turner, Midgley, et al. (2007). "Comparison of the efficacies of five different statins 
on inhibition of human saphenous vein smooth muscle cell proliferation and 
invasion." J Cardiovasc Pharmacol 50(4): 458-61. 
Tuzcu, Kapadia, et al. (2001). "High prevalence of coronary atherosclerosis in 
asymptomatic teenagers and young adults: evidence from intravascular 
ultrasound." Circulation 103(22): 2705-10. 
Upmacis, Crabtree, et al. (2007). "Profound biopterin oxidation and protein tyrosine 
nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of 
inducible nitric oxide synthase." Am J Physiol Heart Circ Physiol 293(5): 
H2878-87. 
 263
Ushio-Fukai (2006). "Localizing NADPH oxidase-derived ROS." Sci STKE 
2006(349): re8. 
Ushio-Fukai (2007). "VEGF signaling through NADPH oxidase-derived ROS." 
Antioxid Redox Signal 9(6): 731-9. 
Ushio-Fukai and Alexander (2004). "Reactive oxygen species as mediators of 
angiogenesis signaling: role of NAD(P)H oxidase." Mol Cell Biochem 264(1-
2): 85-97. 
Ushio-Fukai, Alexander, et al. (1998). "p38 Mitogen-activated protein kinase is a 
critical component of the redox-sensitive signaling pathways activated by 
angiotensin II. Role in vascular smooth muscle cell hypertrophy." J Biol Chem 
273(24): 15022-9. 
Valko, Leibfritz, et al. (2007). "Free radicals and antioxidants in normal physiological 
functions and human disease." Int J Biochem Cell Biol 39(1): 44-84. 
Valko, Rhodes, et al. (2006). "Free radicals, metals and antioxidants in oxidative 
stress-induced cancer." Chem Biol Interact 160(1): 1-40. 
Van Winkle, Christensen, et al. (1985). "Na+-dependent transport of basic, 
zwitterionic, and bicyclic amino acids by a broad-scope system in mouse 
blastocysts." J Biol Chem 260(22): 12118-23. 
Van Winkle, Tesch, et al. (2006). "System B0,+ amino acid transport regulates the 
penetration stage of blastocyst implantation with possible long-term 
developmental consequences through adulthood." Hum Reprod Update 12(2): 
145-57. 
Vasquez-Vivar, Hogg, et al. (1997). "Superoxide anion formation from lucigenin: an 
electron spin resonance spin-trapping study." FEBS Lett 403(2): 127-30. 
 264
Vasquez-Vivar, Kalyanaraman, et al. (1998). "Superoxide generation by endothelial 
nitric oxide synthase: the influence of cofactors." Proc Natl Acad Sci U S A 
95(16): 9220-5. 
Vasquez-Vivar, Martasek, et al. (1997). "Endothelial nitric oxide synthase-dependent 
superoxide generation from adriamycin." Biochemistry 36(38): 11293-7. 
Vaziri, Wang, et al. (2000). "Induction of oxidative stress by glutathione depletion 
causes severe hypertension in normal rats." Hypertension 36(1): 142-6. 
Vigushin, Pepys, et al. (1993). "Metabolic and scintigraphic studies of radioiodinated 
human C-reactive protein in health and disease." J Clin Invest 91(4): 1351-7. 
Visigalli, Bussolati, et al. (2004). "The stimulation of arginine transport by TNFalpha 
in human endothelial cells depends on NF-kappaB activation." Biochim 
Biophys Acta 1664(1): 45-52. 
Voeikov (2006). "Reactive oxygen species--(ROS) pathogens or sources of vital 
energy? Part 1. ROS in normal and pathologic physiology of living systems." J 
Altern Complement Med 12(2): 111-8. 
Vos, Van Goor, et al. (1999). "Expression of inducible nitric oxide synthase in 
endotoxemic rat hepatocytes is dependent on the cellular glutathione status." 
Hepatology 29(2): 421-6. 
Voss, Hajimiragha, et al. (2007). "Irradiation of GAPDH: a model for environmentally 
induced protein damage." Biol Chem 388(6): 583-92. 
Voyta, Via, et al. (1984). "Identification and isolation of endothelial cells based on 
their increased uptake of acetylated-low density lipoprotein." J Cell Biol 99(6): 
2034-40. 
 265
Wagner, Kohler, et al. (2000). "Improvement of nitric oxide-dependent vasodilatation 
by HMG-CoA reductase inhibitors through attenuation of endothelial 
superoxide anion formation." Arterioscler Thromb Vasc Biol 20(1): 61-9. 
Wassmann, Laufs, et al. (2001). "HMG-CoA reductase inhibitors improve endothelial 
dysfunction in normocholesterolemic hypertension via reduced production of 
reactive oxygen species." Hypertension 37(6): 1450-7. 
Wassmann, Laufs, et al. (2002). "Cellular antioxidant effects of atorvastatin in vitro 
and in vivo." Arterioscler Thromb Vasc Biol 22(2): 300-5. 
Watanabe (2008). "[Dyslipidemia as a therapeutic target for prevention of 
cardiovascular events and end-stage renal disease]." Nippon Rinsho 66(9): 
1761-9. 
Wenzel, Daiber, et al. (2008). "Mechanisms underlying recoupling of eNOS by HMG-
CoA reductase inhibition in a rat model of streptozotocin-induced diabetes 
mellitus." Atherosclerosis 198(1): 65-76. 
Westhuyzen and Healy (2000). "Review: Biology and relevance of C-reactive protein 
in cardiovascular and renal disease." Ann Clin Lab Sci 30(2): 133-43. 
White, Gazzola, et al. (1982). "Cationic amino acid transport into cultured animal 
cells. I. Influx into cultured human fibroblasts." J Biol Chem 257(8): 4443-9. 
Wileman, Mann, et al. (1995). "Induction of L-arginine transport and nitric oxide 
synthase in vascular smooth muscle cells: Synergistic actions of pro- 
inflammatory cytokines and bacterial lipopolysaccharide." British Journal of 
Pharmacology 116: 3243-3250. 
Wileman, Mann, et al. (1995). "Induction of L-arginine transport and nitric oxide 
synthase in vascular smooth muscle cells: synergistic actions of pro-
 266
inflammatory cytokines and bacterial lipopolysaccharide." Br J Pharmacol 
116(8): 3243-50. 
Wileman, Mann, et al. (2003). "Role of L-citrulline transport in nitric oxide synthesis in 
rat aortic smooth muscle cells activated with LPS and interferon-gamma." Br J 
Pharmacol 140(1): 179-85. 
Wolf, Janzen, et al. (2002). "Expression of solute carrier 7A4 (SLC7A4) in the 
plasma membrane is not sufficient to mediate amino acid transport activity." 
Biochem J 364(Pt 3): 767-75. 
Wu (2006). "The signaling mechanism of ROS in tumor progression." Cancer 
Metastasis Rev 25(4): 695-705. 
Wu and Juurlink (2001). "The impaired glutathione system and its up-regulation by 
sulforaphane in vascular smooth muscle cells from spontaneously 
hypertensive rats." J Hypertens 19(10): 1819-25. 
Wu, Kathir, et al. (2006). "Antioxidants protect from atherosclerosis by a heme 
oxygenase-1 pathway that is independent of free radical scavenging." J Exp 
Med 203(4): 1117-27. 
Wyatt, Steinert, et al. (2004). "Modulation of the L-arginine/nitric oxide signalling 
pathway in vascular endothelial cells." Biochem Soc Symp(71): 143-56. 
Xie, Kashiwabara, et al. (1994). "Role of transcription factor NF-kappa B/Rel in 
induction of nitric oxide synthase." J Biol Chem 269(7): 4705-8. 
Yamamoto, Hoshi, et al. (1998). "Fluvastatin, an inhibitor of 3-hydroxy-3-
methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid 
peroxidation in rat liver microsomes." Eur J Pharmacol 361(1): 143-9. 
 267
Yamamoto, Takeda, et al. (2003). "HMG-CoA reductase inhibitor enhances inducible 
nitric oxide synthase expression in rat vascular smooth muscle cells; 
involvement of the Rho/Rho kinase pathway." Atherosclerosis 166(2): 213-22. 
Yamanouchi, Banno, et al. (2005). "Hydrophilic statin suppresses vein graft intimal 
hyperplasia via endothelial cell-tropic Rho-kinase inhibition." J Vasc Surg 
42(4): 757-64. 
Yang, Tsai, et al. (2005). "NF-kappaB inhibitors stabilize the mRNA of high-affinity 
type-2 cationic amino acid transporter in LPS-stimulated rat liver." Acta 
Anaesthesiol Scand 49(4): 468-76. 
Yang, Wu, et al. (2004). "Effect of acrolein and glutathione depleting agents on 
thioredoxin." Toxicology 204(2-3): 209-18. 
Yates, Lambert, et al. (1992). "A protective role for nitric oxide in the oxidative 
modification of low density lipoproteins by mouse macrophages." FEBS Lett 
309(2): 135-8. 
Yeh, Graham Barr, et al. (2007). "No effect of cigarette smoking dose on oxidized 
plasma proteins." Environ Res. 
Yokoyama, Inoue, et al. (2000). "Role of the vascular NADH/NADPH oxidase system 
in atherosclerosis." Ann N Y Acad Sci 902: 241-7; discussion 247-8. 
Yu and Chung (2001). "Oxidative stress and vascular aging." Diabetes Res Clin 
Pract 54 Suppl 2: S73-80. 
Yu, Inoguchi, et al. (2005). "Statin attenuates high glucose-induced and angiotensin 
II-induced MAP kinase activity through inhibition of NAD(P)H oxidase activity 
in cultured mesangial cells." Med Chem 1(5): 461-6. 
 268
Yu, Zhang, et al. (2007). "Comparison of intensive and low-dose atorvastatin therapy 
in the reduction of carotid intimal-medial thickness in patients with coronary 
heart disease." Heart 93(8): 933-9. 
Zapolska-Downar, Siennicka, et al. (2004). "Simvastatin modulates TNFalpha-
induced adhesion molecules expression in human endothelial cells." Life Sci 
75(11): 1287-302. 
Zhang and Gutterman (2007). "Mitochondrial reactive oxygen species-mediated 
signaling in endothelial cells." Am J Physiol Heart Circ Physiol 292(5): H2023-
31. 
Zhang, Malik, et al. (2008). "Paradoxical activation of endothelial nitric oxide 
synthase by NADPH oxidase." Arterioscler Thromb Vasc Biol 28(9): 1627-33. 
Zhang and Shah (2007). "Role of reactive oxygen species in myocardial 
remodeling." Curr Heart Fail Rep 4(1): 26-30. 
Zhang, Snead, et al. (2001). "Nitric oxide differentially regulates induction of type II 
nitric oxide synthase in rat vascular smooth muscle cells versus 
macrophages." Arterioscler Thromb Vasc Biol 21(4): 529-35. 
Zhang, Venardos, et al. (2006). "Adverse effects of cigarette smoke on NO 
bioavailability: role of arginine metabolism and oxidative stress." Hypertension 
48(2): 278-85. 
Zheng, Baker, et al. (2006). "Proteomic analysis for the assessment of different lots 
of fetal bovine serum as a raw material for cell culture. Part IV. Application of 
proteomics to the manufacture of biological drugs." Biotechnol Prog 22(5): 
1294-300. 
Zhou, Jaimes, et al. (2004). "Atorvastatin prevents end-organ injury in salt-sensitive 
hypertension: role of eNOS and oxidant stress." Hypertension 44(2): 186-90. 
 269
 
 270
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Table 7.1. Transfer buffer 
Reagent Concentration 
Glycine 39 mM 
TRIS 48 mM 
SDS 0.0375 % 
 
Table 7.2. Washing buffer 
Reagent Concentration 
TRIS 10 mM 
NaCl 100 mM 
 
Table 7.3. Tank buffer 
Reagent Concentration 
TRIS 250 mM 
Glycine 2 M 
SDS 1 % 
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8 . Materials 
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Absolute ethanol – Fluka 
Acrylamide, ProtoGel – National Diagnostics 
Agarose – Sigma 
Ammonium Persulphate – AMRESCO 
Anti-α monoclonal smooth muscle actin – Sigma 
Anti-biotin, HRP-linked antibody, Detection Pack – Cell Signalling 
Anti-Heme Oxygenase-1 mouse monoclonal antibody (HO-1-1) – Calbiochem 
Anti-mouse IgG (whole molecule) FITC Conjugate developed in rabbit – Sigma 
Anti-iNOS/NOS Type II monoclonal antibody – Transduction Laboratories 
Anti-β actin monoclonal antibody – Sigma 
Anti-mouse secondary antibody, Goat anti-mouse HRP – Transduction Labs 
Antimycin A from Streptomyces sp. – Sigma 
Atorvastatin Calcium – Pfizer 
BCA, Bicinchoninic Acid protein assay regent kit – Pierce 
Biotinylated Protein Ladder, Detection Pack – Cell Signalling 
Bromophenol Blue – Sigma 
BSA, Bovine Serum Albumin – Sigma 
CaCl2, Calcium Chloride – BDH 
Chloroform >99.8 % – Sigma-Aldrich 
Collagenase – Roche Diagnostics 
Coomassie brilliant blue – Fluka 
Diethyl maleate (DEM) – Sigma 
Developer (Dektol) – Kodak 
D-glucose – BDH 
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Dil-Ac-LDL, Dil labelled acetylated low density lipoprotein – Calbiochem 
DMEM, Dulbecco’s Modified Eagle’s Medium – GIBCO 
ECL detection reagents – Amersham Biosciences 
Ethanol – BDH 
Extra Thick Blot Paper – BIO-RAD 
Ficoll – Sigma 
FITC, Fluorescein isothiocyanate – Sigma 
Fixer (Unifix) – Kodak 
FBS, Foetal Bovine Serum – GIBCO 
Formaldehyde- Sigma 
Fungizone – GIBCO 
Gentamycin – GIBCO 
Acetic acid – Fisher Scientific 
Glycerol – Sigma 
Glycine – BDH 
H2O2, hydrogen peroxide – Sigma 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) – Sigma 
Hyperfilm (ECK & X-ray) – Amersham 
Horseradish Peroxidase-linked Antibody – Cell Signalling, Detection Pack 
[H3]L-arginine (2 µ Ci/ml) – Amersham Biosciences 
IMS, Industrial Methylated Spirit – BDH 
Interferon-γ, rat, recombinant, E. coli – Calbiochem 
Isopropanol – BDH 
KCl, potassium chloride – BDH 
L-(+)-Arginine Hydrochloride – Sigma 
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LPS, Lipopolysaccharide from E. Coli – Fluka 
Lab-Tek® well plates – Nunc 
Methanol – Fisher Scientific 
Mevalonate, (+)-Mevalonolactone – Sigma 
MOPS, 3-(N-Morpholino)propanesulfonic acid sodium salt – Sigma 
MgCl2, Magnesium Chloride – BDH 
MTT (5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) – Sigma 
Na3VO4, Sodium Orthovanadate – Sigma 
NaCl, Sodium Chloride – BDH 
NaF, Sodium Fluoride - Sigma 
NaH2PO4, Sodium Dihydrogen Orthophosphate 1-hydrate – BDH 
NaHCO3, Sodium Bicarbonate – BDH 
NaOH, Sodium hydroxide – Sigma 
NaNO3, Sodium Nitrate – Sigma 
Napthylethylenediamine – Sigma-Aldrich 
NO2-, Nitrite – Sigma 
PBS, Phosphate Buffered Saline – GIBCO 
Penicillin/Streptomycin – GIBCO 
Phosphoric Acid – BDH 
PMSF, phenyl methyl sulfonyl fluoride – Sigma 
Pravastatin sodium salt – Calbiochem 
PVDF membrane, Membrane Immobilon-P transfere – Millipore 
Random hexamers – Promega 
Scintillation Liquid (Liquiscint) – National Diagnostics 
SDS, Sodium Dodecyl Sulphate – Sigma 
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Simvastatin sodium salt – Calbiochem 
Skimmed milk – Marvel 
Sulfanilamideamine – Sigma-Aldrich 
TEMED, NNN’N’-Tetramethylethylenediamine – BDH 
Trizma base (TRIS) – Sigma 
Trypsin-EDTA – GIBCO 
Tween 20 – Sigma 
Unifix (fixer) – Kodak 
Xylene cyanol – Sigma-Aldrich 
β-mercaptoethanol – Sigma 
 
